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ABSTRACT 
 
Canadian population demographics are shifting to an increase in aged individuals 
and an increase in the prevalence of neurodegenerative diseases.  The post-mitotic nature 
of most neurons highlights the need to understand the etiology and early mechanisms in 
neurodegenerative diseases and design targeted therapies.  Currently, the etiologies of 
neurodegeneration are poorly understood but oxidative stress, mitochondrial dysfunction 
and inflammation are early mechanisms in Alzheimer’s disease, Parkinson’s disease and 
Amyotrophic Lateral Sclerosis.  An anti-aging strategy that can be adapted for use in 
neurodegeneration is hormesis, where repeated low-level exposures to stressors are 
beneficial to the cell.  Hormesis has demonstrated efficacy in inhibiting hepatocarcinoma 
in the rat through administration of dietary phenobarbital, which decreases DNA damage, 
increases DNA repair, and decreases cell proliferation.  Given that phenobarbital 
decreases DNA damage and increases DNA repair, phenobarbital was tested as a 
hormetic agent in murine neurodegeneration. The harlequin (hq) mouse is a model of 
mitochondrial dysfunction and oxidative stress with cerebellar degeneration.  One-month-
old wild type (WT) and hq mice were administered phenobarbital in drinking water at 0, 
2 or 4 ppm provided ad libitum, until euthanized at 3, 7, or 10 months of age.  Eleven 
parameters of nocturnal behaviour were examined in WT and hq mice (n=9 to 14).  In 
situ, post-mortem cerebellar tissue sections were examined for neuron loss, cell damage, 
and reactive oxygen species (ROS) (n=3).  In vivo cerebellar mutations were detected 
using the Big Blue  cII mutation assay (n=5 or 6).  The transcriptome was analyzed to 
survey global markers in hq cerebella and response to phenobarbital exposure (n=3).  The 
hq phenotype had no behavioural changes, but had increased neuron loss, limited cell 
  iv 
damage, a mutation signature of ROS, and elevated ROS with age.  Phenobarbital 
administration did not prevent cerebellar degeneration in hq mice.  Transcriptome data 
revealed inflammation as an early disease mechanism in hq mice.  In hq mice, a down-
regulation in the GABAA receptor was found which potentially limits the efficacy of 
phenobarbital.  The hq mouse could benefit from a strategy addressing mitochondrial 
dysfunction through supplementation with riboflavin, thus increasing activity of complex 
I of the electron transport chain and increasing ATP production. 
 
Key words:  harlequin mouse, cerebellar degeneration, Apoptosis-inducing factor, 
phenobarbital, hormesis, inflammation, mitochondrial dysfunction, aging, murine 
behaviour, Big Blue  cII mutation detection assay, oxidative stress, microarray. 
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CHAPTER ONE - INTRODUCTION 
 
1.1 Aging-associated neurodegenerative diseases 
Neurodegenerative diseases are associated with substantial economic impact on 
society.  In 1998, the cost of neurodegenerative diseases totaled over $400 million 
dollars, which included hospital stays, treatments, and money lost from long-term 
disability and premature death [1].  As of the last Canadian census, individuals aged 65 
and over made up a record 13.7% of the total population [2].  Last year, 2011, was 
momentous as it marked the year the first cohort of the baby-boomer generation reached 
the age of 65.  The proportion of individuals over the age of 65 is expected to continue 
increasing until 2056, at which point seniors will constitute 25% to 30% of the total 
population, more than double the current proportion [2].  As the proportion of Canadians 
over the age of 65 increases, so will the frequency of neurodegenerative disease, as it is 
highly correlated with age [3].  Current estimates are that over 800,000 Canadians suffer 
from either Alzheimer’s disease (AD), Parkinson’s disease (PD), or Amyotrophic Lateral 
Sclerosis (ALS) [2].  Biomarkers for neurodegeneration include testing cerebral spinal 
fluid for amyloid  and/or tau in AD [4], or tumor necrosis factor-  (TNF- ), and 8-
hydroxy-2’-deoxyguanosine (8-OHdG) in PD [5], and glutamate in ALS [6], but lumbar 
punctures required to obtain cerebral spinal fluid are painful and invasive procedures.  
Positron emission tomography imaging can be used to visualize the location of 
neurofibrillary tangles and amyloid plaques in AD [7], the decrease of dopamine 
transporters with disease progression in PD [8], or to measure glucose hypermetabolism 
in ALS [9], all which require the injection of radioactive tracers.  Even with the 
development of early biomarkers, by the time symptoms appear, a significant number of 
  
2 
neurons have already been lost [10, 11].  Currently we are unable to prevent 
neurodegenerative diseases and the treatments that are available are limited to alleviating 
symptoms and are not able to slow disease progression or cure neurodegeneration.  A 
limiting step in drug development is determining the etiology and mechanisms of 
neurodegeneration. 
 
1.2 Genetic basis behind early-onset neurodegenerative diseases 
Families with early-onset neurodegenerative disorders due to single-gene 
mutations have been identified and display simple Mendelian inheritance patterns [12-
14].  Single-gene mutations in Amyloid precursor protein, Presenilin-1, Presenilin-2, -
Synuclein, Parkin, and Copper/zinc superoxide dismutase genes have been identified in 
familial AD [14-17], PD [12, 18], or ALS [13].  Single-gene mutations cause 5 % of the 
cases of neurodegeneration [19-21], although most individuals who develop late-onset 
neurodegeneration have no family history of neurodegenerative disorders.  Thus early-
onset neurodegenerative disorders are a limited model when studying late-onset 
neurodegenerative diseases. 
 
1.3 Late-onset neurodegenerative disorders 
The etiology of late-onset neurodegeneration is poorly understood, has no clear 
genetic basis and combines complex interactions between genes and the environment.  
Several susceptibility genes have been identified in sporadic cases of neurodegeneration, 
but brain injuries and environmental exposure to pesticides as well as heavy metals all 
increase the risk of developing neurodegeneration.  Individuals who experience a 
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traumatic brain injury have an increased risk of AD [22] that is further exacerbated when 
they also have the epsilon 4 allele of the Apolipoprotein E gene [23].  Individuals 
chronically exposed to pesticides have a 70% higher incidence of PD compared to 
individuals not chronically exposed to pesticides [24].  It is thought that the link between 
pesticides and PD lies in the activity of the enzymes that are involved with the 
detoxification, metabolism, and transport of xenobiotics.  The cytochrome P450 enzyme 
2D6 (CYP2D6) is involved in the metabolism of pesticides.  Individuals with a 
polymorphism in the CYP2D6 enzyme causing lower CYP2D6 activity and poor 
pesticide metabolism have a higher incidence of PD [25, 26].  In ALS patients, elevated 
iron levels are detected [27] that can be due to alterations in a number of genes involved 
in iron transport [28].  Iron enters neurons though a complex composed of transferrin and 
its receptor [29, 30] and the gene Ferroportin-1 is responsible for neuronal iron export 
[31].  Dysregulation of genes involved in iron transport could lead to increased 
intracellular levels of iron, causing oxidative stress, inflammation, and microglial 
activation [28].  This highlights the importance of gene and environmental interactions 
and the complexity of disease triggers and genetic basis of disease mechanisms.  
 
1.4 Early mechanisms underlying aging-associated neurodegeneration 
1.4.1 Oxidative stress as a common denominator in aging-associated neurodegeneration 
One suggested theory of neurodegeneration is that aged neurons have increased 
levels of oxidative stress with negative impact on lipids, proteins, RNA, and DNA.  
Oxidative stress is caused by reactive oxygen species (ROS), metabolites of molecular 
oxygen that include lipid peroxide, hydrogen peroxide, and the superoxide anion [32].  
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The free radical theory of aging suggests that ROS are generated as a byproduct of 
metabolism and cause damage to cellular components that accumulate over time, 
resulting in aging and death [33].  The brain is particularly susceptible to oxidative stress 
because of its high levels of oxygen consumption [34], metabolic activity [35], and 
concentration of polyunsaturated fatty acids (PUFA) [36, 37].  Oxidative stress-induced 
damage to proteins, lipid membranes, and nucleic acids are observed in 
neurodegenerative diseases [38-40].  Protein oxidation leads to structural alterations and 
subsequent loss of enzymatic activity critical for neuronal function [41].  Membrane 
integrity is disrupted given the vulnerability of PUFAs to free radical attack since double 
bonds allow easy removal of hydrogen atoms by ROS [42].  Unrepaired DNA damage 
can result in an accumulation of DNA adducts in both nuclear and mitochondrial 
genomes and can inhibit binding of transcriptional and regulatory factors.  Lipofuscin is a 
fluorescent pigment composed of approximately 60-70% proteins, 16-27% oxidized 
lipids, and 1.0 – 1.7% metals [43] that accumulates with age in lysosomes of post-mitotic 
cells such as cardiac myocytes [44], retinal cells [45], and other neurons [44, 46].  The 
presence of lipofuscin is detected with age in neurons in numerous organisms including 
rodents [46], monkeys [47], and humans [48].  Lipofuscin cannot be degraded by 
lysosomal enzymes due to the presence of peptides cross-linked by aldehydes into 
plastic-like structures [49] that is of particular importance since lipofuscin can negatively 
impact cellular processes including protein degradation [45].  Collectively, oxidative 
damage can lead to abnormal functioning of neurons and apoptosis or necrosis.  
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1.4.2 Mitochondrial dysfunction in aging-associated neurodegeneration 
 The mitochondria are responsible for producing energy in the form of adenosine 
triphosphate (ATP) during oxidative phosphorylation but they are also the major source 
of ROS.  NADH is oxidized by complex I of the electron transport chain and the 
electrons are transferred to coenzyme Q while pumping protons across the mitochondrial 
membrane, creating a proton gradient [50].  Approximately 4-5% of the time, oxygen is 
capable of stealing electrons from the electron transport chain components to generate the 
superoxide radical [51].  The main sources of the superoxide radical are complexes I and 
III of the electron transport chain [52, 53].  Mitochondria are particularly vulnerable to 
ROS damage as the mitochondrial DNA is in close proximity to ROS production and 
does not contain histones or other DNA-associated proteins and thus is exposed directly 
to attack by ROS.  Mitochondrial DNA lacks introns [54] and has a low repair rate [55], 
resulting in a high probability of ROS damaging or modifying a coding region.  As a 
result of damage to mitochondrial components, there is a decrease in the amount of 
energy production and an increase in ROS production which can lead to apoptosis [56].  
Both decreased energy production and mitochondrial dysfunction have been detected in 
AD [57, 58], PD [59, 60], and ALS [61]. 
 
1.4.3 Inflammation in aging-associated neurodegeneration 
 Inflammation, which is due to the activation of the immune response, is generally 
protective in that it is an attempt by the organism to remove invading microorganisms as 
well as damaged and dying cells to initiate the healing process.  Inflammation in the 
central nervous system occurs through the activation of microglia.  Microglia are the 
  
6 
resident macrophages of the central nervous system [62], capable of scavenging infected 
[63], damaged [64], or apoptotic neurons [65].  Once microglia become activated, they 
express surface receptors including the major histocompatibility complex [66] and 
complement receptors [67].  These cells also undergo changes in morphology from a 
ramified shape to a mobile amoeboid shape [68].  Activated microglia can secrete 
complement proteins [69], cytokines [70, 71], chemokines [72], ROS [73], proteases [74, 
75], excitatory amino acids [76], and nitric oxide [77].  If the agent causing inflammation 
is not removed, then this can then lead to constant microglial activation and a chronic 
inflammatory state.  Activated microglia can be found in close proximity to amyloid  
deposits in AD [78] and amyloid  is known to stimulate the release of interleukin-1 (IL-
1) [72], interleukin-6 (IL-6) [79], tumour necrosis factor-  (TNF- ) [72, 80], 
macrophage inflammatory protein-1  (MIP-1 ) [72], monocyte chemoattractant protein-
1 (MCP-1) [79], nitric oxide [77], and superoxide radicals [81] from activated microglia.  
Activated microglia are detected in the substantia nigra of PD patients [82].  Similar to 
AD, activated microglia in PD release TNF-  [83], IL-1 , interferon-  (IFN- ) [84], 
inducible nitric oxide synthase (iNOS) [83], and cyclooxygenase-2 (COX-2) [85].  The 
release of inflammatory cytokines as well as factors released from dying neurons can 
amplify the inflammation and lead to further neuronal injury and death.  Microglial 
activation is found in the prefrontal cortex, motor cortex, thalamus, and the pons in 
patients with ALS [86].  Targeting the inflammatory response may be of therapeutic 
benefit since nonsteroidal anti-inflammatory drugs decrease the risk of AD [3], inhibition 
of iNOS provides neuroprotection in PD [87], and minocycline improves motor 
performance and survival in a mouse model of ALS [88]. 
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1.4.4 Gene expression in aging-associated neurodegeneration 
 The neurodegenerative disease process is complex and involves the interaction of 
many different pathways and genes.  Changes in the gene expression profile with 
neurodegenerative diseases can provide information about the onset and progression of 
the diseased state and lead to understanding of the disease pathology.  In AD, an up-
regulated immune response involving complement genes is detected in the entorhinal 
cortex, hippocampus, and midtemporal gyrus in the brain [89].  Elevated expression of 
chemokines and cytokines in AD [90] are capable of inducing iNOS activity [91].  
Cytokines are also able to activate microglia [92] and astrocytes [93], further propagating 
inflammation.  There is reduced expression of genes involved in energy metabolism 
leading to decreased mitochondrial function and ATP production in AD [94].  Also, there 
is a down-regulation in genes that code for cytoskeleton proteins [95] that can lead to 
dysfunction in cellular transport [96].  
Gene expression changes in PD include up-regulated genes involved in the 
immune and inflammatory response [97], indicating a role in the activation of glial cells 
in PD pathology.  In PD, there is an up-regulation of genes involved in apoptosis leading 
to increased cell death [98].  Genes involved in cytoskeleton maintenance are down-
regulated [98] that can affect cellular trafficking, cell-to-cell contact, and stability.  
Mitochondrial genes involved in proper function and energy synthesis are down-
regulated [97, 98] that could lead to impaired energy production.  There is a down-
regulation in an antioxidant enzyme [98], leading to decreased protection in the cell from 
ROS [99].  Genes involved in proteolytic machinery to degrade misfolded and damaged 
proteins are down-regulated [97, 98] that can lead to accumulation of aggregated proteins 
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and inhibition of proteasomal function [100].  Genes involved in synaptic function ( -
aminobutyric acid (GABA) transporter and receptors), are down-regulated [98] that 
disrupts signal transmission and communication between neurons.  Ion channels are also 
down-regulated [97, 98], leading to altered maintenance of the electrochemical gradients.  
Dysregulation of ion channels has been implicated in PD pathogenesis [101]. 
Gene expression changes in ALS diseased brains include an up-regulation of 
glutamate receptors [102, 103] that can lead to excitotoxicity [104].  There is down-
regulation of genes involved in zinc and iron homeostasis [102], suggesting a role of 
metal imbalance in ALS [105].  Down-regulation in proteasomal function is also detected 
in ALS [102, 103] and can lead to an increase in misfolded proteins [106].  Genes 
involved in the organization of the cytoskeleton are also down-regulated [102, 103] and 
can lead to disruption in axonal transport [107].  There is also a down-regulation of genes 
that inhibit apoptosis [102], thus promoting apoptosis [108, 109].  Genes involved in 
mitochondrial metabolism and energy production are down-regulated [102, 103] and can 
lead to impaired energy production.  Genes associated with neuroprotection, such as heat 
shock proteins and antioxidants are down-regulated [102, 110], indicating a lack of 
ability to deal with increased oxidative stress and inflammation.  Up-regulation of genes 
involved in inflammation cascades including the Interleukin-1 receptor accessory protein 
(IL-1RAP), the Chemokine (C-C motif) ligand 5 (CCL5), and Glial fibrilary acidic 
protein (GFAP) have been identified [111].  IL-1RAP is a transmembrane receptor 
complex that binds to IL-1 [112], which can lead to the downstream transduction of 
inflammatory effects of IL-1 [113].  The cytokine CCL5 is a proinflammatory 
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chemoattractant for glial cells [114] and GFAP, a marker of astrogliosis [115], indicates 
that glial cell activation is a pathological event in ALS. 
 
1.5 The use of mice in studying neurodegeneration 
 Studying neurodegeneration in humans is difficult to do, as scientists cannot control 
for diet, environment, or the genetics of human subjects, not to mention that acquiring 
access to neurodegenerative human brain tissue could be a lengthy process due to limited 
supplies from the declining rate of autopsies [116].  Also, precautions need to be taken 
when handling human tissue, as it may contain infectious agents such as the hepatitis 
virus, human immunodeficiency virus, and prions, all of which can be transmitted to 
other humans [117].  Model organisms of neurodegeneration are valuable tools allowing 
the study of the pathological mechanisms as well as new treatments in complex diseases.  
Drosophila melanogaster, Caenorhabditis elegans and Danio rerio have been used to 
study neurodegenerative disease mechanisms [118-120], but their simpler nervous 
systems limit the translation to human-specific neurodegenerative diseases.  Mice are 
commonly used in neurodegenerative research as a mammalian model of human disease 
due to similar genetic composition to humans with 99% of human genes having a mouse 
homolog [121].  Mice also have similar physiology to humans [122], are small in size, 
easy to handle and house, and have large litter sizes and short generation times.  Despite 
the obvious difference in size, all the major brain structures that are present in humans are 
also present in rodents.  However, one major difference is that in humans, the cortex 
contains a large area devoted to vision, while in rodents the visual area is smaller since 
they rely more on auditory and olfactory cues.  Despite these differences, gene expression 
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in the brain is similar between the two species [123].  Thus mice can be useful tools in 
studying neurodegeneration. 
 
1.6 Mice having aging-associated neurodegeneration 
 Mice show limited neuron loss with aging [124-126], but transgenic animal models 
have been created in order to mimic human neurodegenerative diseases.  Although no 
transgenic model is able to replicate exactly all features of a particular neurodegenerative 
disease, mouse models can nonetheless display the different disease pathologies.  The 
triple transgenic mouse (3xTg) for AD, (3xTg-AD), is the only AD mouse that displays 
both amyloid  plaques and neurofibrillary tangles [127].  At 6 months of age, the 3xTg-
AD mouse has a 14.8 fold up-regulation of the pro-inflammatory cytokine, TNF- , and a 
10.8 fold up-regulation of the pro-inflammatory chemokine, MCP-1, as well as activated 
microglia in the entorhinal cortex [128].  The 3xTg-AD mouse also shows elevated 
oxidative stress, a 20% reduction in hippocampal mitochondrial DNA, and decreased 
complex IV and V of the electron transport chain [129].  Another 3xTg-AD mouse model 
shows decreased activity of complex I and IV in the mitochondrial electron transport 
chain, decreased membrane potential, and increased ROS [130]. 
 A PD mouse model that overexpresses -synuclein leads to microglial activation, 
increased TNF- , IL-1 , COX2, NOX2, iNOS, and increased ROS production [131].  -
Synuclein localizes to complex I in neuronal cells [132] and it has been documented in 
vitro and in vivo that overexpression of -synuclein inhibits complex I and increases 
ROS production [133, 134]. 
 A mouse model of ALS that contains a mutated Superoxide dismutase-1 (mSOD1) 
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gene with a glycine to alanine substitution at codon 93 (G93A), has swollen 
mitochondria, decreases in activity of complex IV of the electron transport chain, and 
elevated levels of ROS [99].  In cell cultures, extracellular mSOD1-G93A is capable of 
activating microglia [135] but activated microglia containing the mSOD1-G93A are more 
neurotoxic than activated wild type (WT) microglia [136], likely through the elevated 
production of superoxide anions, nitric oxide, and peroxynitrite radicals [99].  In fact, 
replacement of microglia in mSOD1-G93A transgenic mice with microglia expressing 
WT SOD1 slows disease progression and increases survival [137], indicating microglial 
activation as a source of neuroinflammation in mSOD1-G93A mice. 
 
1.7 Altered mouse behaviour with neurodegeneration 
In humans, neurodegenerative diseases are characterized by cognitive decline and 
motor deficits including slower gait and decreased stride length that can be detected in 
individuals prior to confirmation with post-mortem analysis [138-141].  Behavioural 
differences can also be detected in mouse models of neurodegeneration.  The 3xTg-AD 
mouse has similar locomotor activity as non-transgenic WT controls prior to disease 
onset and has decreased activity at 15 months of age, but with no impairment in balance 
[142].  A different mouse model of AD, expressing human P301S tau protein, 
demonstrates elevated locomotor activity but decreased motor co-ordination compared to 
non-transgenic WT controls [143].  Mouse models of PD caused by administration of the 
neurotoxin 1-methyl 4-phenyl 1-,2-, 3-, 6-tetrahydropyridine (MPTP), depleting the brain 
of dopamine, display motor deficits [144, 145].  The major changes include a decrease in 
stride length and duration that leads to an increase in frequency of steps, indicating that 
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MPTP-treated mice are taking more steps in a shorter period of time when compared to 
controls [145].  A different mouse model of PD, which overexpresses a mutated version 
of the human -Synuclein gene, displays decreased locomotion, with impaired motor co-
ordination and balance [146].  The ALS mouse model containing a G93A substitution in 
the SOD1 gene shows gait disturbances with an increase of time spent in the propulsion 
portion of the stride, an increase in stride time, a decrease in stride frequency, and a 
decrease in walking velocity [147].  Thus, mouse models of neurodegeneration exhibit 
phenotypes consistent with affected humans suggesting that they are useful tools in the 
study of neurodegenerative diseases through the monitoring of early biological markers 
of altered animal behaviour.  Early markers widen the window of opportunity for 
treatment to delay or prevent the occurrence of severe disease symptoms.  
 
1.8 Human cerebellar ataxias are a model of neurodegeneration 
 Human cerebellar ataxias have a strong behavioural component and the genetics 
behind the most common cerebellar ataxias in humans are well known.  The most 
common autosomal recessive cerebellar ataxia is Friedreich’s ataxia due to a GAA triplet 
repeat expansion in the Frataxin gene [148].  Ataxia telangiectasia is the second most 
common autosomal recessive cerebellar ataxia due to a mutation in the Ataxia 
telangiectasia mutated gene [149].  There are also autosomal dominant cerebellar ataxias 
that are caused by the trinucleotide CAG repeat expansion leading to spinocerebellar 
ataxia [150].  Cerebellar ataxias have early onset of disease [151, 152] and known genetic 
etiologies making these diseases very specific examples of neurodegeneration.  To 
understand general mechanisms of aging-associated neurodegenerative disorders, genetic 
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models of cerebellar degeneration with predominant neurodegenerative phenotypes are 
needed. 
 
1.9 The cerebellum as a model for studying neurodegenerative diseases 
 The brain is a complex tissue to study as it consists of different anatomically and 
histologically distinct areas with different neuronal and non-neuronal cell types [153].  
Also, neurodegeneration tends to occur in distinct regions of the brain such as the 
cerebral cortex and hippocampus in AD, substantia nigra in PD, and in upper and lower 
motor neurons in the motor cortex, brain stem, and spinal cord in ALS.  Thus, in order to 
study pathological changes in the brain, it would be better to focus on a specific area with 
a certain cell type rather than a whole brain region.  
The cerebellum is an ideal brain area of study since the majority of neurons are 
located in the cerebellum [154].  Also, the cerebellum shows degenerative changes in 
humans with neurodegenerative disorders such as AD, PD, and ALS.   Atrophy of the 
neuronal layers, decreased neuronal density, decreased synapses, and amyloid  
accumulations are observed in the cerebella of patients with AD [155-159].  Atrophy of 
the posterior cerebellum is also associated with poorer cognitive performance in 
individuals with AD [160].  In PD, there is a reduction in the amount of cerebellar 
inhibition leading to the generation of postural tremor [161].  Changes in the cerebella 
have been reported in ALS, including loss of Purkinje cells and basophilic inclusions, 
which are a pathologic feature in ALS [162].  Also, uncoordinated movement is a 
common feature in neurodegenerative diseases [163-165] and the cerebellum plays a role 
in motor control [166]. 
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1.10 The function and organization of the cerebellum 
The cerebellum is involved in motor control but specifically co-ordination and 
fine-tuning of movements.  Electrical stimulation of the cerebellum does not cause 
sensation or produce motor movements, yet the cerebellum is vital for movements that 
require co-ordination of different muscle groups like running and playing the piano.  The 
role of the cerebellum in movement was first discovered after World War I, where 
individuals with lesions in the cerebellum lost the ability to move properly [167].  Their 
movements were ataxic and they had problems with muscle weakness, posture, and 
balance without signs of paralysis [167, 168].  The cerebellum receives sensory 
information from voluntary muscle movements, compares those movements with what 
was intended by the motor cortex, and is able to make corrective adjustments during 
execution [169-171].   
In order to understand the function of the cerebellum, knowledge of the structure 
and organization of the cerebellar circuitry is needed.  The cerebellum is located at the 
base of the brainstem and can be divided medio-laterally and anterior-posteriorly (Figure 
1.1a).  Medio-laterally the cerebellum can be divided into the vermis and two lateral 
hemispheres [172].  In the anterior-posterior direction, two fissures divide the vermis 
cerebellum into three major lobes.  The primary fissure separates the anterior and 
posterior lobes, and the posterolateral fissure separates the flocculonodular lobe from the  
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Figure 1.1 – A dorsal view of the mouse brain.  A) The location of the cerebellum in 
relation to other structures of the mouse brain. The cerebellum is divided medio-laterally 
into the vermis and the hemispheres.  The image of the whole mouse brain was taken by 
Eric Diehl. B) A schematic diagram of the unrolled cerebellum from anterior to posterior.  
The fissures separate the cerebellum into different lobes. 
Figure 1.1 - A dorsal view of the mouse brain 
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posterior lobe [172] (Figure 1.1b).  Due to the fact that the cerebellum contains the 
majority of neurons in the brain in such a small space [173-175], the cerebellum is 
intricately folded and the lobes can be further divided into ten lobules numbered with 
Roman numerals I–X [172] (Figure 1.2a).  Gene expression patterns however, suggest 
that there are four different zones including the anterior zone (AZ: lobules, I-V), the 
central zone (CZ: lobules VI, VII), the posterior zone (PZ: lobules VIII, IX), and the 
nodular zone (NZ: lobule X) [176]. 
The cerebellum consists of four distinct layers (Figure 1.2b).  The molecular layer 
contains scattered stellate and basket neurons that are inhibitory in nature.  The next layer 
is the single cell layer of Purkinje cells.  Underneath the Purkinje cell layer is the granule 
layer, which consists of densely packed granule cells and scattered Golgi cells with a 
granule cell to Golgi cell ratio of 414:1 [177].  And lastly, the white matter layer contains 
myelinated afferent (input) and efferent (output) fibers as well as the deep cerebellar 
nuclei.  The afferents to the cerebellum are climbing fibers and mossy fibers (Figure 1.3).  
The climbing fibers originate from the inferior olive in the medulla oblongata in the 
brainstem and synapse on the deep cerebellar nuclei as well as on Purkinje cells in the 
cerebellar cortex.  Mossy fibers on the other hand originate from various regions 
including the spinal cord and the precerebellar nuclei in the hindbrain [178], and synapse 
on the deep cerebellar nuclei [179] and granule cells [180].  Both climbing and mossy 
fibers are excitatory.  Climbing fibers release aspartate [181] and glutamate [182], and 
mossy fibers release glutamate [183] and acetylcholine [184, 185]. The axons of granule 
cells, also called parallel fibers, synapse onto the dendrites of Purkinje, basket, stellate, 
and Golgi cells and are able to induce excitation. 
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Figure 1.2 – The structure and organization of the mouse cerebellum.  A) An image 
of a sagittally sectioned mouse cerebellum stained with hematoxylin and eosin showing 
the organization of the lobules labeled with Roman numerals I-X [172].  B) Histology of 
the four different layers in the mouse cerebellum.  The cryopreserved cerebellum was 
sagittally sectioned to a thickness of 10 µm and stained with hematoxylin and eosin.  
Arrows are pointing to the different layers of the cerebellum.  The molecular layer 
contains stellate and basket neurons.  The Purkinje cell layer is a single cell layer 
comprised of Purkinje cells.  The granule layer contains granule cells and Golgi cells.  
The layer of white matter contains both afferent (input) and efferent (output) fibers of the 
cerebellum. Scale bars: A = 1 mm, B = 100 µm 
 
Figure 1.2 - The structure and organization of the mouse cerebellum 
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Figure 1.3 - A schematic diagram of the circuitry of the cerebellum.  Input into the 
cerebellum in the form of mossy and climbing fibers originates in the precerebellar nuclei 
and the inferior olive respectively.  Mossy fibers synapse onto granule cells and the deep 
cerebellar nuclei and climbing fibers synapse onto Purkinje cells and the deep cerebellar 
nuclei.  Purkinje cells are the point of convergence of multiple signals from climbing 
fibers, granule cells, basket cells, and stellate cells. Purkinje cell output can be inhibited 
by basket and stellate cells and excited by granule cells.  Purkinje cells then send 
inhibitory signals to the deep cerebellar nuclei in the white matter.  Golgi cells can inhibit 
granule cell output.  Mossy fibers, climbing fibers, and granule cells induce excitation, all 
other neurons in the cerebellum induce inhibition. 
Figure 1.3 - A schematic diagram of the circuitry of the cerebellum 
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 Basket cells and stellate cells inhibit Purkinje cells, and Golgi cells inhibit the mossy 
fiber-granule cell synapse [180].  Purkinje cells are the point of convergence of separate 
incoming signals and are the sole efferents of the cerebellar cortex, which is inhibitory in 
nature.  The axons of Purkinje cells synapse onto the deep cerebellar nuclei in the white 
matter of the cerebellum [186], as well as the vestibular nuclei located in the medulla 
[187].  The efferent fibers of the deep cerebellar nuclei send excitatory signals to the 
thalamus and various regions in the brainstem including red nucleus, the vestibular 
nuclei, and the inferior olive [188, 189] (Figure 1.4).  The thalamus receives input from 
the cerebellum and the basal ganglia, and projects the input to the motor cortex [190, 
191].  The brainstem sends output to muscles [192] and the motor cortex [193, 194] and 
the motor cortex relays the information to the brainstem.  Mossy and climbing fibers of 
the precerebellar nuclei and inferior olive synapse on granule cells and Purkinje cells 
respectively, but also on deep cerebellar nuclei in the cerebellum, thus forming the 
cerebrocerebellar communication loop. 
1.11 Age-associated changes in the cerebellum 
The human cerebellum shows a number of age-associated changes including the 
reduction of cerebellar mass, loss of white matter volume, reduction of the volume of the 
perikaryon, and loss of Purkinje and granule cells [195].  A previous study determined 
that there is a 27% reduction of myelinated fibers with age in the cerebrum [196], which 
could potentially be the origin of the decrease in white matter in the cerebellum.  Gene 
expression analysis of the aging cerebellum in mice shows alterations in lipid 
biosynthesis [197], possibly leading to defective myelin synthesis and signal 
transduction.  Aged mice also have a reduced number of Purkinje cells [124, 198, 199],
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Figure 1.4 – A schematic diagram of the involvement of the cerebellum in co-
coordinated movement.  To initiate movement, the motor cortex sends signals to the 
muscles and the cerebellum.  The cerebellum receives input from the motor cortex and 
the muscles, compares the two signals and modifies the signal back to the motor cortex 
and muscles via the thalamus, brainstem, and spinal cord.  
Figure 1.4 - A schematic diagram of the involvement of the cerebellum in 
coordinated movement 
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basket cells, and stellate cells [124].  Decreased Purkinje cell numbers are detected at 18 
months of age in C57Bl/6J [198] and CBA [199] inbred mouse strains.  In addition, genes 
involved in cellular immune and inflammatory responses are up-regulated in the 
cerebellum with age in seven different inbred mouse strains (129sv, BALB/c, CBA, 
DBA, C57BL, C3H and B6C3F1) [200].  Other studies have shown increases in genes 
associated with apoptosis and mitochondrial dysfunction and decreases in neurotrophic 
factors [201, 202].  All of these responses have been implicated in normal human brain 
aging [203]. 
 
1.12 Similarities and differences in the human and mouse cerebellum 
The most obvious difference between the human and mouse cerebellum is size.  
The average surface area of the human cerebellum is 1,128 cm
2
 compared to the mouse 
cerebellum at 190 mm
2 
[204].  The larger surface area in the human cerebellum increases 
the complexity of the convolutions in the cerebellum, but the major cerebellar lobules can 
be identified in humans and mice.  Due to evolution from a common ancestor, the 
cerebellum is present in all vertebrate brains [205].  Despite the similar structures and 
organization of the cerebellum, the functional topography of the cerebellum, on the other 
hand, is complex and assumptions cannot be made regarding the functionality of the same 
lobule in different species as determined through electrophysiological mapping [206].  
Humans have four deep cerebellar nuclei (dentate, emboliform, globose, fastigial), and 
mice have three (dentate, interpositus, fastigial), but the neurons in the cerebellum and 
their connections are the same in humans and mice.  Overall, the similarities in the 
cerebellar structure, organization, function, and aging in the human and mouse 
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cerebellum make mouse models an acceptable choice for the examination of cerebellar 
disease mechanisms. 
 
1.13 Mouse models of cerebellar degeneration 
Several mouse models of cerebellar degeneration have been characterized.  
Leaner mice are the result of a recessive mutation for a component of the voltage-gated 
calcium channel, mimicking spinocerebellar ataxia type 6 [207].  Granule cell death is 
detected at postnatal day 10 with the most dramatic loss occurring between postnatal day 
15 and 40 in leaner mice [208].  Purkinje cell loss is minor until postnatal day 26 then 
degeneration accelerates for the next 4 to 6 weeks in leaner mice [208].  The 
heterozygous lurcher mouse contains a mutation in the Glutamate receptor delta-2 
subunit gene [209], causing large scale degeneration of the cerebellar Purkinje and 
granule cells starting at postnatal day 8 [210], with almost no Purkinje cells and few 
granule cells remaining at postnatal day 90 [211].  The staggerer mutant mouse has a 
deletion of the Rora gene which codes for a retinoid-like nuclear receptor involved in 
neuronal differentiation and maturation and is expressed in high levels in the cerebellar 
Purkinje cells [212].  In staggerer mice, Purkinje cells are reduced in number prior to 
postnatal day 5 and only 25% of Purkinje cells are left at the end of the first postnatal 
month [213].  Granule cells are nearly all degenerated by the end of the first postnatal 
month [214], but this is secondary to the Purkinje cell degeneration [215].  Reeler mice 
have a mutation in the Reln gene, which encodes the protein REELIN, an extracellular 
matrix protein involved in neural adhesion and migration during development [216].  The 
mutation in Reln leads to disorganization of cells in the cerebellum [217], inferior olive 
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[218], cochlear nucleus [219], dopaminergic neurons [220], and hippocampus [221].  
Approximately 50% of Purkinje cells degenerate in reeler mice [222].  The weaver 
mouse contains a mutation in the G-protein-gated potassium channel 2 (Grik2) gene that 
codes for a rectifying potassium channel [223] resulting in loss of almost all granule cells 
[224] and 28% of Purkinje cells are lost by 3 months of age [225].  The loss of granule 
cells occurs just shortly after birth, prior to migration into the internal granule cell layer 
[224].  In addition, these mouse models of cerebellar degeneration leaner, lurcher, reeler, 
staggerer, and weaver display ataxia or disturbances in gait [226-231].  However, it is 
important to note that these mouse models of cerebellar degeneration all display loss of 
Purkinje and granule cells with early disease onset in the postnatal period, which does not 
make them ideal mouse models in testing anti-aging strategies.  An ideal mouse model 
would be symptom-free at young ages, and have a late onset of cerebellar degeneration 
that allows for a wide treatment window. 
 
1.14 The harlequin mouse as a model of oxidative stress and cerebellar 
neurodegeneration 
 The harlequin (hq, X
hq
Y) mouse is a model of mitochondrial dysfunction leading 
to elevated oxidative stress and retinal and cerebellar neurodegeneration [232-234].  The 
hq mouse contains a proviral insertion in the first intron of the X-linked Apoptosis-
inducing factor (Aif) gene, also known as Programmed cell death 8 (Pdcd8) [232].  The 
proviral insertion results in aberrant splicing and a reduction in Aif expression in all 
tissues examined including the cerebrum, cerebellum, retina, heart, kidney, muscle, lung, 
spinal cord, stomach and liver [232, 233, 235].  Under normal conditions, AIF is located 
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in the inner [236] and outer [237] mitochondrial membrane, but AIF induces apoptosis 
when translocated to the nucleus inducing chromatin condensation and large scale DNA 
fragmentation [238].   
Despite the fact that hq mice arose due to a single gene mutation, the phenotype 
of the hq mouse is quite complex and can be used to model changes in behaviour, 
oxidative stress, and mitochondrial dysfunction.  Aif has sequence similarity to bacterial 
oxidoreductases [238] and thus may be able to convert hydrogen peroxide to water, with 
AIF deficiency leading to an increase in ROS production and oxidative stress [232].   
Neurons and cardiomyocytes from hq mice are sensitive to hydrogen peroxide induced 
cell death [232, 235], and heart tissue when examined for increased oxidative stress has 
elevated levels of the superoxide radical [239].  Elevated levels of superoxide radicals are 
also detected in the skin of hq mice, which are also accompanied by a 1.7-fold increase in 
mutation frequency [240].  Using the human placental alkaline phosphatase (PLAP) 
assay, capable of detecting a single guanine deletion, the mutant frequency in the brain of 
hq mice is 3-fold higher when compared to WT mice [241].  This elevation in brain 
mutant frequency does not change with age and is not seen in the kidney, heart, and liver 
in hq mice [241].  This elevated mutant and mutation frequency in hq mice contrasts to 
previous studies where spontaneous mutation frequency in C57Bl/6J mice is similar 
regardless of tissue type from 3 to 10 months of age [242, 243].  Increases in mutation 
frequency from 10 to 25 months of age are reported in liver and adipose tissue, while the 
mutation frequencies in brain and male germ-line remain low throughout development 
and into old age in C57Bl/6J mice [242-244].  In hq mice, the olfactory epithelium has 
increased lipofuscin autofluorescence and increased oxidative damage to RNA and 
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mitochondrial DNA as well as increased apoptotic cells [245].  The sensitivity displayed 
by neurons, cardiomyocytes, skin, and olfactory epithelium to oxidative stress and 
increased markers of oxidative stress in tissues from hq mice and AIF-knockout mice 
suggests a role of AIF as an antioxidant enzyme [232, 239-241, 246, 247].  
AIF plays an undefined role in oxidative phosphorylation (OXPHOS), perhaps 
related to correct assembly and/or maintenance of the respiratory chain complex I [248].  
Decreased activity of complex I and III of the electron transport chain are detected in the 
brain and retinal tissue but not in the muscle or kidney from hq mice [248].  AIF-
knockout embryonic stem cells or AIF knockdown cell lines are associated with 
decreased complex I proteins [248-250].  A targeted deletion of the Aif gene in striated 
muscle leads to increased mitochondrial dysfunction, dilated cardiomyopathy, atrophy of 
skeletal muscle, and death at 4 months of age [246].  Complete Aif-knockout is lethal in 
mouse embryos with death occurring at embryonic day 11 [251].  Human patients with 
mitochondrial disorders also have similar defects in oxidative phosphorylation in a tissue-
specific manner [252, 253]. Two related individuals, with a trinucleotide deletion in exon 
5 of the Aif gene, were identified recently [254].  Both individuals presented with 
developmental delay, hypotonia, an absence of reflexes, muscle atrophy, and reduced 
activity of the electron transport chain complexes III and IV [254].  Altogether these 
results suggest a role of AIF in mitochondrial electron transport chain assembly or 
maintenance.  
 In the olfactory epithelial tissue, global analysis of gene expression in hq mice has 
only been examined at 6 months of age.  Altered genes were classified into categories of 
cell signaling/apoptosis, oxidative stress/aging, cytoskeleton/extracellular matrix 
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transport, and neurogenesis [245].  The Programmed cell death 6 (Pdcd6) gene is up-
regulated in hq mice, and is induced by endoplasmic reticulum stress, and mediates a cell 
death pathway [255].  Pdcd6 also accelerates apoptosis mediated by caspase-3 [256].  
Another gene induced by endoplasmic reticulum stress, Dnaj homolog, subfamily C, 
member 10 (Dnajc10), is up-regulated in hq mice.  Dnajc10 is required for the correct 
folding of proteins in the endoplasmic reticulum [257].  Up-regulated genes involved in 
the endoplasmic reticulum stress response could be due to misfolded proteins that can be 
induced by oxidative stress [258].  Genes involved in DNA repair, are also up-regulated 
in the olfactory epithelial tissue in hq mice [245].  The expression of the Damage-specific 
DNA binding protein-1 gene, a component of nucleotide excision repair [259], and the 
Werner syndrome gene, a DNA repair gene [260], are elevated consistent with oxidative 
DNA damage.  The Chemokine (C-X-C motif) ligand-12 (Cxcl12) gene is up-regulated in 
the olfactory epithelium and attracts immune cells to a site of injury or infection [261] 
and could lead to immune system activation and inflammation.  In fact, a previous study 
shows an increase in macrophage recruitment in the olfactory epithelium following large-
scale apoptosis [262].  Down-regulated genes in the olfactory epithelium in hq mice are 
involved in cytoskeleton organization, which includes Protein tyrosine kinase-2 [245].  
Protein tyrosine kinase-2 is involved in the disassembly of focal adhesions [263] and 
may lead to increased cell migration or limit the proliferation of progenitor cells.  The 
Cyclin D2 gene is down-regulated in the olfactory epithelium in hq mice and is required 
for adult neurogenesis [264] that occurs in the olfactory epithelium [265, 266].  The Bone 
morphogenetic protein receptor type-1 A gene is also down-regulated and promotes 
neurogenesis in the olfactory epithelium [267].  The transcriptome of the olfactory 
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epithelium is consistent with increased oxidative stress, apoptosis, and decreased 
neurogenesis.  
 
1.15 Disease progression timeline in hq mice 
As a result of Aif down-regulation, hq mice can be distinguished from WT mice at 
birth due to decreased body mass that persists into adulthood, as well as patchy or no hair 
growth, and minimal accumulation of intraperitoneal fat stores [233].  Deficits in retinal 
function and loss of cells from multiple retinal layers are evident by four months of age 
[232].  Ataxia onset, an unsteady gait, and lateral tremor are observed at five months of 
age [268].  At six months of age, hq mice have increased levels of oxidative stress and 
apoptosis in the olfactory epithelium [245].  By seven months of age, necrotic Purkinje 
cells are evident and there is a significant decrease in the size of the cerebellum [232].  
Complete vision loss is reported for 10-month-old hq mice [232, 269].  The hq phenotype 
demonstrates the effects of mitochondrial dysfunction and neurodegeneration. 
 
1.16 The hq mouse is not specifically a model of Alzheimer’s Disease, Parkinson’s 
Disease, or Amyotrophic Lateral Sclerosis 
The most obvious difference between neurodegeneration in hq mice and 
neurodegeneration in AD, PD, and ALS is the location of neurodegeneration.  In hq mice 
neuron loss is limited to the retina and the cerebellum whereas in AD, PD, and ALS 
neuron loss occurs in the neocortex, limbic system, basal ganglia, or spinal cord.  
Individuals with AD lose neurons in the entorhinal cortex [10], hippocampus [270], 
motor cortex, and sensory cortex [271].  Individuals with PD lose dopaminergic neurons 
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in the substantia nigra [272] and those with ALS lose upper and lower motor neurons in 
the frontal cortex and spinal cord [273, 274].  The pathological features in AD, PD, and 
ALS are also different compared to those seen in hq mice.  In individuals with AD, the 
brain contains amyloid  plaques and neurofibrillary tangles comprised of 
hyperphosphorylated tau protein [275].  In PD, the brain contains Lewy bodies [276], and 
in ALS diseased brains, the motor neurons contain Lewy body-like inclusions [277], 
skein-like inclusions [278], and Bunina bodies [279].  Hyperphosphorylated tau protein is 
not elevated in hq mice compared to WT mice [280], but levels of amyloid  plaques, 
Lewy bodies, Lewy body-like inclusions, skein-like inclusions, and Bunina bodies have 
not been studied in hq mice.  Although cerebellar degeneration of hq mice does not 
strictly resemble neurodegeneration in AD, PD, and ALS, neurodegeneration in hq mice 
does share common mechanisms with AD, PD, and ALS.  These mechanisms include 
disturbances in movement, increased oxidative stress, mitochondrial dysfunction, 
inflammation, and a progressive loss of neurons with age.  Thus, hq mice share features 
that are in common with AD, PD, and ALS and can permit the examination of the 
neurodegenerative processes that are common to all.  
 
1.17 Hormesis as an anti-aging strategy 
Hormesis is a potential anti-aging strategy with a long history in lifespan 
extension and cancer prevention, but very little has been studied in the context of 
neurodegeneration.  In hormesis, low doses of a stressor stimulates resistance to that 
stressor and are beneficial to an organism [281].  Hormesis has been studied in a variety 
of different organisms with different stressors.  Seedlings of Vicia faba (fava beans) 
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exposed to low doses of lead in the soil grew taller [282].  The low doses of lead induced 
expression of heat shock proteins, as well as antioxidant enzymes to produce an enhanced 
defense against oxidative stress [282].  In Drosophila, low doses of ethanol increases the 
longevity in three different strains [283].  This increase in Drosophila lifespan could be 
due to elevated levels of sirtuin mRNA which is increased after ethanol feeding [284].  
Exposure of C. elegans to a low dose of juglone, a chemical that stimulates oxidative 
stress, increases survival by 23% when exposed to lethal doses of juglone and juglone 
produces cross-tolerance to a different oxidative stressor [285].  In another study using an 
oxidative stressor in C. elegans, pretreatment with high concentrations of oxygen 
increases survival from X-irradiation through increases in the expression of heat shock 
proteins [286], suggesting that a single stressor can induce resistance to different 
stressors.  Mallards (Anas platyrhynchos) that consume a diet with low concentrations of 
mercury exhibit enhanced hatching success and increased mean weights of six-day-old 
ducklings [287].  Caloric restriction increases the lifespan of animals by preventing 
diseases associated with age including cancer [288], diabetes [289], obesity [288, 289], 
and cardiovascular disease [289].  Gene expression in calorically restricted mice reveals 
decreased expression of genes involved in immunity, defence, and inflammation [200, 
202, 290, 291].  In a mouse model of retinitis pigmentosa, low-dose radiation delays 
retinal loss due to up-regulation of the peroxdoxin-2 gene, which is an antioxidant 
enzyme [292].  Voluntary exercise on the running wheel is not able to reduce amyloid  
and tau accumulation in 3xTg-AD mice but is able to reduce lipid peroxidation, as well 
as increase glutathione peroxidase to levels seen in control mice [293].  Long-term 
endurance exercise improves movement, balance, mitochondrial function, and prevents 
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loss of dopaminergic neurons in the substantia nigra in a mouse model of PD [294].  Two 
ppm of phenobarbital (PB) decreases the amount of liver cancer in rats treated with N-
diethylnitrosamine, a potent inducer of hepatocarcinoma [295].  Aside from studies of 
caloric restriction and exercise and their effects on lifespan extension and 
neurodegeneration, other hormetic agents have not yet been studied in a mouse model of 
neurodegeneration. 
 
1.18 Phenobarbital as a hormetic agent 
Phenobarbital is a barbiturate commonly used to treat epilepsy in humans.  
Phenobarbital binds the -aminobutyric acid (GABAA) receptor, allowing chloride ions to 
enter neurons causing hyperpolarization and suppression of neuronal activity [296-298] 
and locomotor activity [299].  Cases of increased physical activity are also observed with 
PB administration [299, 300].  Phenobarbital is known to target neurons in the cortex, 
hypothalamus, limbic system, caudate nucleus, cervical spinal cord, trigeminal ganglion, 
and the cerebellum [301].  Treatment of pregnant mice with high doses of PB leads to 
structural abnormalities in the cerebellum of the offspring, in particular to the 
mitochondria, myelin sheaths, and lamellar bodies of the granule cell layer [302].  
Phenobarbital is a known tumour promoter in rodents [303-306] but is considered to be a 
weak mutagen, since in the absence of liver microsomal enzymes, PB induces only a two-
fold increase in mutations in Salmonella typhimurium straim TA 1535 [307, 308] and is 
negative in strains TA98, TA100, TA1537, and TA1538 [309, 310].  However, in vivo 
studies using the Big Blue  mouse transgenic mutation detection assay, PB is not able to 
increase the frequency of mutations at a dose of 2500 ppm but is able to change the 
  
35 
mutation spectra of mutation types [305, 306].  Phenobarbital would be of use as a 
hormetic agent since at high doses, PB inhibits locomotor activity, causes structural 
damage to the cerebellum, changes mutation spectra, and is a known promoter of liver 
tumours in rodents [303-306], but at low doses PB increases locomotor activity [300] and 
prevents liver cancer in a rat model of hepatocarcinoma [295].  Low doses of PB in the 
range of 1 to 7.5 ppm reduced the number of preneoplastic lesions in rats injected with 
diethylnitrosamine [311].  The molecular mechanisms underlying the hormetic effects of 
different stressors have not been elucidated, but in the case of the rat model of 
hepatocarcinoma, 2 ppm of PB decreases the amount of 8-hydroxy-2'-deoxyguanosine (8-
OHdG), a marker of oxidative DNA damage, through the up-regulation the of 8-OHdG 
repair enzyme Oxoguanine glycosylase-1 [295].  Phenobarbital also suppresses cellular 
proliferation and apoptosis in the liver through decreased expression of Mitogen activated 
protein kinase p38 as well as other kinases [295].   
Hormesis has thus demonstrated success as an anti-aging and anti-carcinogenesis 
strategy and PB has demonstrated success in vivo with anti-carcinogenesis.  If the 
mechanisms by which PB is able to reduce hepatocarcinoma are similar to the 
mechanisms demonstrated in exercise and caloric restriction in anti-aging, then PB 
should be successful as an anti-aging strategy in the hq mouse, a model of 
neurodegeneration.  We know that 2 ppm of PB reduces ROS-induced DNA damage and 
increases DNA repair [295], while the hq mouse has elevated ROS-induced mutations 
[241], and neurodegenerative diseases have elevated DNA damage in nuclear and 
mitochondrial DNA [40].  Neuronal cells have reduced base-excision repair [203] and 
DNA repair was decreased in fibroblast and lymphoblastoid cell lines from individuals 
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with neurodegenerative diseases [312, 313].  Since both cancer and neurodegeneration 
display increased ROS, DNA damage, and decreased DNA repair, then it could be 
hypothesized that PB would prevent neurodegeneration even though PB hormesis has not 
been demonstrated in an anti-aging capacity.  
 
1.19 Phenobarbital metabolism in mice 
Phenobarbital is metabolized and inactivated in the liver.  The metabolism of PB 
occurs in two phases.  In the first phase, PB undergoes hydroxylation by the cytochrome 
P450 monooxygenases, producing p-hydroxyphenobarbital [314, 315].  In the second 
phase, PB and p-hydroxyphenobarbital can be conjugated with glucuronic acid (N-
glycoslyation) by the mircosomal enzyme glucuronyl transferase to produce PB N-
glucuronides and p-hydroxyphenobarbital O-glucuronides respectively [316-318].  In 
addition, PB can be conjugated with glucose (N-glucosylation) by the enzyme glucosyl 
transferase to produce PB N-glucosides [319-321].  Once PB is hydroxylated or 
conjugated it is considered inactivated [319, 322].  Phenobarbital enters the brain through 
passive diffusion [323] and is eliminated from the kidney through urine, from the liver 
through bile, and from the gastrointestinal tract through feces [314].  Urine analysis in 
mice shows that most of the PB is eliminated as p-hydroxyphenobarbital followed by 
unmetabolized PB, and finally PB N-glucuronides and PB N-glucosides [317].  The half-
life of PB in mice is 11.5 hours [324].  PB eliminated via the bile can be reabsorbed in 
the intestine or eliminated in feces [314, 325, 326].  
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1.20 Biomarkers for the assessment of an anti-aging strategy  
Behavioural assays can be used as markers to assess cerebellar dysfunction.  
Using rotarod, a rotating cylinder suspended above the ground, hq mice display deficits 
in balance and coordination [280].  Locomotor assays have been used previously in 
mouse models prior to the onset of neurodegeneration [327-329].  However, a global 
assessment of nocturnal behaviour would provide insight into different parameters 
involved in movement and an automated home cage decreases the amount of time spent 
on manual observations while also decreasing observer bias [330].  Mouse models of 
cerebellar degeneration, despite having ataxia, display either higher or lower activity 
levels when compared to control mice.  The Lurcher mutant mouse has higher levels of 
activity compared to control mice [227, 331] and spends more time walking and covers 
more distance compared to WT mice [331].  The reeler mutant mouse has higher activity 
levels but a lower number of rearing events compared to WT control mice [332].  
However both weaver [333] and staggerer [334]  mutant mice are hypoactive and rear 
less compared to control mice.  Leaner mutant mice also have decreased motor activity 
[335].  An assessment of nocturnal behaviour would also determine whether low-dose 
administration of PB is able to target the brain and induce the expected effect of 
hyperactivity in WT and hq mice. 
Another neurodegenerative assessment marker is tissue pathology.  Tissue 
pathology can be identified using hematoxylin and eosin staining of tissue sections to 
examine tissue structure, architecture, thinning of the granule cell layer, and cell loss of 
the Purkinje cell layer.  Hematoxylin is a basic dye that binds acidic compounds of the 
nuclei a blue/purple, while eosin stains basic compounds in the cytoplasm a red/pink 
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[336].  Neuropathology has been assessed previously using hematoxylin and eosin [232, 
277], and will give a qualitative assessment of neuron loss.  A quantitative measurement 
of the number of degenerating neurons can be determined through the use of Fluoro-
Jade  B staining, a fluorochrome capable of staining apoptotic neurons resulting from 
exposure to a variety of different neurotoxic insults [337]. 
Another marker employed to assess neurodegeneration is the level of ROS in the 
cerebellum.  The effect of elevated ROS can be examined by measuring the damage to 
cellular components including lipids, proteins, and DNA.  Damage to lipids and proteins 
can be assayed by lipofuscin accumulation.  Lipofuscin is a fluorescent pigment 
composed of oxidized lipids, proteins, and metals [43, 338] that accumulate with age in 
post-mitotic neurons [46-48].  Lipofuscin accumulation is detected in mouse models of 
neurodegeneration [339, 340].  Mutation frequency and pattern can be assessed to see if 
ROS-associated DNA damage is replicated in the DNA as mutations leading to elevated 
mutation load in hq mice.  Mutations in the DNA can be determined through the use of 
transgenic mutation detection assays.  Using the human placental alkaline phosphatase 
(PLAP) assay, hq mice have a 3-fold elevation in mutant frequency in the brain and this 
is not seen in other tissues in hq or WT mice [241].  However, the PLAP assay is 
restricted to the detection of single base pair deletions, which is only one signature of 
oxidative stress.  Oxidative stress is associated with chromosome loss [341], DNA strand 
breaks [342], chromosome rearrangements [343], mitotic recombination [344], large 
[345] and small deletions [346], and the induction of point mutations with the most 
common being G:C to T:A transversions [347], although other base pair changes are 
implicated as well [345, 347].  In contrast to the PLAP assay, a forward mutation 
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detection assay such as the cII assay in Big Blue
®
 mice [348] offers analysis of mutation 
load using multiple susceptible DNA sequence contexts.  
The production of ROS in the form of superoxide anions may be detected using 
dihydroethidium (DHE), a dye that fluoresces when oxidized by superoxide anions into 
ethidium [349].  Ethidium is a DNA intercalating agent that fluoresces red when excited 
by ultraviolet light and is capable of detection with fluorescence microscopy [350].  
Levels of superoxide
 
anions in the brain have been assessed by DHE previously [351].   
Lastly, microarray technology is a powerful tool that provides researchers with 
the opportunity to analyze the level of mRNA of thousands of genes simultaneously 
[352].  Gene expression analyses in mouse models of neurodegeneration have implicated 
oxidative stress, mitochondrial dysfunction, and inflammatory response [353-357], as 
well as mitochondrial dysfunction leading to decreased energy metabolism [358].  The 
use of high-density microarrays can identify genome-wide changes in the levels of 
mRNA in the mouse cerebellum and can identify altered pathways early in the 
neurodegeneration process.  
 
1.21 Central hypothesis and Experimental Aims 
 Given that cancer and neurodegenerative diseases are associated with elevated 
DNA damage and decreased DNA repair and given that hormesis has demonstrated 
efficacy as an anti-carcinogenesis strategy in a mouse model of hepatocarcinoma, I 
hypothesize that chronic low doses of PB treatment in hq mice will delay cerebellar 
neurodegeneration.  
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  Given that cerebellar function is required for coordinated movement, I 
hypothesize that hq mice will have decreased nocturnal behaviours compared to WT 
mice.  In addition, given that PB administration increases activity in rodents, I 
hypothesize that PB administration will limit age-related decreases in nocturnal 
behaviours in hq mice through mechanisms that will reduce cerebellar degeneration.  
Three age groups will be tested, representing three stages in the progression of cerebellar 
degeneration in hq mice.  Three months of age represents early disease onset, 7 months of 
age represents mid-disease onset, and 10 months of age represents late-stage disease.  
Mice at 3 and 7 months of age will be administered 0, 2, or 4 ppm of PB in the drinking 
water ad libitum.  Nocturnal behaviours will be measured overnight.  I predict that hq 
mice will have cerebellar deficits leading to decreased nocturnal activity compared to WT 
mice and the nocturnal activity will decrease with age.  I also predict that PB will reverse 
age-related declines in nocturnal behaviours and that it will increase nocturnal activity in 
WT mice, given the evidence reported to date.   
Given that hq mice are undergoing cerebellar neurodegeneration, I hypothesize 
that there will be an increase in cell loss, apoptosis, lipofuscin accumulation, and 
superoxide anion levels compared to WT mice.  In addition, given that PB administration 
affects different anti-aging pathways, I hypothesize that hormetic PB administration will 
limit cell loss, apoptosis, lipofuscin accumulation, and superoxide anion levels.  
Hematoxylin and eosin histological assessments will be used to look at cerebellum size, 
structure, and evidence of cell loss in the granule and Purkinje cell layers.  In situ Fluoro-
Jade  B staining will be used to assess the number and location of neurons undergoing 
apoptosis.  The accumulation of damaged cellular components in the form of lipofuscin 
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will be assessed.  The amount of superoxide anions will be measured to determine 
whether increased ROS is associated with cerebellar neurodegeneration in hq mice.  I 
predict that hq mice will have smaller cerebella and increased cell loss of the granule and 
Purkinje cell layers over time.  In addition, I predict that biomarkers of 
neurodegeneration will be elevated in hq mice and will increase with age compared to 
WT mice.  Phenobarbital treatment is predicted to decrease the biomarkers of 
neurodegeneration. 
Given that hq mice had an elevated number of single nucleotide deletions in the 
whole brain compared to WT mice, I hypothesize there will be an increase in the 
spontaneous mutant and mutation frequency of the cII gene and a change in the mutation 
pattern in the cerebellum of hq mice when compared to WT mice.  The hq mice will be 
bred with Big Blue  transgenic mice to allow for mutation detection.  Spontaneous 
mutant and mutation frequency and pattern will be studied in 3- and 7-month-old WT and 
hq mice in the absence of PB administration.  I predict that hq mice will have an elevated 
mutant and mutation frequency when compared to WT mice.  In addition, the mutation 
pattern will be altered and contain signatures of oxidative stress in hq mice. 
Given that pathways involving oxidative stress, mitochondrial dysfunction, and 
inflammation have been detected in neurodegenerative disorders, I hypothesize that hq 
mice will have altered pathways involved in oxidative stress, mitochondrial dysfunction, 
and inflammation when compared to WT mice.  Also, given that PB administration may 
affect anti-cancer pathways, I hypothesize that PB administration will counteract 
oxidative stress, mitochondrial dysfunction, and inflammation in hq mice.  Gene 
expression in hq and WT mice will be assayed prior to onset of cerebellar degeneration at 
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3 months of age.  I predict that hq mice will have down-regulated gene expression in 
pathways involved in cellular repair and up-regulated genes involved antioxidant 
response, mitochondrial dysfunction, and inflammation when compared to WT mice and 
that PB administration will up-regulate genes involved in cellular repair or down-regulate 
genes involved in mitochondrial dysfunction and inflammation.  
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CHAPTER TWO – MATERIALS AND METHODS 
 
2.1 Animals 
2.1.1 General care 
Animal protocols were approved by The Animal Use Subcommittee of the 
University Council on Animal Care of The University of Western Ontario (Appendix A). 
All mice were housed two or three in a cage on a 12 h light/dark cycle at a constant 
temperature of 21 ± 1°C and relative humidity of 44 to 60%.  Mice were fed a standard 
diet (PMI Foods, St. Louis, MO) ad libitum.  All experimental mice were male and either 
wild type (WT) for the Aif gene or harlequin (hq; B6CBACa A
w-J
/A-Pdcd8
Hq
/J; Bar 
Harbor, Maine). 
 
2.1.2 Hormetic treatment 
Mice of both genotypes were given phenobarbital (PB) (Sigma-Aldrich, St. Louis, 
MO) in concentrations of 2 or 4 ppm administered in the drinking water provided ad 
libitum from 1 month of age until euthanized at 3 or 7 months of age.  Drinking water 
intake was measured everyday for a three-week period for a subset of mice at 7 months of 
age.  This was done to determine the amount of water consumed (mL/g/day) for each 
genotype and to confirm no PB taste aversion.  A two-factor Analysis of Variance 
(ANOVA) for genotype and treatment was performed on the amount of water consumed 
in WT and hq mice with and without PB treatment. 
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2.1.3 Breeding hq/Big Blue  transgenic mice for transgene mutation detection and 
increased inbred mouse background 
Four-month-old heterozygous female hq (X
hq
X) mice (B6CBACa A
w-J
/A-
Pdcd8
Hq
/J; The Jackson Laboratory, Bar Harbor, ME), were bred to 3-month-old male 
Big Blue
®
 mice (C57Bl/6) homozygous for the lambda phage cII transgene (Taconic 
Farms, Germantown, NY) in order to incorporate the cII mutation detection target in hq 
mice (Figure 2.1).  The first generation progeny were either WT (XY or XX) or had the 
hq mutation (X
hq
Y or X
hq
X) and all mice were hemizygous for the cII transgene (cII/0) 
and were brother and sister mated to generate additional mice with both the hq  
mutation and the cII transgene.  This mating strategy produced an increased number of 
mice having hydrocephaly and microphthalmia, due to the background of C57Bl/6J mice 
[359, 360].  As a result, both male and female progeny from the second generation were 
bred with inbred CBA/CaJ mice (The Jackson Laboratory, Bar Harbor, ME).  The 
inbreeding of hq mice to the CBA/CaJ background continued for a total of four 
generations.  Additional brother to sister matings were performed for three more 
generations to increase the number of male mice with the hq mutation and the 
(hemizygous or homozygous) presence of the cII transgene.  The zygosity of Big Blue
®
 
mice for the cII gene does not affect the spontaneous mutant or mutation frequencies 
[361].  Mice used in this study were male WT mice (XY) or hemizgyous hq mice (X
hq
Y) 
from generations four through nine (G4 – G9) with 75 to 94% CBA/CaJ inbred mouse 
background. 
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Figure 2.1 – The harlequin (hq) mouse breeding strategy.  Heterozygous hq female 
mice (X
hq
X; B6CBACa) were initially bred with Big Blue
®
 transgenic mice (C57Bl/6J) 
homozygous for the cII transgene.  The offspring were brother and sister mated (G1) to 
increase the number of hq mice with the cII transgene.  Mice from this generation were 
mated with CBA/CaJ inbred mice and this breeding strategy continued for four 
generations (G2 - G5) in order to decrease the genetic variability in the mice on a 
primarily CBA/CaJ background.  Additional brother and sister matings were performed 
to increase the number of hq male mice with the cII mutation target (G6 - G8). 
Figure 2.1 - The harlequin (hq) mouse breeding strategy 
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2.1.4 Genotyping of WT and hq mice 
 Animals were ear notched and tail clipped at 10 to 12 days of age and DNA was 
extracted using a small-scale genomic DNA extraction protocol.  Tail clippings were 
digested overnight at 55ºC in TENS buffer and Proteinase K (Invitrogen, Burlington, 
ON).  After digestion, the suspension was transferred to a 1.5 mL Phase Lock Gel™ tube 
(Qiagen, Mississauga, ON) with an equal volume of a 50:50 phenol:chloroform mix.  The 
suspension was centrifuged for 5 min at 14,000 rpm.  The aqueous layer was transferred 
to a clean 1.5 mL Eppendorf tube.  DNA was precipitated with 100% ethanol and 
centrifuged at 14,000 rpm for 10 min.  The supernatant was decanted and the pellet was 
allowed to air dry.  The pellet was dissolved in 30 l of TE buffer.  DNA was stored at 
4ºC until used for genotyping the cII and Aif gene. 
The presence of the cII sequence in Big Blue
®
 mice was detected using polymerase 
chain reaction (PCR) amplification.  A 476 bp sequence containing the cII gene was 
amplified using the primer set ASPCIIF 38248: 5’ CCG CTC TTA CAC ATT CCA GC 
3’ and JAKCIIR 38723:  5’ CCT CTG CCG AAG TTG AGT AT 3’ [362].  PCR was 
performed with the following conditions: 1.2 g of sample DNA, 0.32 mM dNTP, 1X 
PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl) 2 mM MgCl2, 0.08 µM of each 
primer, and 0.02 U/µl Taq DNA polymerase in a 30 µl reaction volume.  The reaction 
consisted of an initial denaturation at 94ºC for 5 min, followed by 35 cycles of template 
denaturation at 94°C for 20 sec, primer annealing at 53°C for 80 sec, primer extension at 
72ºC for 2 min, with a final primer elongation at 72°C for 10 min (GeneAmp PCR 
System 9600, Applied Biosystems, Foster City, CA).   
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The Aif genotype was determined by PCR amplification using a tri-primer protocol 
[232].  The forward, Aif 3468 5’ AGT GTC CAG TCA AAG TAC CGG G 3’ and 
reverse, Aif 4000 5’ CTA TGC CCT TCT CCA TGT AGT T 3’ primers were designed 
for exons one and two respectively of the Aif gene.  Another forward primer was 
designed from the long terminal repeat of the murine C-type ecotropic virus hqLTR2 5’ 
GAA CAA GGA AGT ACA GAG AGG C 3’located in intron one of the Aif gene in hq 
and carrier mice.  PCR was performed with the following conditions 1.2 g of sample 
DNA, 0.32 mM dNTP, 1X PCR buffer, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 3.5 mM 
MgCl2, 0.08 µM of each primer, and 0.02 U/µl Taq DNA polymerase in a 30 µl reaction 
volume.  Cycling conditions included an initial denaturation at 94ºC for 3 min, followed 
by 35 cycles of 94ºC for 30 sec, 62ºC for 1 min, 72ºC for 1 min, followed by 72ºC for 2 
min (GeneAmp PCR System 9600, Applied Biosystems, Foster City, CA).  
 
2.2 The experimental cohorts 
The experimental design consisted of 152 mice from G4 – G9, with 70 WT (XY) 
and 82 hq (X
hq
Y) mice (Figure 2.2).  The mice were further divided into three groups 
according to age; 3 months of age (WT n=29, hq n=35), 7 months of age (WT n=32, hq 
n=38) and 10 months of age (WT n=9, hq n=9).  Each genotype was administered 0, 2, 
and 4 ppm of PB in the drinking water provided ad libitum from 1 month of age until 
euthanized at 3 or 7 months of age.  The control cohorts of mice received untreated 
drinking water ad libitum.  Mice were euthanized according to the standard operating 
procedure (protocol# 320-02) at 3, 7, or 10 months of age by CO2 inhalation and mouse 
body mass was recorded. 
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Figure 2.2 – Experimental design used to assess cerebellar degeneration and a 
potential intervention strategy using phenobarbital (PB).  The experimental design 
included 152 male mice, 70 wild type (WT) and 82 harlequin (hq) mice.  The mice were 
further divided into three different age groups representing three different disease time 
points.  Mice at 3 months of age represent the early disease time point, mice at 7 months 
of age represent the mid-disease time point, and mice at 10 months of age represent the 
late stage of the disease time point.  In the 3 and 7 months of age cohorts, mice were 
treated with 0, 2, or 4 ppm of PB.  The untreated cohorts received drinking water ad 
libitum and the treated cohorts received 2 or 4 ppm of PB dissolved in the drinking water 
ad libitum.  Cerebellar function and response to PB were assessed by monitoring 
nocturnal cage behaviour.  Postmortem in situ histopathology assays were performed on 
the cerebellum to determine changes with disease progression.  Mutation detection with 
the cII transgene mutation detection assay was performed on the cerebellum to determine 
whether mutations were elevated and accumulated with age in the cerebellum of hq mice 
compared to age-matched WT mice.  Gene expression analysis was performed to 
determine early changes in gene expression associated with the hq genotype.
Figure 2.2 - Experimental design used to assess cerebellar degeneration and a potential intervention 
strategy using phenobarbital (PB). 
  
50 
 
  
51 
2.3 Behaviour testing of WT and hq mice 
Mouse behaviour was recorded using the ActiTrack
®
 apparatus and software 
(Panlab Harvard Apparatus, Barcelona, ES) in a mouse test cage that simulates the home 
cage environment.  Eleven different parameters of mouse movement were quantified 
using the ActiTrack
®
 system: activity, locomotion, stereotypes, distance, resting time, 
time spent moving slowly, time spent moving quickly, maximum velocity, mean velocity, 
number of rearings, and mean rearing duration, as they best characterized mouse 
behaviour (Table 2.1).  Each mouse was placed individually into a clear plastic test cage 
measuring 14.7 inches deep x 9.2 inches wide x 5.5 inches high (Innovive, San Diego, 
CA), which was similar in size to a home cage, with a thin layer of cedar shavings 
(Nepco, Warrensburg, NY).  Five to six food pellets were placed in one corner and water 
(containing 0, 2, or 4 ppm PB as per the animal treatment cohort study) was made 
available overhead ad libitum.  Mouse access to the water bottle does not register as a 
rearing event because the upper infrared beam that records movement in the z-axis is 
higher than the water bottle spout.  No nestlet material was provided to avoid interference 
with the infrared beams used to track mouse movement in the ActiTrack
®
 apparatus.  The 
test cage was assembled and the mouse placed into the testing arena at 1400 hours, 4 
hours before testing was started to allow familiarization with the new environment. The 
threshold values for velocity were set so resting was defined as any movement less than 2 
cm/s, moving slow as any movement between 2 cm/s and 5 cm/s, and moving fast was as 
any movement above 5 cm/s [363].  Rearings were measured when the mouse stood on 
its hind legs and blocked the infrared beams of the upper grid in the arena.  The upper  
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Table 2.1 Description of the behaviours measured in wild type and harlequin mice using the 
ActiTrack  apparatus 
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beam was adjusted according to the mouse body size, which was empirically determined, 
to ensure the mouse was able to trigger the upper beam.  Daylight and nocturnal 
behaviour were recorded at hourly intervals beginning at 1800 hours until 2000 hours and 
2000 hours to 0300 hours, respectively.  Behaviour was studied for two consecutive 
nights for each mouse and analyses were performed on overnight data for WT and hq 
mice at 3 months of age (n=9 WT and n=14 hq mice, no drug treatment; n=10 WT and hq 
mice, 2 ppm PB; n=10 WT and n=11 hq mice, 4 ppm PB), 7 months of age (n=9 WT and 
n=12 hq disease mice, no drug treatment; n=12, WT and hq mice, 2 ppm PB; n=11 WT 
and n=14 hq mice, 4 ppm PB), and 10 months of age (n=9, WT and hq mice, no drug 
treatment).   
 
2.3.1 Statistical analysis of WT and hq mouse behaviour 
A principal component analysis (PCA) with varimax rotation and Kaiser 
normalization was performed to identify interrelationships between nocturnal test cage 
behavior parameters.  Missing values were converted to group means for PCA. Factors 
with eigenvalues >1 were used for further analysis.  A three-factor (genotype, age and 
treatment) MANOVA (p<0.05) followed by Tukey’s test for post hoc analysis was used 
to compare the 11 parameters of behaviour measured by the Actitrack in WT and hq mice 
at 3, 7, and 10 months of age with three different concentrations of phenobarbital 0, 2, 
and 4 ppm in the drinking water.  One-factor ANOVA (p<0.05) was performed to further 
analyze significant interactions found with the three-factor MANOVA, or three-factor 
ANOVA.  All statistics were performed with Statistical Package for the Social Sciences 
(SPSS) Version 17.0 (IBM, Somers, NY).  
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2.4 In situ histological assays for neurodegeneration and testing ROS as an underlying 
hypothesized mechanism of disease 
2.4.1 Mouse tissue collection 
Mice were euthanized according to standard operating procedures (protocol# 320-
02) at 3, 7, and 10 months of age by CO2 inhalation and body mass was recorded.  The 
whole cerebellum was harvested and either flash frozen in liquid nitrogen for some mice 
for use in the cII assay or half of the cerebellum was placed into a cryomold containing 
optimal cutting temperature media (Somagen Diagnostics, Edmonton, Alberta) for 
cryosectioning and the other half of the cerebellum was flash frozen in liquid nitrogen for 
RNA isolation and stored at -80°C until further use.  All animals were healthy at the time 
of tissue harvest, with a healthy shiny fur coat with no visible wounds and were able to 
move and obtain food and water.  No gross tissue pathology was observed for any major 
organ. 
 
2.4.2 Cryosectioning of the mouse cerebellum  
 Half of the cerebellum of WT and hq mice was cryosectioned sagittally at a 10 
µm thickness, 200-450 µm distal to the midline using a Leica CM350 Cryostat (Leica 
Microsystems, Houston, TX), with two sections being placed per slide on a positively 
charged poly-L-lysine microscope slide (VWR, Mississauga, ON), and stored at -20˚C.  
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2.4.3 Hematoxylin and eosin tissue section staining to assay cerebellar histopathology 
including cell loss 
Hematoxylin and eosin staining was performed on frozen unfixed cerebellar 
tissue.  Slides were immersed in 70% ethanol and then stained with hematoxylin for 5 
min and rinsed with water until runoff was colourless.  Slides were dipped in 500 mL of 
70% ethanol containing 5 drops of 1N hydrochloric acid, immersed in tap water, and 
immersed in 1% lithium carbonate (BDH Laboratory Supplies, Poole, England).  Sections 
were counterstained with Eosin Y (Sigma-Aldrich, Oakville, ON) for 30 sec and 
dehydrated by rinsing in increasing concentrations of ethanol 50%, 70%, 95%, and 100%, 
followed by a wash in fresh 100% ethanol.  Slides were then submerged in xylene until 
coverslipped (VWR, Mississauga, ON) with Permount® Mounting Media (Ottawa, ON).  
Images of the cerebellum were captured at 20X magnification using the Arcturus 
Veritas  Microdissection System (Molecular Devices, Sunnyvale, CA) to assess the size 
and extent of the nature of gross abnormalities.  Further imaging was performed at 200X 
magnification to quantify the nuclear density.   Images at the base and apex of lobules 
I/II, III, VIa, IX and X were captured representing four different zones in the cerebellum 
[176] (Figure 2.3).  Images were converted into grayscale and the threshold was set to 
140 to highlight nuclei (Figure 2.4) using ImageJ analysis software (National Institute of 
Health, Bethesda, MD).  ImageJ quantified the percentage area containing granule cell 
nuclei and are representative of cell numbers.  Three nuclear count measurements were 
taken per image using a 120 x 90 pixel box corresponding to 57.5 m x 43.1 m.  Two 
independent scorers, blinded to animal cohort identifiers, determined the percentage of 
the area containing nuclei to determine granule cell loss.   
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Figure 2.3 – An illustration depicting where images were taken in the sagittal 
hematoxylin and eosin stained sections of the mouse cerebellum in order to 
determine the neuron counts in the granule cell layer of specific lobules.  The images 
were taken at the base (B) and apex (A) of lobules I/II, III, VIa, IX, and X representing 
four different zones, anterior zone (AZ: lobules, I-V), the central zone (CZ: lobules VI, 
VII), the posterior zone (PZ: lobules VIII, IX), and the nodular zone (NZ: lobule X), in 
the mouse cerebellum based on the previously reported unique expression of molecular 
markers for determining compartmentalization of the cerebellum [176]. Scale bar = 1 mm
Figure 2.3 - An illustration depicting where images were taken in the sagittal hematoxylin and eosin 
stained sections of the mouse cerebellum in order to determine the neuron counts in the granule cell 
layer of specific lobules 
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Figure 2.4 - Neuron counting in the granule cell layer in wild type (WT) and 
harlequin (hq) mice.  A) A hematoxylin and eosin image of the apex of lobule I/II of the 
cerebellum in 3-month-old WT mice.  B) Images were converted into white nuclei on a 
black background in ImageJ.  White nuclei were calculated and converted into percentage 
area occupied by nuclei.  Three nuclear counts were made in both the base and apex of 
each lobule for two different cerebellar sections.  The nuclear counts in the base and apex 
were compared with a one-way ANOVA.  The nuclear counts in the base and apex were 
similar and the average was taken for the six nuclear counts. Nuclear counts were taken 
in three different mice per experimental group by two independent observers.  Scale bar = 
100 µm.
Figure 2.4 - Neuron counting in the granule cell layer in 
wild type (WT) and harlequin (hq) mice 
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2.4.4 Purkinje cell counts to assay Purkinje cell loss 
 Tissue sections were stained with hematoxylin and eosin as in section 2.5.3.  
Purkinje cells, based on morphology and location, were counted from the base to the 
apex, and from the apex to the base of lobules I/II, III, VIa, IX, and X for two different 
sections per mouse (Figure 2.5).  The Purkinje cell counts for each section were averaged 
together for each mouse.  Purkinje cell counts were taken in three different mice per 
experimental group. 
 
2.4.5 Fluoro-Jade
®
 B to assay degenerating neurons with paraquat-treated tissue 
controls 
Frozen and unfixed cryosections were heated on a 45ºC heat block to evaporate 
moisture, stained with hematoxylin and eosin (see section 2.4.3), and subsequently 
stained with Fluoro-Jade
®
 B as described previously [337].  Hematoxylin and eosin 
stained sections were washed in deionized water for 1 min and transferred to 0.001% 
Fluoro-Jade
®
 B (Millipore, Temecula, CA) in deionized water with 0.1% acetic acid for 
30 min on a rotating platform.  Sections were rinsed in water for 3 min and air dried 
before immersing in xylene for 5 min and coverslipping using Permount  mounting 
media (Fisher Scientific, Pittsburgh, PA).  Sections were viewed at 200X under the FITC 
filter of the Arcturus Veritas
®
 Microdissection System (Molecular Devices, Sunnyvale, 
CA).  Fluoro-Jade
®
 B positive cells were counted per whole section with a minimum of 2 
sections per animal. Positive and negative controls were created by injecting WT mice 
with 10 mg/kg of paraquat or a vehicle control [239], since paraquat is known to  
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Figure 2.5 – A hematoxylin and eosin image of the cerebellum of a wild type (WT) 
mouse indicating the location were the Purkinje cell counts were made.  Purkinje 
cells were identified by location and morphology and counted in lobules I/II, III, VIa, IX, 
and X for two separate sections and the average was calculated for each lobule.  There 
were three different mice per experimental group. Scale bar = 1 mm. 
Figure 2.5 - A hematoxylin and eosin image of the cerebellum of a wild type (WT) 
mouse indicating the location were the Purkinje cell counts were made 
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degenerate neurons in the substantia nigra [364] and Fluoro-Jade
®
 B is able to stain 
paraquat-treated cells [365].  These mice were euthanized 15 days after injection with 
paraquat and the cerebrum was fixed in 4% paraformaldehyde, embedded in paraffin wax 
(Leica ASP300, Leica Microsystems, Richmond Hill, ON) [239] and sectioned sagittally 
at a thickness of 5 μm (Leica RM2255 Microtome, Leica Microsystems) and 
deparaffinized in xylene prior to hematoxylin and eosin staining.  Hematoxylin, eosin, 
and Fluoro-Jade
®
 B staining were performed as described above (Appendix B, Figure 
B.1). 
 
2.4.6 Autofluorescence of the cerebellar tissue to assay lipofuscin accumulation and ROS 
damage 
Frozen and unfixed cryosections were examined for lipofuscin accumulation 
through yellow tissue autofluorescence [44] using the FITC filter (Excitation: 455-495 
nm; Emission: > 510 nm) of the Arcturus Veritas
®
 Microdissection System (Molecular 
Devices, Sunnyvale, CA).  Images were captured at 200X magnification and one image 
was taken at the apex of each lobule (I/II, III, VIa, IX, and X) of the cerebellum across 
two tissue sections for each mouse.  All images where set to a threshold of 140 to get rid 
of the green autofluorescence and six measurements were taken in the Purkinje cell layer 
using a 100 x 50 pixel box to determine the yellow lipofuscin autofluorescence 
(Appendix B, Figure B.2).  Quantification was performed by two independent scorers, 
blinded to animal cohort identifiers, using ImageJ analysis software (National Institute of 
Health, Bethesda, MD).   
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2.4.7 Dihydroethidium (DHE) staining of cerebellar tissue sections to assess superoxide 
anion levels 
 Dihydroethidium staining was performed on frozen sectioned cerebellar tissue 
that was embedded in optimal cutting temperature media.  Frozen slides were heated on a 
45ºC heat block to evaporate moisture.  A negative control was created by pre-treating 
the slide with 30 µl of 1000 U/ml superoxide dismutase (SOD, Sigma-Aldrich Canada 
Inc., Oakville, ON) for 10 min at room temperature to remove superoxide anions.  A 
positive control was created by pre-treating the slide with 20 µl of 0.5 M hydrogen 
peroxide solution for 5 min at room temperature.  The SOD and hydrogen peroxide 
solutions were removed before proceeding with DHE staining in a dark room.  
Cryosectioned cerebella were treated with 50 µl of 50 µM DHE in dimethyl-sulphoxide 
(DMSO) and incubated in a humidified chamber at 37ºC for 30 min [349] (Appendix B, 
Figure B.3).  Superoxide anions were quantified on the tissue sections using the green 
fluorescence filter (Excitation: 503-548 nm; Emission: > 565 nm) on an inverted Zeiss 
microscope (Carl Zeiss Incorporated, Toronto, ON) capable of detecting the DHE 
emission wavelength of 590 nm.  The fluorescent lamp was set to a gain of ‘1’ and 
exposure time of 500 ms for all images and analyses.  DHE staining has a very short 
duration of fluorescence before quenching begins to occur so time to image capture was 
consistently restricted to 3 min per section.  Images were captured at 200 X magnification 
and one image was taken at the apex of lobules I/II, III, VIa, IX, and X representing four 
different zones in the cerebellum determined by gene expression
173
 for two tissue sections 
for each DHE treatment and control.  Fluorescence intensity was determined in three 
regions per image by drawing a 120 x 90 pixel box in ImageJ analysis software (National 
Institute of Health, Bethesda, MD).  ImageJ quantifies the fluorescence intensity by 
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assigning the detected fluorescence a grey scale brightness value, thus it allows one to 
measure the DHE fluorescence. 
 
2.4.8 Statistical analysis for in situ cerebellar phenotyping assays to characterize hq mice 
and response to PB treatment 
 Three-factor MANOVA followed by one-factor ANOVAs (p<0.05) were 
performed to further analyze statistically significant interactions found with the three-
factor MANOVA.  Tukey’s test for post hoc comparison was used to determine 
differences in mean granule cell and Purkinje neuron counts, mean fluorescence intensity 
of lipofuscin and DHE across genotype, age, and drug treatment, with the level of 
significance p<0.05.  A three-factor ANOVA was used to determine mean differences in 
the number of Fluoro-Jade  B positive cells across, genotype, age, and drug treatment.  
All data were analyzed using SPSS version 17.0 (IBM, Somers, NY). 
 
2.5 The Big Blue
®
 cII assay for mutation detection 
To analyze mutations in the cII gene, high molecular weight genomic DNA was 
extracted from 50% of the cerebellum (60 mg) of WT mice and the entire cerebellum (90 
mg) from hq mice using the RecoverEase™ DNA Isolation Kit protocol (Stratagene, 
LaJolla, CA).  Tissues were homogenized, digested with Proteinase K and dialyzed in TE 
(pH 7.5) at room temperature for 48 hours.  DNA was transferred into a sterile 
microcentrifuge tube using a flamed glass capillary rod and stored at 4ºC.  The Big Blue
®
 
cII mutation detection assay was carried out using the Transpak
®
 and the lambda Select-
cII™ protocol [366].  Briefly, lambda phage genomes containing the Big Blue® cII 
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construct were excised from extracted genomic DNA from 21 mice and packaged in vitro 
to produce virulent lambda phage, used to infect E. coli strain G1250 and plated.    Plates 
were incubated under cII mutant selective (24ºC, 40 hours) or nonselective control (37ºC, 
24 hours) conditions. 
Putative cII mutants were cored using sterile pipette tips and stored at 4ºC in 500 
µl of SM buffer containing 5 µl chloroform and were used to reinfect E. coli to confirm 
the mutant phenotype under cII mutant selective conditions [366].  Mutants with 
confirmed phenotype were cored and placed in 100 μL of sterile TE (pH 7.5) and stored 
at -20ºC until needed.  Mutant frequency was calculated by dividing the number of 
mutant plaques by the total number of plaque forming units (pfu’s) as estimated from the 
number of plaques on titer plates incubated under the nonselective temperature condition 
[366]. 
The cII gene was PCR amplified using primers ASPCIIF 38248 and JAKCIIR 
38723 [366].  To remove excess primer and unincorporated dNTPs for sequencing, the 
amplified PCR products were incubated with 10 U/ l exonuclease I and 2 U/ l shrimp 
alkaline phosphatase for 15 min at 37°C followed by heat inactivation at 80°C for 15 min 
(USB Corporation, Cleveland, Ohio).   Purified products were sequenced at the Robarts 
Research Institute (London, ON) with 2 µM of KOHCIIF 38272 cII primer 5’ AAA AAG 
GGC ATC AAA TTA AAC C 3’ [366].  Sequences were compared in a multiple 
sequence alignment to the WT cII Genbank reference sequence (J02459) [362] and 
mutations were analyzed using Seqscape
®
 v2.0 (ABI) and Sequencher software (Gene 
Codes Inc. Ann Arbor, MI).  Sequence chromatograms were analyzed by two individuals.  
Mutation frequency was obtained for each cerebellar sample and mouse by correcting the 
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mutant frequency for recurrent mutations in the same mouse tissue and dividing by the 
total pfu’s assayed.   
At least five mice were used per experimental group at 3 and 7 months of age.  
Three to six estimates of mutant frequency per mouse were made using the Big Blue
®
 cII 
assay with an average packaging efficiency of about 130,000 mutation targets assayed.  
The experimental design for the Big Blue
®
 cII assay exceeded recommended guidelines 
to achieve the statistical power (66 to 88%) necessary to detect as significant a 50% 
change in mutant frequency [367-369].  Also, the mutation(s) in each mutant was(were) 
identified and clones removed from the estimate of mutation frequency, further reducing 
inter-animal variation in the estimate of mutation frequency [370] and further increasing 
statistical power.  Mutant and mutation frequencies in the cerebellum of WT and hq mice 
were analyzed using a two-factor ANOVA (Microsoft Excel 2007 and SPSS, Somers, 
NY).  The frequency of Class II deletions [i.e., >1 bp but < 1 kb] [371] in the cerebellum 
of young hq mice was compared to the other mouse cohorts in this study and to our 
database of cII mutations in WT and hq mice (Ward, unpublished) [239, 240] using a the 
Fisher-Freeman-Halton test in StatXact statistical analysis software (CYTEL Software, 
Cambridge, MA).  Differences in mutation frequencies were significant if p<0.05.  The 
mutation pattern, the proportion of eleven different mutations, was analyzed using Fisher-
Freeman-Halton test (Monte Carlo simulation) in the StatXact statistical analysis 
software package (CYTEL Software, Cambridge, MA) and was considered significantly 
different if p<0.05.   The mutation spectrum, a visual representation of all the mutations 
in the cII gene, was analyzed by plotting all the mutations on the cII sequence to visualize 
areas of mutation hot spots.  
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2.6 Gene expression in cerebellar tissues to study early mechanisms of degeneration 
and response to PB treatment 
2.6.1 RNA isolation and purification for gene expression analysis 
Total RNA was extracted from half of the cerebellum of WT and hq mice using 1 mL 
Qiazol lysis reagent and homogenized with 20 strokes in a 7 mL dounce homogenizer 
with pestle A (Wheaton, Millville, NJ).   The remainder of the RNA isolation was 
processed using the RNeasy
®
 Mini Kit according to the manufacturer’s protocol (Qiagen, 
Valencia, CA).   Total RNA was purified with 0.25 volumes of 3 M sodium acetate and 4 
volumes of 100% ethanol and left overnight in a -20˚C freezer.  RNA was pelleted by 
centrifugation at 12,000 xg for 30 min, washed twice in 80% ethanol and centrifuged at 
4 C for 30 min at 12,000 xg.  The pellet was air dried and resuspended in RNase free 
water.  
Total RNA purity was determined with spectrophotometric A260/280 and A260/230 ratios 
in the range of 2.0-2.2, and 1.8-2.1, respectively with the NanoVue
TM
 (GE Healthcare 
Bio-Sciences, Piscataway, NJ).  RNA integrity was determined by the presence of 
prominent 28S and 18S peaks on an electropherogram using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA).  RNA was used if the RNA integrity 
number (RIN) was 8.8 or greater.  RNA was stored at -80˚C. 
 
2.6.2 Gene expression assayed by microarray hybridization 
Total RNA (100 ng) was used to synthesize mRNA into double stranded cDNA with 
T7-Oligo (dT) Promoter Primer (Affymetrix, Santa Clara, CA) followed by an in vitro 
transcription with T7 RNA polymerase and biotin-labeled nucleotides to form cRNA  
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(Affymetrix GeneChip
®
 user manual, 2005).  The cRNA was amplified, fragmented, and 
hybridized.  Each sample was hybridized to a single GeneChip
®
 Mouse Gene 1.0 ST 
Array (Affymetrix, Santa Clara, CA) containing 770,317 probes corresponding to 28,853 
genes to obtain expression data.  After hybridization, Streptavidin-Phycoerythrin (SAPE) 
solution was used to stain the chip by binding to the biotin molecules and emitting 
fluorescence which was detected when scanned.  The scanned files containing the raw 
expression values from the GeneChip
®
 Mouse Gene 1.0 ST Array were imported into 
Partek Genomics Suite v6.5 (Partek Inc, St Louis, MO), normalized using Robust 
Multichip Average (RMA) protocols and were log2 transformed and analyzed in an a 
two-factor ANOVA to obtain a p-value and a fold change.  The GeneChips
®
 were 
processed at the London Regional Genomics Centre (Robarts Research Institute, London, 
Ontario, Canada).  Initially, genes with a fold change > 2.0 or < -2.0 with a p-value <0.05 
were considered to be differentially-expressed, but the conditions were too stringent and 
only a handful of genes (<10) met the criteria.  The filtering parameters where changed to 
genes with a fold change > 1.5 or < -1.5 [372] with a p-value <0.05 to be considered 
differentially-expressed.   
 
2.6.3 Pathway analysis of gene expression data 
 Ingenuity Systems Pathway Analysis
®
 (IPA
®
) software version 9 (Ingenuity 
Systems, Redwood City, CA) was used to determine which predefined biological 
pathways had altered gene expression.  A list of the Affymetrix gene identifiers, 
corresponding fold changes and p-values were uploaded onto the IPA
®
 website for all the 
filtered genes.  Each Affymetrix gene identifier was mapped to its corresponding gene in 
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the Ingenuity’s database.  The canonical pathways analysis identified biological pathways 
whose genes were altered so that it may have a significant impact on the pathway.  Genes 
from the data set that were associated with the canonical pathway in Ingenuity’s database 
were considered for further analysis.  The significance of the association between the 
differentially-expressed genes and the canonical pathway was measured in two ways.  
First, a ratio was generated of the number of differentially-expressed genes from the data 
set that map to the pathway, divided by the total number of genes in the canonical 
pathway.   Second, a Fisher’s exact test (IPA, Ingenuity Systems, Redwood City, CA) 
was used to calculate a p-value to determine the probability that the association between 
the genes in the dataset and the canonical pathway was explained by chance alone.  
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CHAPTER THREE - RESULTS 
 
3.1 Wild type (WT) and harlequin (hq) mice consumed the same amount of water 
regardless of phenobarbital (PB) concentration 
 A two-factor analysis of variance (ANOVA) determined that untreated WT and 
hq mice consumed similar amounts of water (WT: 0.14  0.04 ml/g/day; hq: 0.16  0.06 
ml/g/day) and that there was no taste aversion due to PB treatment (WT 2 ppm: 0.15  
0.04; hq 2 ppm: 0.20  0.01; hq 4 ppm: 0.16  0.03 ml/g/day).  
 
3.2. Compared to WT mice, hq mice were smaller and gained less mass with age 
 A three-factor ANOVA showed that body mass was significantly lower in hq 
mice compared to WT mice at all ages (Figure 3.1a; p<0.001).  At 3, 7, and 10 months of 
age, hq mice weighed 30%, 36%, and 35% less than age-matched WT mice, respectively.  
Body mass increased with age in WT and hq mice (p<0.001).  However, WT mice had a 
faster rate of body mass increase with age, gaining 6.6% of WT body mass per month 
compared to 4.9% of hq body mass per month between 3 and 7 months of age.   
 
3.2.1 WT, more so than hq mice, gain mass with PB treatment 
 Phenobarbital treatment increased body mass in WT and hq mice when compared 
to untreated control mice (Figure 3.1b; p=0.007).  The rate of body mass increase was 
higher in WT mice with 2 ppm and 4 ppm PB treatment, gaining 7.9% and 8.1% of WT 
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Figure 3.1 – Mouse body mass increased with age and phenobarbital (PB) treatment 
for wild type (WT) and harlequin (hq) mice.  A) Mean final body mass (g) was 
determined for WT and hq mice at 3, 7, or 10 months of age.  Body mass was lower in hq 
mice compared to WT mice at all three ages (p<0.001). Body mass increased with age for 
both genotypes (p<0.001). B) Mean final body mass (g) was determined for WT and hq 
mice at 3, 7, or 10 months of age with three PB treatments (0, 2, and 4 ppm) at the 
younger ages.  Body mass increased with PB treatment in WT and hq mice (p=0.007).  
Error bars represent ± S.E.M.
Figure 3.1 - Mouse body mass increased with age and phenobarbital (PB) treatment for wild type 
(WT) and harlequin (hq) mice 
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 body mass per month compared to 5.6% and 7.0% of hq body mass per month, 
respectively.  The rate of change in body mass when compared to the untreated WT and 
hq mice was 1.3% and 1.5% in WT mice at 2 and 4 ppm, while it was 0.7% and 
2.1% in hq mice at 2 and 4 ppm.  
 
3.3. WT and not hq mice were responsive to PB treatment showing increased activity 
A three-factor multivariate analysis of variance (MANOVA) indicated a 
significant three-way interaction of genotype, age, and treatment in the total amount of 
overnight activity (p=0.006; Figure 3.2).  A genotype-treatment interaction (p=0.001) 
was also detected as well as the main effects of genotype (p<0.001) and treatment 
(p<0.001).  Activity was similar for untreated WT and hq mice and did not change with 
increased age.  Phenobarbital had a different effect on each genotype.  In 3-month-old 
WT mice, activity increased with PB treatment (p<0.001), with both 2 and 4 ppm 
increasing activity (2 ppm: p=0.006; 4 ppm: p<0.001).  In 7-month-old WT mice, activity 
also increased with PB treatment (p=0.019), but only 2 ppm PB (2 ppm: p=0.017) and not 
4 ppm increased activity.  In hq mice, PB treatment did not have any effect on activity 
levels at either age.   
 
3.3.1 Phenobarbital-treated WT mice had greater locomotion 
 There was a three-factor interaction of genotype, age, and treatment (p=0.010) as 
well as an interaction of genotype and treatment (p=0.002) on the total number of 
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Figure 3.2 – Mouse activity increased with phenobarbital (PB) treatment in wild 
type (WT) but not harlequin (hq) mice.  Mean activity (events) over 9 hours was 
determined for WT and hq mice in three age groups (3, 7, and 10 months) with three PB 
treatments (0, 2, and 4 ppm).  Activity was similar for untreated WT and hq mice and did 
not change with aging.  Phenobarbital treatment increased activity in WT mice at 3 
(p<0.001) and 7 (p=0.019) months of age.  At 3 months of age, 2 and 4 ppm of PB 
increased activity levels of WT mice (2 ppm: p=0.006; 4 ppm: p<0.001), but at 7 months 
of age, only 2 ppm increased the activity levels of WT mice (2 ppm: p=0.017).  Error bars 
represent S.E.M. 
Figure 3.2 - Mouse activity increased with phenobarbital (PB) treatment in wild type (WT) but not 
harlequin (hq) mice 
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locomotion events.  Each individual factor had an effect on locomotion as well: genotype 
(p=0.001), age (p=0.005), and treatment (p<0.001; Figure 3.3).  Locomotor activity was 
similar for WT and hq mice without any treatment.  Increased age did not alter locomotor 
activity in WT or hq mice.  In WT mice, PB treatment increased locomotion at 3 months 
of age (p<0.001).  Both 2 and 4 ppm of PB increased locomotion in 3-month-old WT 
mice (2 ppm: p=0.004; 4 ppm: p<0.001).  At 7 months of age, PB treatment increased 
locomotion (p=0.048), but after post hoc analysis 2 and 4 ppm had p-values > 0.05.  In hq 
mice, locomotion did not change with PB treatment. 
 
3.3.2 Phenobarbital-treated WT mice had more stereotypic movements 
 An age-treatment interaction was detected for the number of stereotypic 
movements (p=0.006; Figure 3.4).  Stereotypic movements were similar in untreated WT 
and hq mice and there was no change with increased age.  Phenobarbital treatment 
increased stereotypic movements in 3-month-old WT mice (p=0.026), with 4 ppm of PB 
showing a significant increase in the number of stereotypic movements (4 ppm: p=0.042).  
However, in 7-month-old WT mice, PB did not increase stereotypic movements.  
Phenobarbital treatment had no effect on hq mice at either age.  
 
3.3.3 Phenobarbital-treated WT mice traveled greater distances 
 An age-treatment interaction was detected for the distance travelled (p=0.018; 
Figure 3.5).  For untreated WT and hq mice, distance travelled was similar and did not 
change with increased age for either genotype.  In WT mice, 4 ppm PB  
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Figure 3.3 – Mouse locomotion increased with phenobarbital treatment in wild type 
(WT) but not harlequin (hq) mice.  Mean locomotion (events) over 9 hours was 
determined for WT and harlequin (hq) mice in three age groups (3, 7, and 10 months) 
with three PB treatments (0, 2, and 4 ppm).  Locomotion was similar for untreated WT 
and hq mice and did not change with aging.  Phenobarbital treatment increased 
locomotion in WT mice at both 3 (p<0.001) and 7 (p=0.048) months of age. At 3 months 
of age, 2 and 4 ppm of PB increased locomotion levels of WT mice (2 ppm: p=0.004; 4 
ppm: p<0.001), but at 7 months of age, after post hoc analysis, 2 and 4 ppm had p-values 
>0.05.  Error bars represent ± S.E.M.
Figure 3.3 - Mouse locomotion increased with phenobarbital treatment in wild type (WT) but not 
harlequin (hq) mice 
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Figure 3.4 –Stereotypic behaviour increased with phenobarbital (PB) treatment in 
wild type (WT) but not harlequin (hq) mice.  Mean stereotypes (events) over 9 hours 
was determined for WT and hq mice in three age groups (3, 7, and 10 months) with three 
PB treatments (0, 2, and 4 ppm).  Stereotypic behaviour was similar for untreated WT 
and hq mice and did not change with aging.  Phenobarbital treatment increased 
stereotypic behaviour in WT mice at 3 (p=0.026) and not 7 months of age.  Error bars 
represent ± S.E.M.
Figure 3.4 - Stereotypic behaviour increased with phenobarbital (PB) treatment in wild type (WT) 
but not harlequin (hq) mice 
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Figure 3.5 –Distance travelled increased with phenobarbital (PB) treatment in wild 
type (WT) but not harlequin (hq) mice.  Mean total distance travelled (cm) over 9 hours 
was determined for WT and hq mice in three age groups (3, 7, and 10 months) with three 
PB treatments (0, 2, and 4 ppm).  Distance travelled was similar for untreated WT and hq 
mice and did not change with aging.  Phenobarbital treatment increased distance travelled 
in WT mice at 3 (p=0.010) and 7 (p=0.038) months of age.  At 3 months of age, only 4 
ppm of PB increased distance travelled in WT mice (4 ppm: p=0.009), and at 7 months of 
age, only 2 ppm of PB increased distance travelled (p=0.037).  Error bars ±represent 
S.E.M. 
Figure 3.5 - Distance travelled increased with phenobarbital (PB) treatment in wild type (WT) but 
not harlequin (hq) mice 
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increased distance travelled at 3 months of age (treatment: p=0.010; 4 ppm: p=0.009), 
and at 7 months of age, 2 ppm of PB increased distance travelled (treatment: p=0.038; 2 
ppm: p=0.037).  Phenobarbital did not affect distance travelled in hq mice at either age.  
 
3.3.4 Phenobarbital-treated WT mice spent less time resting 
 There was a significant three-way interaction of genotype, age, and treatment for 
the total amount of time spent resting (p=0.004; Figure 3.6).  A genotype-age interaction 
(p=0.032) and a genotype-treatment interaction (p=0.002) were detected.  The individual 
factors of genotype (p=0.008) and treatment (p<0.001) also had an effect on the amount 
of time spent resting.  Untreated WT and hq mice spent a similar amount of time resting 
and did not change with increased age.  Phenobarbital treatment was associated with 
decreased resting time in WT mice at 3 months of age (treatment: p<0.001; 2 ppm: 
p=0.033; 4 ppm: p<0.001) and 7 months of age (treatment: p=0.009; 2 ppm: p=0.007).  
Phenobarbital treatment had no effect on the amount of time spent resting in 3-month-old 
hq mice.  Phenobarbital treatment decreased the amount of time spent resting in 7-month-
old hq mice (treatment: p=0.038) but after post hoc analysis both 2 and 4 ppm of PB had 
p-values > 0.05.  
 
3.3.5 Phenobarbital-treated WT mice spent more time moving 
There was a significant three-way interaction in the amount of time spent moving 
slowly (p=0.004; Figure 3.7).  There was a genotype-age interaction (p=0.006) and a 
genotype-treatment interaction (p=0.036) on the amount of time moving slowly.  The  
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Figure 3.6 – Time spent resting decreased with phenobarbital (PB) treatment in 
wild type (WT) but not in harlequin (hq) mice.  Mean time (s) spent resting (moving 
<2 cm/s) over 9 hours was determined for WT and hq mice in three age groups (3, 7, and 
10 months) with three PB treatments (0, 2, and 4 ppm).  The amount of time spent resting 
was similar for untreated WT and hq mice and did not change with aging.  Phenobarbital 
treatment decreased time spent resting in WT mice at 3 (p<0.001) and 7 (p=0.009) 
months of age.  At 3 months of age, 2 and 4 ppm of PB decreased time spent resting in 
WT mice (2 ppm: p=0.033; 4 ppm: p<0.001), and at 7 months of age, only 2 ppm of PB 
decreased time spent resting (p=0.007).  Phenobarbital did not have any effect on time 
spent resting in 3-month-old hq mice, but PB treatment decreased time spent resting in hq 
mice at 7 months of age (p=0.038), but after post hoc analysis 2 and 4 ppm of PB had p-
values > 0.05.  Error bars represent ± S.E.M. 
Figure 3.6 - Time spent resting decreased with phenobarbital (PB) treatment in wild type (WT) but 
not in harlequin (hq) mice 
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Figure 3.7 – Time spent moving slowly increased with phenobarbital (PB) treatment 
in wild type (WT) but not in harlequin (hq) mice.  The time (s) spent moving slowly 
(moving between 2 cm/s - 5 cm/s) over 9 hours for WT and hq mice in three age groups 
(3, 7, and 10 months) with three PB treatments (0, 2, and 4 ppm). The amount of time 
spent moving slowly was similar for untreated WT and hq mice and did not change with 
aging.  Phenobarbital treatment increased time spent moving slowly in WT mice at 3 
months of age (p<0.001) and 7 months of age (p=0.005).  At 3 months of age, 2 and 4 
ppm of PB increased the amount of time spent moving slowly in WT mice (2 ppm: 
p=0.012; 4 ppm: p<0.001), and at 7 months of age, 2 and 4 ppm of PB also increased the 
amount of time spent moving slowly in WT mice (2 ppm: p=0.005; 4 ppm: p=0.037).  
Phenobarbital did not have any effect on time spent moving slowly in 3-month-old hq 
mice, but PB treatment increased the amount of time spent moving slowly in hq mice at 7 
months of age (p=0.025).  At 7 months of age, 4 ppm of PB increased the amount of time 
spent moving slowly in hq mice (p=0.020).  Error bars represent ± S.E.M
Figure 3.7 - Time spent moving slowly increased with phenobarbital (PB) treatment in wild type 
(WT) but not in harlequin (hq) mice 
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individual factors of genotype (p=0.018) and treatment (p<0.001) had an effect on the 
amount of time spent moving slowly.  The amount of time spent moving slowly was 
similar in untreated WT and hq mice and did not change with increased age for either 
genotype.  Phenobarbital increased the amount of time spent moving slowly in WT mice 
at 3 months of age (treatment: p<0.001; 2 ppm: p=0.012; 4 ppm: p<0.001) and 7 months 
of age (treatment: p=0.005; 2ppm: p=0.005; 4 ppm: p=0.037).  The amount of time spent 
moving slowly in hq mice at 3 months of age was unaltered by PB.  However, 4 ppm of 
PB did increase the amount of time spent moving slowly in hq mice at 7 months of age 
(treatment: p=0.025; 4 ppm: p=0.020).  
 The time spent moving quickly was influenced by a genotype-treatment (p=0.009) 
interaction (Figure 3.8).  The individual factor of treatment (p=0.028) also had an effect 
on the time spent moving quickly.  The amount of time spent moving quickly was similar 
in untreated WT and hq mice did not change with increased age in either genotype.  
Treatment with 4 ppm of PB increased time spent moving quickly in WT mice at 3 
months of age (treatment: p=0.003, 4 ppm: p=0.002).  At 7 months of age, 2 ppm of PB 
increased time spent moving quickly in WT mice (treatment: p=0.035; 2 ppm: p=0.027).  
Treatment with PB had no effect on the amount of time spent moving quickly in hq mice.  
 
3.3.6 Phenobarbital-treated WT mice attained greater maximum and mean velocities 
A significant three-way interaction was detected with maximum velocity 
(p=0.047; Figure 3.9).  There was also a genotype-treatment interaction (p=0.031) effect 
on the maximum velocity.  Individual factors of genotype (p=0.016) and age (p=0.010) 
had an effect on maximum velocity.  Maximum velocity was similar for untreated WT 
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Figure 3.8 – Time spent moving quickly increased with phenobarbital (PB) 
treatment in wild type (WT) but not in harlequin (hq) mice.  Mean time (s) spent 
moving quickly (moving >5 cm/s) over 9 hours was determined for WT and hq mice in 
three age groups (3, 7, and 10 months) with three PB treatments (0, 2, and 4 ppm).  The 
amount of time spent moving quickly was similar for untreated WT and hq mice and did 
not change with aging.  Phenobarbital treatment increased time spent moving quickly in 
WT mice at 3 months of age (p=0.003) and at 7 months of age (p=0.035).  At 3 months of 
age, 4 ppm of PB increased the amount of time spent moving quickly in WT mice 
(p=0.002), and at 7 months of age, 2 ppm of PB increased the amount of time spent 
moving quickly in WT mice (p=0.027).  Error bars represent ± S.E.M
Figure 3.8 - Time spent moving quickly increased with phenobarbital (PB) treatment in wild type 
(WT) but not in harlequin (hq) mice 
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Figure 3.9 – Maximum velocity increased with phenobarbital (PB) treatment in wild 
type (WT) mice but not in harlequin (hq) mice.  Mean maximum velocity (cm/s) over 9 
hours was determined for WT and hq mice in three age groups (3, 7, and 10 months) with 
three PB treatments (0, 2, and 4 ppm).  Maximum velocity was similar for untreated WT 
and hq mice and did not change with aging.  Phenobarbital treatment increased maximum 
velocity in WT mice at 3 months of age mice (p=0.006) but not at 7 months of age.  Error 
bars represent ± S.E.M.
Figure 3.9 - Maximum velocity increased with phenobarbital (PB) treatment in wild type (WT) mice 
but not in harlequin (hq) mice 
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and hq mice and there was no change with increased age.  In WT mice, PB treatment 
increased maximum velocity at 3 months of age (treatment: p=0.006; 4 ppm: p=0.005), 
but there was no change with maximum velocity with PB treatment at 7 months of age. 
Phenobarbital did not affect maximum velocity in hq mice at either age.  
 Mean velocity was influenced by a significant age-treatment interaction (p=0.016; 
Figure 3.10).  There was no difference in mean velocity between WT and hq mice and 
mean velocity did not change with age for either genotype (Figure 3.10).  Treatment with 
4 ppm of PB increased mean velocity in 3-month-old WT mice (treatment: p=0.010; 4 
ppm: p=0.010).  At 7 months of age, 2 ppm of PB increased mean velocity in WT mice 
(treatment: p=0.043; 2 ppm: p=0.043).  Phenobarbital treatment did not affect mean 
velocity in hq mice for either age. 
 
3.3.7 Phenobarbital-treated WT mice reared more but the duration of the events was 
unchanged 
 No interactions were detected in the number of rearings with a three-way 
MANOVA but two of the main factors had an effect on the number of rearings: genotype 
(p=0.009), and age (p=0.026; Figure 3.11).  There was no difference in the number of 
rearing events in untreated WT and hq mice and age did not affect the number of rearing 
events in either genotype.  Both 2 and 4 ppm of PB increased the number of rearing 
events in WT mice at 3 months of age (treatment: p=0.006; 2ppm: p=0.019; 4 ppm: 
p=0.008) but PB did not have an effect on the number of rearing events at 7 months of 
age.  Phenobarbital had no effect on the number of rearing events in hq mice at either 
age.  There was no difference in mean duration of rearing events for genotype, age, or PB 
treatment (Figure 3.12).   
  
95 
Figure 3.10 - Mean velocity increased with phenobarbital (PB) in wild type (WT) 
mice but not in harlequin (hq) mice.  Mean velocity (cm/s) over 9 hours was 
determined for WT and hq mice in three age groups (3, 7, and 10 months) with three PB 
treatments (0, 2, and 4 ppm).  Mean velocity was similar for untreated WT and hq mice 
and did not change with aging.  Phenobarbital treatment increased mean velocity in WT 
mice at 3 months of age mice (p=0.010) and at 7 months of age (p=0.043).  At 3 months 
of age, 4 ppm of PB increased mean velocity in WT mice (p=0.010) and at 7 months of 
age, 2 ppm of PB increased mean velocity in WT mice (p=0.043).  Error bars represent ± 
S.E.M. 
Figure 3.10 - Mean velocity increased with phenobarbital (PB) in wild type (WT) mice but not in 
harlequin (hq) mice 
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Figure 3.11 – Rearing behaviour increased with phenobarbital (PB) treatment in 
WT but not harlequin (hq) mice.  Mean number of rearings (events) over 9 hours was 
determined for WT and hq mice in three age groups (3, 7, and 10 months) with three PB 
treatments (0, 2, and 4 ppm).  Rearings behaviour was similar for untreated WT and hq 
mice and did not change with aging.  Phenobarbital treatment increased the rearing 
behaviour in WT mice at 3 months of age (p=0.006) but not at 7 months of age.   At 3 
months of age, 2 and 4 ppm of PB increased the rearing behaviour (2ppm: p=0.019; 4 
ppm: p=0.008).  Error bars represent ± S.E.M.
Figure 3.11 - Rearing behaviour increased with phenobarbital (PB) treatment in WT but not 
harlequin (hq) mice 
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Figure 3.12 – Rearing duration showed no effect of genotype, age, or phenobarbital 
(PB) treatment.  Mean rearing duration (s) over 9 hours was determined for wild type 
(WT) and harlequin (hq) mice in three age groups (3, 7, and 10 months) with three PB 
treatments (0, 2, and 4 ppm).  Error bars represent ± S.E.M.  
Figure 3.12 - Rearing duration showed no effect of genotype, age, or phenobarbital (PB) treatment 
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. 3.4. Smaller cerebella were characteristic of PB-treated and untreated hq mice 
 A three-factor analysis of variance (ANOVA) showed a main effect of genotype 
(p=0.001) on the mass of the cerebellum, and that the cerebellar mass did not change with 
age or PB treatment in WT or hq mice.  One-way ANOVA also confirmed that the hq 
cerebella had a significantly smaller mass at 3, 7, and 10 months of age when compared 
to age-matched WT mice (p=0.001; Figure 3.13a).  A three-way ANOVA for the ratio of 
the cerebellar mass to body mass showed a main effect of age (p<0.001).  The cerebellar 
mass to body mass ratio was similar in WT and hq mice and decreased with age for each 
genotype (WT: p<0.001; hq: p=0.009; Figure 3.13b).  For both genotypes, the cerebellar 
mass to body mass ratio decreased at 7 and 10 months of age when compared to mice at 3 
months of age (WT 7 months: p=0.001; WT 10 months: p=0.001; hq 7 months: p=0.009; 
hq: 10 months: p=0.031).  The hq cerebellum is visibly smaller at 7 and 10 months of age 
when compared to age-matched WT controls (Figure 3.14).  Phenobarbital did not have 
an effect on the mass of the cerebellum in WT or hq mice (Figure 3.15; Figure 3.16).  
 
3.4.1 Lobule specific early loss of granule neurons progressed across hq cerebella 
unaffected by PB treatment 
 A three-factor MANOVA was performed on the nuclear counts of the granule cell 
layer in WT and hq mice at three different ages with PB treatments and detected a  
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Figure 3.13 – Cerebellar mass is lower in harlequin (hq) mice but the cerebellar 
mass to body mass ratio is similar to wild type (WT) mice at all ages. A) WT mice 
had a greater cerebellar mass at all three ages (p<0.001) and cerebellar mass did not 
change with age or phenobarbital (PB) treatment in either genotype. B) The cerebellar 
mass to body mass ratio was similar in WT and hq mice and decreased with age in both 
genotypes (p<0.001). Five mice were used per experimental group. Error bars represent ± 
S.E.M.
Figure 3.13 - Cerebellar mass is lower in harlequin (hq) mice but the cerebellar mass to body mass 
ratio is similar to wild type (WT) mice at all ages.  
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Figure 3.14 - Histology of the cerebellum in 3-, 7-, and 10-month-old mice displays visible aging-
associated cerebellar degeneration in hq mice with age. 
Figure 3.14 - Histology of the cerebellum in 3-, 7-, and 10-month-old mice displays 
visible aging-associated cerebellar degeneration in hq mice with age.   A) 
Hematoxylin and eosin staining of a 10 m sagittal section of the cerebellum in 3-month-
old WT with Roman numerals indicating cerebellar lobule numbers.  B)  Hematoxylin 
and eosin staining of a 10 m sagittal section of the cerebellum in 3-month-old hq mice 
with absence of histopathology. C)  An image of the cerebellum from 7-month-old WT 
and (D) hq mice with visible loss of the granule cell layer.  E)  The cerebellum of 10-
month-old WT and (F) hq mice, where the hq cerebellum remained similar in size to (D) 
7-month-old hq mice but is still visibly smaller compared to (E) 10-month-old WT mice.  
Scale bars: A-F = 1 mm
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Figure 3.15 - Phenobarbital (PB) had no visible effect on the histology of the cerebellum of wild type 
(WT) mice. 
 
Figure 3.15 - Phenobarbital (PB) had no visible effect on the histology of the 
cerebellum of wild type (WT) mice.  The histopathology of the cerebellum in 3-, and 7-
month-old WT mice with PB treatment at 0, 2, or 4 ppm was examined.  Hematoxylin 
and eosin staining of a 10 m sagittal section of the cerebellum in (A) 3-month-old WT 
mouse with no PB treatment.  Roman numerals indicate cerebellar lobule numbers.  B) 
An image of 3-month-old WT mouse treated with 2 ppm of PB treatment.  C) An image 
of 3-month-old WT mouse treated with 4 ppm of PB treatment.  D) An image of the 
cerebellum from 7-month-old WT mouse with no PB treatment.  E) An image of the 
cerebellum from 7-month-old WT mouse treated with 2 ppm of PB.  F) An image of the 
cerebellum from 7-month-old WT mouse treated with 4 ppm of PB. Scale bars: A-F = 1 
mm
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Figure 3.16 – Phenobarbital (PB) had no visible effect on the histology of the 
cerebellum of harlequin (hq) mice.  The histopathology of the cerebellum in 3-, and 7-
month-old hq mice with PB treatment at 0, 2, or 4 ppm. Hematoxylin and eosin staining 
of a 10 m sagittal section of the cerebellum in (A) 3-month-old hq mouse with no PB 
treatment.  Roman numerals indicate lobule cerebellar numbers.  B) An image of 3-
month-old hq mouse treated with 2 ppm of PB.  C) An image of 3-month-old hq mouse 
treated with 4 ppm of PB.  D) An image of the cerebellum from 7-month-old hq mouse 
with no PB treatment.  E) An image of the cerebellum from 7-month-old hq mouse 
treated with 2 ppm of PB.  F) An image of the cerebellum from 7-month-old hq mouse 
treated with 4 ppm of PB. Scale bars: A-F = 1 mm 
 
Figure 3.16 - Phenobarbital (PB) had no visible effect on the histology of the cerebellum of harlequin 
(hq) mice. 
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significant interaction between genotype and age for lobules IX and X (IX: p=0.019; X: 
p=0.037).  Main effects for genotype and age were also detected in all lobules (genotype, 
all lobules: p<0.001; age, I/II: p=0.002; III: p=0.002; VIa: p=0.001; IX: p=0.001; X: 
p=0.006; Figure 3.17).  At 3 months of age, hq mice had similar nuclear counts for all 
lobules studied when compared to WT mice.  At 7 months of age, hq mice had 
significantly decreased nuclear counts in lobules IX and X when compared to WT mice 
(IX: p=0.003; X: p=0.009).  At 10 months of age, all lobules examined had a decreased 
nuclear count when compared to WT mice (I/II: p=0.004; III: p=0.004; VIa: p=0.009; IX: 
p=0.002; X: p=0.001).   
 The nuclear count did not change with age in WT mice for all lobules studied.  In 
contrast, the nuclear count decreased with age in hq mice (I/II: p=0.036, III: p=0.012; 
VIa: p=0.007; IX: p=0.016; X: p=0.012; Figure 3.17).  At 7 months of age, degeneration 
was visible in the granule cell layer as hq mice had decreased nuclear counts for lobules 
IX and X when compared to 3-month-old hq mice (IX: p=0.045; X: p=0.045).   At 10 
months of age, all of the lobules studied had decreased nuclear counts (I/II: p=0.042, III: 
p=0.028; VIa: p=0.014; IX: p=0.017; X: p=0.013) when compared to hq mice at 3 
months of age.  Phenobarbital treatment did not have any effect on the nuclear count in 
any of the cerebellar lobules in WT or hq mice (Figure 3.17).   
 
3.4.2 Loss of Purkinje cells in hq mice was lobule specific, progressed with age, and was 
unaffected by PB treatment 
 A three-factor MANOVA was performed on the number of Purkinje cells in WT 
and hq mice at three different ages with PB treatments detected a significant  
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Figure 3.17 – Granule neuron cell counts decreased with age in all lobules examined 
in harlequin (hq) mice.  For all lobules, the granule neuron count did not change with 
age in wild type (WT) mice and PB treatment had no effect on the granule neuron count 
in either WT or hq mice.  A) The nuclear count in lobule I/II of the cerebellum.  The 
nuclear count was similar for WT and hq mice at 3 and 7 months of age.  At 10 months of 
age, hq mice had a decreased nuclear count when compared to WT mice (p=0.004).  The 
nuclear count of lobule I/II decreased with age in hq mice (p=0.036) with decreased 
nuclear count in 10-month-old hq mice when compared to 3-month-old hq mice 
(p=0.042).  B) The nuclear count in lobule III of the cerebellum.  The nuclear count was 
similar for WT and hq mice at 3 and 7 months of age.  At 10 months of age, hq mice had 
a decreased nuclear count when compared to WT mice (p=0.004).  The nuclear count 
decreased with age in hq mice (p=0.012) with decreased nuclear count in 10-month-old 
hq mice when compared to 3-month-old hq mice (p=0.028).  C) The nuclear count in 
lobule VIa of the cerebellum.  The nuclear count was similar for WT and hq mice at 3 
and 7 months of age.  At 10 months of age, hq mice had a decreased nuclear count when 
compared to WT mice (p=0.009).  The nuclear count decreased with age in hq mice 
(p=0.007) with decreased nuclear count in 10-month-old hq mice when compared to 3-
month-old hq mice (p=0.014).  D) The nuclear count in lobule IX of the cerebellum.  The 
nuclear count was similar for WT and hq mice at 3 months of age.  At 7 and 10 months of 
age, hq mice had a decreased nuclear count when compared to WT mice (7: p=0.003; 10: 
p=0.002).  The nuclear count decreased with age in hq mice (p=0.016).  In 7- and 10-
month-old hq mice, the nuclear count was decreased when compared to 3-month-old hq 
mice (7 months: p=0.045; 10 months: p=0.017).  E) The nuclear count in lobule X of the 
cerebellum.  The nuclear count was similar for WT and hq mice at 3 months of age.  At 7 
and 10 months of age, hq mice had a decreased nuclear count when compared to WT 
mice (7: p=0.009; 10: p=0.001).  The nuclear count decreased with age in hq mice 
(p=0.002).  In 7- and 10-month-old hq mice, the nuclear count was decreased when 
compared to 3-month-old hq mice (7 months: p=0.045; 10 months: p=0.013).  Error bars 
represent ± S.E.M.  
Figure 3.17 - Granule neuron cell counts decreased with age in all lobules examined in 
harlequin (hq) mice 
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 interaction between genotype and age for lobules I/II, III, VIa, IX, and X (I/II: p=0.006; 
III: p=0.002; VIa: p<0.001; IX: p<0.001; X: p=0.002; Figure 3.18).  The main effect of 
genotype was detected in all lobules, and the main effect of age was detected in lobules 
III, VIa, IX, and X (genotype, all lobules: p<0.001; age, III: p<0.001; VIa: p<0.001; IX: 
p<0.001; X: p=0.022; Figure 3.18).  At 3 months of age, WT and hq mice had a similar 
number of Purkinje cells for all lobules studied.  At 7 months of age, hq mice had 
significantly decreased number of Purkinje cells in lobules III, VIa, IX, and X when 
compared to WT mice (III: p=0.001; VIa: p=0.036; IX: p=0.024; X: p=0.025).  At 10 
months of age, hq mice had a decreased number of Purkinje cells in lobules III, VIa, and 
IX when compared to WT mice (III: p=0.017; VIa: p=0.007; IX: p=0.017).   
 The number of Purkinje cells did not change with age in WT mice for any of the 
lobules studied.  In contrast, the number of Purkinje cells decreased with age in lobules 
I/II, III, VIa, and IX in hq mice (I/II: p=0.010, III: p<0.001; VIa: p=0.006; IX: p=0.014; 
Figure 3.18).  At 7 months of age, Purkinje cells were reduced in lobules I/II, III, VIa, 
and IX when compared to hq mice at 3 months of age (I/II: p=0.021; III: p<0.001; VIa: 
p=0.046; IX: p=0.030).  At 10 months of age, Purkinje cells were reduced in lobules I/II, 
III, VIa, and IX when compared to hq mice at 3 months of age (I/II: p=0.013; III: 
p<0.001; VIa: p=0.005; IX: p=0.017).  In addition, at 10 months of age, lobule VIa had a 
reduced number of Purkinje cells when compared to hq mice at 7 months of age 
(p=0.001).  Phenobarbital treatment did not have any effect on the number of Purkinje 
cells in any of the cerebellar lobules in WT or hq mice (Figure 3.18). 
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Figure 3.18 – Purkinje cell numbers were decreased in harlequin (hq) mice. For all 
lobules the number of Purkinje cells did not change with age in wild type (WT) mice and 
PB treatment had no effect on the number of Purkinje cells in WT or hq mice.  A) The 
Purkinje cell numbers in lobule I/II of the cerebellum.  The Purkinje cell number was 
similar for WT and hq mice at 3, 7, and 10 months of age.  The number of Purkinje cells 
decreased with age in lobule I/II in hq mice (p=0.010).  At 7 and 10 months of age, 
Purkinje cells were significantly decreased when compared to hq mice at 3 months of age 
(7 months: p=0.021; 10 months: p=0.013).  B) The Purkinje cell numbers in lobule III of 
the cerebellum. The Purkinje cell number was similar for WT and hq mice at 3 months of 
age.  At 7 and 10 months of age, hq mice had decreased numbers of Purkinje cells in 
lobule III when compared to WT mice (7 months: p=0.001; 10 months: p=0.017). The 
number of Purkinje cells decreased with age in lobule III in hq mice (p<0.001).  At 7 and 
10 months of age, Purkinje cells were significantly decreased when compared to hq mice 
at 3 months of age (7 months: p<0.001; 10 months: p<0.001).  C) The Purkinje cell 
numbers in lobule VIa of the cerebellum. The Purkinje cell number was similar for WT 
and hq mice at 3 months of age.  At 7 and 10 months of age, hq mice had decreased 
numbers of Purkinje cells in lobule VIa when compared to WT mice (7 months: p=0.06; 
10 months: p=0.007).  The number of Purkinje cells decreased with age in lobule VIa in 
hq mice (p<0.001).  At 7 and 10 months of age, Purkinje cells were significantly 
decreased when compared to hq mice at 3 months of age (7 months: p=0.046; 10 months: 
p=0.005).  At 10 months of age, lobule VIa had a decreased number of Purkinje cells 
when compared to hq mice at 7 months of age (p=0.001).  D) The Purkinje cell numbers 
in lobule IX of the cerebellum. The Purkinje cell number was similar for WT and hq mice 
at 3 months of age.  At 7 and 10 months of age, hq mice had decreased numbers of 
Purkinje cells in lobule IX when compared to WT mice (7 months: p=0.024; 10 months: 
p=0.007).  The number of Purkinje cells decreased with age in lobule IX in hq mice 
(p=0.014).  At 7 and 10 months of age, Purkinje cells were significantly decreased when 
compared to hq mice at 3 months of age (7 months: p=0.030; 10 months: p=0.017).  E) 
The Purkinje cell numbers in lobule X of the cerebellum. The Purkinje cell number was 
similar for WT and hq mice at 3 months of age.  At 7 months of age, hq mice had 
decreased numbers of Purkinje cells in lobule X when compared to WT mice (7 months: 
p=0.025).  At 10 months of age, the number of Purkinje cells in WT and hq mice were 
similar.  Error bars represent ± S.E.M.
Figure 3.18 - Purkinje cell numbers were decreased in harlequin (hq) mice 
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3.4.3 Neurodegeneration was evident in 7-month-old hq mice and unaffected by PB 
treatment 
 A three-factor ANOVA for the number of Fluoro-Jade  B positive cells indicated 
that there was a significant interaction between genotype and age (p<0.001).  At 3 months 
of age, WT and hq mice had a similar number of Fluoro-Jade  B positive cells (Figure 
3.19).  At 7 months of age, hq mice had an elevated number of Fluoro-Jade  B positive 
cells compared to WT mice at 7 months of age (p=0.014).  At 10 months of age, WT and 
hq mice had a similar number of Fluoro-Jade  B positive cells.  In WT mice, the number 
of Fluoro-Jade  B positive cells did not change with age.  Fluoro-Jade  B positive cells 
were more numerous at 7 months of age in hq mice when compared to hq mice at 3 and 
10 months of age (3 months: p=0.003, 10 months: p=0.002).  Phenobarbital treatment had 
no effect on the number of Fluoro-Jade  B positive cells in WT or hq mice. 
 
3.4.4 Lipofuscin accumulation with age was lobule specific in both WT and hq mice and 
unaffected by PB treatment 
 A three-factor MANOVA on lipofuscin accumulation indicated that there was a 
significant genotype and age interaction in lobule III (p=0.049), as well as a genotype 
effect in lobules IX and X (IX: p<0.001; X: p=0.012) and age effect in lobules I/II, VIa, 
and IX (I/II; p=0.002; VIa: p<0.001; IX: p=0.012).  WT and hq mice had a similar 
amount of lipofuscin in 3-, 7-, and 10-month-old mice for all lobules despite the reported 
genotype effect for lobules IX and X (Figure 3.20).  
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Figure 3.19 – There were elevated numbers of dying cells in 7-month-old harlequin 
(hq) mice.  Fluoro-Jade
®
 B positive cells were similar in wild type (WT) and hq mice at 3 
and 10 months of age.  The number of Fluoro-Jade
®
 B positive cells did not change with 
age in WT mice.  Fluoro-Jade
®
 B positive cells were elevated at 7 months of age in hq 
mice when compared to age-matched WT mice (p=0.014).  Fluoro-Jade  B positive cells 
were elevated at 7 months of age in hq mice when compared to hq mice at 3 and 10 
months of age (3 months: p=0.003, 10 months: p=0.002). Phenobarbital had no effect on 
the number of Fluoro-Jade
®
 positive cells in WT or hq mice. Error bars represent ± 
S.E.M.
Figure 3.19 - There were elevated numbers of dying cells in 7-month-old harlequin (hq) mice. 
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Figure 3.20 – Lipofuscin accumulation was similar in wild type (WT) and harlequin 
(hq) mice and increased with age in certain lobules.  For all lobules PB treatment had 
no effect on lipofuscin accumulation. A)  The lipofuscin autofluorescence profile in 
lobule I/II of the cerebellum.  Lipofuscin autofluorescence was similar in WT and hq 
mice for all ages studied and PB treatment. Lipofuscin autofluorescence did not change 
with age in WT mice.  Within hq mice, lipofuscin autofluorescence increased with age in 
lobule I/II (p=0.016).  Lipofuscin autofluorescence in lobule I/II was elevated in 7- and 
10-month-old hq mice when compared 3-month-old hq mice (7 months: p=0.026; 10 
months: p=0.023). B)  The lipofuscin autofluorescence profile in lobule III of the 
cerebellum.  The lipofuscin autofluorescence was similar in WT and hq mice for all ages 
studied. C)  The lipofuscin autofluorescence profile in lobule VIa of the cerebellum.  The 
lipofuscin autofluorescence was similar in WT and hq mice for all ages studied.  In WT 
mice, lipofuscin autofluorescence in lobule VIa was elevated with age (p=0.037).  At 10 
months of age, WT mice had elevated lipofuscin autofluorescence in lobule VIa when 
compared to WT mice at 3 months of age (p=0.040).  In hq mice, lipofuscin 
autofluorescence in lobule VIa was elevated with age (p=0.037), with increased 
lipofuscin autofluorescence at 10 months of age when compared to 3 months of age 
(p=0.040). D)  The lipofuscin autofluorescence profile in lobule IX of the cerebellum.  
The lipofuscin autofluorescence was similar in WT and hq mice and did not change with 
age. E)  The lipofuscin autofluorescence profile in lobule X of the cerebellum.  The 
lipofuscin autofluorescence was similar in WT and hq mice and did not change with age.  
Error bars represent ± S.E.M. 
 
Figure 3.20 - Lipofuscin accumulation was similar in wild type (WT) and harlequin (hq) mice and 
increased with age in certain lobules. 
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             Lipofuscin accumulated with age in lobule VIa (p=0.037) in WT mice (Figure 3. 
20).  In lobule VIa, lipofuscin was elevated at 10 months (p=0.040) when compared to 
WT mice at 3 months of age.  In hq mice, lipofuscin also accumulated with age in lobule 
I/II and VIa (I/II: p=0.016; VIa: p=0.037).  Lipofuscin in lobule I/II was elevated at 7 and 
10 months of age when compared to hq mice at 3 months of age (7 months: p=0.026; 10 
months: p=0.023).  In lobule VIa, lipofuscin was elevated at 10 months (p=0.040) when 
compared to hq mice at 3 months of age.  Despite the genotype and age interaction 
reported for lobule III, and the age effect for lobule I/II and IX, further analysis with one 
way-ANOVA testing both showed no change with genotype or age.  Both 2 and 4 ppm 
PB had no effect on lipofuscin accumulation in WT and hq mice (Figure 3.20). 
 
3.4.5 ROS increased with age in lobules I/II, III, VIa in both PB-treated and untreated hq 
mice 
 A three-factor MANOVA for DHE fluorescence detected a significant effect of 
age in lobules I/II, III, and VIa (I/II: p=0.050; III: p=0.017; VIa: p=0.002).  There was no 
difference in DHE fluorescence between WT and hq mice at any age in lobules I/II, III, 
VIa, XI, and X of the cerebellum (Figure 3.21).  In WT mice, the DHE fluorescence did 
not increase with age in any lobule.  In hq mice, DHE fluorescence was increased at 10 
months of age when compared to 3 months of age for lobules I/II, III, and VIa (I/II: 
p=0.011; III: p=0.003; VIa: p=0.009).  Phenobarbital had no effect on DHE fluorescence 
in WT or hq mice.  
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Figure 3.21 - The ROS profiles in wild type (WT) and harlequin (hq) mice were 
similar at all three ages but ROS did increase with age in hq mice.  A) The ROS 
profile in lobule I/II of the cerebellum.  The DHE intensity was similar in WT and hq 
mice for all ages studied and PB treatment.  The DHE intensity increased at 10 months of 
age within hq mice (p=0.011), however it was still not different from WT mice.  B) The 
ROS profile in lobule III of the cerebellum.  The DHE intensity was similar in WT and 
hq mice for all ages studied and PB treatment.  The DHE intensity increased at 10 months 
of age within hq mice (p=0.003), however it was still not different from WT mice.  C) 
The ROS profile in lobule VIa of the cerebellum.  The DHE intensity was similar in WT 
and hq mice both genotypes for all ages studied and PB treatment.  The DHE intensity 
increased at 10 months of age within hq mice (p=0.009), however it was still not different 
from WT mice.  D) The ROS profile in lobule IX of the cerebellum.  The DHE intensity 
was similar in WT and hq mice for all ages studied and PB treatment.  E) The ROS 
profile in lobule X of the cerebellum.  The DHE intensity was similar in WT and hq mice 
for all ages studied and PB treatment. Error bars represent ± S.E.M. 
Figure 3.21 - The ROS profiles in wild type (WT) and harlequin (hq) mice were similar at all three 
ages but ROS did increase with age in hq mice 
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3.5. Mutation frequencies were similar in WT and hq mice but a ROS mutation 
signature was more frequent in young hq mice 
 In total, 12.5 million plaque forming units (pfu’s) were assayed, 414 mutants were 
collected and 273 independent cII mutations were identified (Table 3.1).  The average 
packaging efficiency was 130,000 pfu’s with a minimum of three and a maximum of six 
packaging reactions per mouse.  A linear regression showed that mutation frequency in 
hq mice was not correlated with body mass.  Spontaneous mutant and mutation frequency 
showed no significant differences with mouse genotype or age.  Mutation patterns were 
similar between mouse genotypes and ages (Table 3.2).  The majority of mutations were 
G:C to A:T transitions at CpG dinucleotides followed by small deletions less than 50 base 
pairs in size.  Hotspots for mutation in the cII sequence were at CpG dinucleotides and 
mononucleotide repeats (Figure 3.22).   With one exception, single nucleotide insertions 
and deletions extended or shortened mononucleotide runs.  Single base pair deletions and 
insertions at monobasic runs were not elevated significantly in the cerebellum of hq mice 
compared to age-matched WT mice. One GC to CT tandem-base mutation was found in a 
young WT mouse.  This same mouse also had one mutant with seven proximal point 
mutations spanning only 21 base pairs (Figure 3.22). 
  Four deletions, ranging in length from 10 to 21 base pairs, were found in four of 
the five young hq mice.  Sequences both upstream and downstream the deletion junctions 
were analyzed for direct sequence repeats but none were found.  These deletions were 
found exclusively in the cerebellum of hq mice in this study (p=0.004) and not in our 
larger database of 657 cII mutations in kidney, heart, and skin of hq and WT mice 
(p=0.0001). 
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Table 3.1 – Mutant and mutation frequency in the cerebellum of hq (XhqY) and wild type (XY) mice at three and 
seven months of age    
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Table 3.2 – Pattern of 
independent mutations in 
the cerebellum of hq (X
hq
Y) 
and wild type (XY) mice at 
three and seven months of 
age 
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Figure 3.22 - Spontaneous mutations in the cII transgene harvested from the cerebellum of 3- and 7-
month old wild type (WT) and harlequin (hq) Big Blue
®
 mice. 
 
3.22 - Spontaneous mutations in the cII transgene harvested from the cerebellum of 
3- and 7-month old wild type (WT) and harlequin (hq) Big Blue
®
 mice. The 
numbering convention used for the cII nucleotide positions is that reported previously 
[362].  Single base substitutions are written above the base position affected. Each 
independent mutation type has a superscript to designate the experimental cohort (Y = 3-
month-old Young wild type, W = 7-month-old middle adult Wild type, H = 3-month-old 
young adulthood Harlequin, Q = 7-month-old middle adulthood harleQuin). The boxed 
base pairs below the wild type sequence are nucleotides inserted and lines below the 
sequence underline the nucleotides deleted. The tandem-base mutation is circled and the 
seven mutations observed in a single mutant are marked with triangles.
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3.6. The transcriptomes of the cerebellum of hq mice displayed immune and 
inflammatory response markers 
 A total of 55 genes were differentially expressed with 48 up-regulated and seven 
down-regulated in the cerebellum of 3-month-old hq mice compared to WT mice with 
fold changes greater than 1.5 (p<0.05, Table 3.3).  Significantly altered pathways 
included the classical complement system, crosstalk between dendritic cells and natural 
killer cells, the neuroprotective role of thimet oligopeptidase-1 (THOP1) in AD, and 
communication between innate and adaptive immune cells (Table 3.4).   
 
3.6.1 Phenobarbital treatment had a minimal effect on the transcriptomes of WT and hq 
mice 
 Phenobarbital treatment (4 ppm) in WT mice resulted in five differentially 
expressed genes.  Four genes were up-regulated and one gene was down-regulated in WT 
mice treated with 4 ppm of PB when compared to untreated WT mice (Table 3.5).  
Phenobarbital treatment (4 ppm) in hq mice resulted in eight differentially expressed 
genes when compared to untreated hq mice.  Seven genes were up-regulated and one 
gene was down-regulated in hq mice treated with 4 ppm of PB when compared to 
untreated hq mice (Table 3.6).  For WT and hq mice treated with PB, too few genes were 
differentially-expressed to perform pathway analysis.  
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Table 3.3 List of differentially-expressed genes in 
the cerebellum of 3-month-old hq mice compared 
to age-matched wild type mice 
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Table 3.4 
Pathways affected 
significantly by 
differentially-
expressed genes in 
the cerebellum of 
3-month-old hq 
mice compared to 
wild type mice 
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Table 3.5 List of differentially-
expressed genes in the 
cerebellum of 3-month-old wild 
type mice treated with 4 ppm 
phenobarbital compared to age-
matched untreated wild type 
mice 
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Table 3.6  List of 
differentially-expressed 
genes in the cerebellum of 3-
month-old hq mice treated 
with 4 ppm phenobarbital 
compared to untreated hq 
mice 
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CHAPTER FOUR – DISCUSSION  
 
Given that individuals with cancer and neurodegenerative diseases have elevated 
DNA damage and decreased DNA repair and given that hormesis has demonstrated 
efficacy as an anti-carcinogenesis strategy in a mouse model of hepatocarcinoma, I 
hypothesized that chronic low doses of PB treatment would delay cerebellar 
neurodegeneration.  The hq mouse had no detectable change in nocturnal behaviour 
compared to WT mice and this did not change with increased age.  Losses of granule and 
Purkinje cells were observed in hq mice, but increased ROS and ROS-associated damage 
were not the initiating factors and likely a consequence of mitochondrial dysfunction.  
The transcriptome analysis implicated inflammation as an early mechanism of cerebellar 
degeneration in hq mice.  Unfortunately chronic low doses of PB did not delay the onset 
of the symptoms associated with neurodegeneration in hq mice.    
My objective was to study the effect of cerebellar degeneration on 11 different 
parameters of nocturnal behaviour as measured by the ActiTrack  apparatus with and 
without PB treatment in WT and hq mice.  Given that cerebellar function is required for 
coordinated movement, I hypothesized that hq mice would have decreased nocturnal 
behaviours compared to WT mice.  Given that phenobarbital administration increases 
activity in rodents, I hypothesized that phenobarbital administration would ameliorate 
age-related decreases in nocturnal behaviours in hq mice through mechanisms that would 
reduce cerebellar degeneration. 
 My second objective was to measure different markers of cerebellar degeneration 
with and without PB treatment in WT and hq mice.  Given that hq mice undergo 
cerebellar neurodegeneration, I hypothesized that there would be an increase in cell loss, 
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apoptosis, lipofuscin accumulation, and superoxide anion levels.  Given that 
phenobarbital administration affects different anti-aging pathways, then hormetic 
phenobarbital administration would limit cell loss, apoptosis, lipofuscin accumulation 
and superoxide anion levels. 
 My third objective was to determine the mutant and mutation frequency and 
mutation pattern in WT and hq mice.  Given that hq mice had an elevated number of 
single nucleotide deletions in the brain compared to WT mice using the PLAP assay, I 
hypothesized that there would be an increase in the spontaneous mutant and mutation 
frequency of the cII gene and a change in the mutation pattern in the cerebellum of hq 
mice when compared to WT mice. 
My fourth objective was to determine what genes and pathways were altered in hq 
mice with and without PB treatment early in the cerebellar degenerative process.  Given 
that pathways of ROS, mitochondrial dysfunction, and inflammation have been detected 
in neurodegenerative disorders, I hypothesized that hq mice would have altered pathways 
involved in ROS, mitochondrial dysfunction, and inflammation.  Given that PB 
administration may affect different anti-cancer pathways, I hypothesized that 
phenobarbital administration would counter act pathways involved in ROS, 
mitochondrial dysfunction, and inflammation in hq mice. 
 
4.1 Chronic low doses of PB did not delay or ameliorate cerebellar degeneration in hq 
mice  
Cell loss in the cerebellum of hq mice was evident at 7 months of age and 
progressed further at 10 months of age.  Phenobarbital administration did not delay 
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granule or Purkinje cell loss.  Low doses of PB did not reduce lipofuscin accumulation or 
superoxide anion levels and did not reverse the inflammatory and immune response in hq 
mice.  The transcriptome analysis suggests that hq mice have lower expression of a 
component of the GABAA receptor, -aminobutyric acid (GABA) A receptor  6, 
potentially reducing the effect of PB compared to WT mice.  Although low-dose PB 
treatment in hq mice was not effective at delaying or limiting cell loss, there are other 
treatments available for testing in hq mice.  Possible hormetic and targeted treatments are 
discussed herein with the new knowledge of the mechanisms of cerebellar cell loss in hq 
mice.  
 
4.1.1 The cerebella of hq disease mice display normal early development  
Cytologically and histologically there were no differences in the 3-month-old 
cerebellum of hq mice compared to WT mice, suggesting that the cerebellum undergoes 
normal development despite the down-regulation of Aif.  Aif is required for development 
as complete knockout of Aif leads to embryonic lethality at day 11.5 [251] and targeted 
knockout of Aif in the cerebellum and midbrain at embryonic day 8.75 leads to lethality 
after birth with both granule and Purkinje cells having aberrant cell cycles [373].  
Another targeted knockout of Aif further on in development leads to normal granule and 
Purkinje cell development at postnatal day 1 but lethality occurs between postnatal days 5 
and 8 [373].  The two targeted knockout experiments suggest that Aif is required for 
neurogenesis but the embryos are still able to develop normally for a short period of time 
[373].  Thus, despite the 80% down-regulation of Aif in hq mice [232], there is enough 
Aif for the cerebellum to develop normally. 
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4.1.2 Unlike WT mice, hq mice show early cerebellar degeneration 
With all of the biomarkers that were used to evaluate neurodegeneration in hq 
mice, it appeared that in WT mice, the biomarkers did not change across the three age 
cohorts tested.  The number of nuclei in the granule and Purkinje cell layers did not 
change with increasing age in WT mice.  Previous research found that granule cell 
number is constant in mice ranging from 10 to 31 months of age [124, 374].  
Furthermore, granule cell numbers do not vary in the different lobules or change medio-
laterally [375].  Decreased numbers of Purkinje cells are found in mice at 18, 28, or 31 
months of age [124, 198, 374], which is much older than the cohorts of WT mice in the 
experiment herein.  Out of the 35 degeneration markers examined, the only marker that 
did change with age was lipofuscin autofluorescence in lobule VIa.  Since most of the 
neurodegenerative markers that were used did not change with increasing age, the mixed 
CBA/CaJ and C57BL/6 background is a suitable control for studying early 
neurodegeneration in hq mice. 
At 7 months of age, Fluoro-Jade  B positive degenerating neurons were elevated 
in the cerebellum of hq mice (Figure 3.19).  Very few granule cells were positive for 
apoptosis, but rather it was the white matter layer containing axons, cell bodies, and 
neurites in the deep cerebellar nuclei where motor outputs leave the cerebellum toward 
the thalamus that were degenerating at 7 months of age.  Cerebellar cell loss was evident 
affecting both granule and Purkinje cells.  Cell loss of the granule layer was confined to 
lobules IX and X, and at 10 months of age, all lobules studied had fewer granule cells 
(Figure 3.14 and Figure 3.17).  Additionally at 7 months of age, Purkinje cell numbers 
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were reduced in all lobules assayed but lobule X (Figure 3.18). The regional patterning of 
granule cell loss observed herein was similar to previous findings [232, 376] suggesting 
that the down-regulation of Aif leads to an initial regional and temporal pattern of neuron 
loss followed by widespread degeneration in all lobules.   
Regional patterning of cell loss is not unique to the granule cell layer but was also 
detected in the Purkinje cell layer in hq mice.  The pattern of Purkinje cell loss in the 
anterior cerebellum herein is different to a previous finding where Purkinje cell loss in 7-
month-old hq mice is worse in the posterior lobules in the cerebellum [232] although the 
exact number of Purkinje cells are not quantified.   In a different study with 8-month-old 
hq mice, Purkinje cell loss is seen in the hemisphere region of the anterior cerebellum 
lobules (I-V) and in the central and posterior cerebellar lobules VI-VIII [376].  In 11-
month-old hq mice, widespread Purkinje cell loss is extended into the vermis cerebellum 
[376].  By 14 months of age, most Purkinje cells are lost, with surviving Purkinje cells 
located mostly in lobule X [376].  In hq mice, Purkinje cells resistant to degeneration 
express heat shock protein 25 [376].  Heat shock protein 25 is expressed in a small 
number of Purkinje cells in lobule VI and VII and is expressed constitutively in lobule X 
[377].  Even though heat shock protein 25 is also expressed in lobules VI and VII, 
Purkinje cells in these regions are not protected from degeneration as demonstrated 
herein and previous reports [376], so something in addition to heat shock protein 25 is 
protective in Purkinje cells in lobule X.  The cerebellum has an intricate pattern of gene 
expression that is not yet fully understood.  As there is a spatial and temporal pattern to 
cerebellar degeneration in hq mice, knowing whether Aif or other genes are expressed in 
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the different lobules at different time points would help shed light on what genes are 
contributing to the spatial resistance of degeneration in granule or Purkinje cells.  
 
4.1.3 The cerebella of hq mice do not show features of premature aging and are different 
from other models of cerebellar degeneration 
The anterior-posterior patterning of granule and Purkinje cell loss is not restricted 
to hq mice but has also been seen in other mouse models of cerebellar degeneration.  
Leaner mutant mice display massive granule cell loss in the anterior lobules of the 
cerebellum [208].  Lurcher mutant mice, similar to hq mice, lose Purkinje cells in all 
lobules, however, Purkinje cells in lobule X of lurcher mice that are positive for heat 
shock protein 25 are more resistant to cell death [378].  In weaver mutant mice, Purkinje 
cell loss occurs in all lobules but is the worst in the central lobules (VI-VII) followed by 
the anterior lobules (I-V) [379].  Together, these examples demonstrate the asymmetric 
molecular organization of the cerebellum, and further analysis needs to be performed to 
determine whether there are temporal and spatial differences in Aif levels in the lobules of 
the cerebellum resulting in the pattern of granule and Purkinje cell loss or whether the up-
regulation of other stress response genes, like heat shock factors in Purkinje cells are also 
responsible for granule cell survival. 
 
4.1.4 The hq mouse is a model of mitochondrial dysfunction instead of increased 
oxidative stress 
 The hq mouse most resembles a model of mitochondrial dysfunction.  Two cases 
of mutated AIF have been documented in humans [254].  A trinucleotide deletion was 
detected in the AIF gene at position 601-603 in exon 5, leading to the deletion of an 
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arginine residue in two related individuals [254].  Both individuals had muscle weakness 
and atrophy and magnetic resonance imaging of the brain revealed abnormal signals in 
the neostriatum.  Fibroblast cells show a reduction in the activity of complex III and IV 
of the electron transport chain.  Mitochondria are necessary for producing cellular energy 
for the cell in the form of ATP, and defects in the components of electron transport chain 
can lead to a multitude of disorders.  Mitochondrial dysfunction can affect the retina 
[252], brain [252, 380, 381], heart [380], skeletal muscle [252, 381], skin [382], and hair 
[382].  Mitochondrial dysfunction has a frequency of 1 in 7,600 births with complex I 
dysfunction being the most common [383].  Unfortunately there are no cures for 
mitochondrial dysfunction.  Although hq mice have been studied in different contexts 
relating to neurodegeneration, the hq mouse would make a useful tool in studying the 
multisystem disorder that occurs with mitochondrial dysfunction as well as testing 
possible treatments.  
 
4.2. Cerebellar ataxia did not affect nocturnal cage behaviour in hq mice  
To examine the hypothesis that hq mice will have decreased nocturnal behaviours 
compared to WT mice, 3-, 7-, and 10-month-old WT and hq mice were placed 
individually into the ActiTrack  home cage and 11 nocturnal behaviours were monitored. 
 
4.2.1 Nocturnal cage behaviour in WT mice is unchanged with age 
The observation that WT behaviour did not change with age was not unexpected.  
Since the mean lifespan of CBA mice is 25 months of age and the lifespan of C57BL/6J 
mice is 25-28 months of age [384], 7- or 10-month-old mice are still considered to be in 
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middle adulthood and expected to have minimal behavioural changes.  In fact, a recent 
behavioural study in adult and aged C57BL/6 mice shows that 7-month-old and 29-
month-old WT mice have similar locomotor activity levels [385].  However, it is 
important to keep in mind that there are strain-specific behavioural aging patterns.  For 
example, locomotor activity is elevated in C57BL/6 when compared to BALB/C and 
DBA/2 mice [386].  Furthermore, C57BL/6 locomotor activity levels do not change 
between 5 and 27 months of age whereas locomotor activity at the same ages decreases in 
BALB/C mice and locomotor activity levels remain low and do not change in DBA/2 
mice [386].  The mixed CBA/CaJ and C57BL/6J background was suitable as a baseline 
comparison for early cerebellar degeneration. 
 
4.2.2 hq mice have unaltered nocturnal cage behaviour compared to WT mice 
Contrary to the central hypothesis, hq mice did not show evidence of decreased 
nocturnal behaviours compared to WT mice and this did not change with age, which was 
unexpected.  Although the cerebellum plays an important role in the coordination of 
movement, multiple regions of the brain are required for locomotion including the motor 
cortex, thalamus, basal ganglia, brain stem, and spinal cord.  The hq mice have some 
apoptotic neurons in the motor cortex, thalamus, and basal ganglia at 4 months, but 
neuron loss is not progressive and is limited [234].  Since the parameters of nocturnal 
behaviour were similar in WT and hq mice this suggests that these other regions of the 
brain involved in locomotion are resistant to neuron loss as a result of Aif deficiency.  
The cerebellum is the primary site of neurodegenerative disease in hq mice and there is 
limited impact on mouse nocturnal locomotor behaviour up to 10 months of age.  
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4.2.3 Other models of cerebellar degeneration have behavioural changes 
Other mouse models of cerebellar degeneration have either increased or decreased 
activity levels when compared to control mice [227, 331-335].  Hyperactivity is seen in 
both lurcher [227, 331] and reeler [332] mutant mice.  Most granule cells and nearly all 
Purkinje cells degenerate in lurcher mice [211].  Since Purkinje cells are inhibitory and 
the only output of the cerebellar cortex, a decrease in Purkinje cells leads to a decrease in 
cerebellar inhibition and can lead to an increase in excitatory messages to the motor 
cortex and subsequent hyperactivity [387].  Increased cerebellar disinhibition is not likely 
in reeler mice as Purkinje cell degeneration is mild with a 50% loss of Purkinje cells 
[222].  Since the ratio of Purkinje cells to deep cerebellar nuclei is 10:1 in mice [210], 
severe Purkinje cell degeneration is needed for a 1:1 ratio or less of Purkinje cells to deep 
cerebellar nuclei and cerebellar disinhibition [226].  The hyperactivity seen in reeler mice 
could be due to increased glutamate dehydrogenase activity in the forebrain [388], 
possibly due to elevated glutamate, an excitatory neurotransmitter involved in locomotor 
activity [389].  Weaver mutant mice, in addition to cerebellar degeneration also have 
degeneration in the basal ganglia, specifically of the dopaminergic neurons in substantia 
nigra pars compacta [390] that can lead to hypoactivity.  On the other hand both 
staggerer and leaner mutant mice have degeneration in the inferior olive [391], which 
can also lead to hypoactivity [392].  These mouse models of cerebellar degeneration all 
show alterations to regions of the brain other than the cerebellum and combined this leads 
to altered nocturnal cage behaviour, unlike hq mice.   
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4.2.4 Qualitative changes in behaviour are not tracked with an actimeter 
 The ActiTrack  actimeter is able to quantify behaviours in mice involved in 
simple movements like locomotion, stereotypes, and rearing.  However, mouse behaviour 
is complex and mice with neurodegeneration can have behavioural changes that may not 
affect parameters of activity.  A decrease in stride length and duration is detected in a 
mouse model of PD [145] and an increase in stride duration and a decrease in 
coordination are detected in a mouse model of ALS [147, 393].  Although behaviour did 
not change with age, the location of the most severe degeneration of granule cells 
occurred in lobules IX and X in hq mice, which is the location of afferent and efferent 
connections with the vestibular nuclei [394-396].  Ablation of lobules IX and X in cats 
leads to an unsteady gate [397], and lesions in lobules VIII-X in rats enhances tremors 
induced by harmaline, a reversible inhibitor of monoamine oxidase [398].  It has been 
well documented that hq mice have ataxia characterized by an unsteady gait and lateral 
tremors [232, 268], but it appears that the ataxia doesn’t alter nocturnal behaviours that 
were measured in hq mice.  One caveat of the ActiTrack  system is that it is able to 
measure quantitative parameters of activity but not able to assess the quality of 
movement.  To better study the behaviour of hq mice with progressive 
neurodegeneration, studies using rotarod, gait analysis, and video surveillance in 
conjunction with nocturnal behaviour would better indicate the quality of motor 
coordination and behaviour with neurodegeneration.   
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4.3 Phenobarbital was delivered in a hormetic dose producing expected behavioural 
effects in WT mice 
4.3.1 Low-dose PB had a stimulatory effect on nocturnal behaviour in WT mice  
Phenobarbital administration increases activity in rodents [299, 300], and indeed 
that is the case in the WT mice herein.  All the parameters that were measured showed a 
significant shift towards increased nocturnal activity with the exception of the duration of 
rearing events, which was not altered with PB treatment.  Phenobarbital treatment of WT 
mice could be described as having a biphasic or hormetic effect on behaviour.  High-dose 
PB treatment in mice causes inhibition of the central nervous system by binding GABAA 
receptors leading to an increase in chloride ion conductivity and subsequent 
hyperpolarization [296].  Low-dose PB treatment in WT mice had an overall stimulatory 
affect.  This excitatory action of PB has been documented before in humans and in 
animals [300, 399-401].  Evidence suggests that the excitatory mechanism of PB occurs 
through elevated levels of dopamine.  Rats treated with PB show a two- to five-fold 
increase in dopamine levels in the caudate nucleus, cortex, midbrain, and the cerebellum 
and this occurs during the dark phase when rats are at their most active [402].  Another 
study was able to show that the dopamine receptor blocker, haloperidol, inhibits the PB 
stimulant effect on locomotor activity in mice [300].  In addition, –methyl-p-tyrosine 
(AMPT), a tyrosine hydroxylase inhibitor, suppresses locomotor activity in mice treated 
with PB [300].  Tyrosine hydroxylase is required for the conversion of the amino acid L-
tyrosine to dihydroxyphenylalanine (DOPA) [403], a dopamine precursor, and suggests 
that newly synthesized dopamine is involved in the increased locomotor activity of WT 
mice treated with PB.  The exact mechanism of how PB causes an increase in dopamine 
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levels has not yet been elucidated but low concentrations of PB increases calcium 
conductance in Aplysia [404], and calcium is able to increase tyrosine hydroxylase 
activity and dopamine production [405].  Even though PB administration resulted in 
increased nocturnal behaviour, prolonged exposure of WT mice to 4 ppm of PB resulted 
in desensitization to PB at 7 months of age.  This is consistent with physiological 
tolerance to PB where the organism has increased resistance after repeated exposure to a 
drug.  Chronic exposure to PB in mice leads to an 18% down-regulation in the protein 
levels of the GABAA receptor [406].  In rats, chronic exposure to PB leads to a 45% 
decrease in the protein levels of GABAA receptor subunit  1 [407].  This suggests that 
chronic exposure to 4 ppm of PB could lead to a down-regulation of the GABAA receptor 
and should be confirmed.  The observed stimulatory effect of PB on WT mice herein, 
even at low doses, is consistent with an exposure to a dose of PB that is capable of 
eliciting a response.    
 
4.3.2 Low-dose PB increased body mass in WT and hq mice  
 A hypothesis that could explain weight gain in both WT and hq mice with PB 
treatment is that PB stimulates feeding systems located in the hypothalamus.  There is 
evidence that GABA and GABAA receptors are involved in feeding behaviours.  GABA 
agonists, muscimol and flurazepam, when injected into the medial hypothalamus, 
increases feeding behaviour while GABA antagonists inhibits feeding behaviour [408].  
In addition, silencing of the Huntingtin-associated protein-1 gene, capable of stabilizing 
GABAA receptors, reduces the level and activity of hypothalamic GABAA receptors and 
leads to a decrease in food intake and body weight [409].  Since hq mice have down-
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regulated -aminobutyric acid A receptor,  6 (Gabra6) which is a GABAA receptor 
subunit, this could decrease feeding behaviour and could explain why hq mice have a 
smaller body mass and a lower rate of weight gain when compared to WT mice.  Since 
PB binds the GABAA receptor, it would also explain why both WT and hq mice gained 
weight with PB treatment, however, the rate of weight gain was lower in hq mice which 
would be consistent with a down-regulated GABAA receptor gene.  The hq mice showed 
a dose response effect with 4 ppm of PB having a faster rate of weight gain than 2 ppm in 
hq mice, indicating that more PB is required to increase body mass in hq mice because of 
the Gabra6 down-regulation.  WT mice did not show the same dose response in weight 
gain possibly because all the GABAA receptors were saturated with 2 ppm but also 
because there may be less capacity for larger WT mice to increase in body mass 
compared to hq mice.  To test the hypothesis that the Gabra6 subunit down-regulation 
leads to increased feeding behaviour, the daily mass of food consumed could be 
measured to determine whether PB stimulates appetite in both WT and hq mice.  
 
4.4 Elevated ROS levels do not appear to be a major driver or consequence of hq 
cerebellar degeneration 
 To test the hypothesis that hq mice will have elevated levels of ROS, the mutant 
and mutation frequency and pattern, lipofuscin autofluorescence, and superoxide anion 
levels were determined for WT and hq mice at 3, 7, and 10 months of age.  The 
transcriptome was also examined for genes involved in the oxidative stress response. 
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4.4.1 ROS-induced mutations in the nuclear DNA do not appear to be a predominant 
feature of hq cerebellar degeneration 
 Unlike the previous observation of elevated frequency of mutation in the brain of 
hq mice, the cII assay did not reveal significant elevation in spontaneous mutation 
frequency in the cerebellum of hq mice in young and middle adulthood [410].  This 
observation of a constant mutation frequency is consistent with previous observations 
that mutation frequency is constant in the cerebellum over the mouse life span [242, 243].  
Even in mouse mimics of premature aging, the frequency of spontaneous mutation would 
not be expected to be significantly elevated in brain tissues.  Elevated mutation frequency 
in skin [240] but not cerebellum of hq mice may result from replication of skin 
epithelium and fixation of mutations in comparison to the postmitotic granule neurons of 
the cerebellum.  
 There was no change in mutation pattern in the cerebellum of hq mice compared 
to WT mice at 3 and 7 months of age [410], consistent with previous observations of 
relatively unchanged mutation pattern over the lifespan of the mouse [242, 243].  A 
change in mutation pattern would be difficult to detect since 20 different base lesions are 
associated with oxidative DNA damage [411], thus decreasing the sensitivity of the cII 
assay to detect individual signature mutations for modest increases above the background 
level of mutation.  The most common mutation signature of oxidative stress, G:T 
transversions [347], was not over represented in hq mice.  Mutagenesis does not appear to 
be a major driver or consequence of decreased Aif levels. 
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4.4.2 Contrary to a previous report, mutation frequency in the cerebellum of hq mice was 
not elevated 
 The observation that mutation frequency and pattern in hq mice were not different 
from WT mice conflicted with a previous report where the mutant frequency was 
elevated three-fold in the brain of hq mice [241].  The cII assay is a forward mutation 
detection assay capable of detecting all types of base substitutions and small deletions 
and insertions while the previously used PLAP assay detects the frequency of a −1 base 
pair deletion at a monobasic run of 11 guanines [241]. The longest monobasic runs in the 
cII mutation target are runs of six guanines and six adenines.  These monobasic runs 
enable comparison with the PLAP frameshift mutations, but these monobasic runs did not 
show greater mutant frequency in single nucleotide deletions in the cerebellum of hq 
mice at either age.  Guanines are the most common target of oxidative damage and a run 
of 11 guanines is hypermutable, consistent with a previous report of increased frequency 
of mutations in longer repeats [412].  Guanine repeats have an innate stacking nature and 
an increased susceptibility to adduct formation [413].  Oxidative stress in the brains of hq 
mice combined with the susceptibility of guanine adducts and inherent instability of 
guanine stacking could contribute to the previous in situ observation of increased 
mutation frequency in brains of hq mice.  One other possibility is the potential for the 
PLAP assay to detect transcriptional errors in addition to mutation.  Monobasic runs are 
susceptible to both replication and transcription errors and transcriptional errors are 
hypothesized to increase with increased oxidative stress associated with aging [414].  In 
the PLAP assay, clusters of positive cells are consistent with mutation and replication of 
mutant cells and the reversion mutation has been confirmed [415] but single isolated cells 
with positive signal could be examined to confirm mutation status and rule out any 
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contribution by transcriptional error.  PLAP over representation could be due to 
measuring errors in transcription, leading to the inflation in the mutant frequency 
compared to that measured using the cII transgene. 
 
4.4.3 One ROS mutation signature was observed in young hq mice 
 There was evidence of oxidative stress-induced mutations in the form of four 
deletions between 10 and 21 base pairs in length identified in four out of five hq mice in 
the 3-month-old cohort [410].  No homologous sequences were found in the deletion 
junctions to implicate sequence context driven mechanisms and as such, these deletions 
are representative of Class II deletions [371].  Class II deletions have been reported in 
mice exposed to γ-radiation [371, 416] and dimethylnitrosamine [417] and associated 
with elevated endogenous oxidative stress [418].  Thus, a ROS mutation signature was 
detected but overall was not dramatically more frequent and not a major consequence of 
the down-regulation of Aif.  
 
4.4.4 Mutations in nuclear DNA are not associated with neurodegeneration in hq mice  
 The hq phenotype is not associated with elevated frequency and significant 
alterations in the overall pattern of independent mutations in the cerebellum likely for 
several reasons.  Mutation frequency in nuclear DNA is not elevated because nuclear 
DNA is protected with histones and is distant from the site of ROS production in the 
mitochondria.  A more plausible target of oxidative stress-induced mutation is 
mitochondrial DNA.  Approximately 2% of consumed oxygen is converted to superoxide 
radicals during respiration [51] that can then go on to cause DNA strand breaks and base 
  
164 
modifications in mitochondrial DNA [419].  Individuals with AD have 10-fold higher 
levels of oxidized bases in the mitochondrial DNA compared to nuclear DNA [40].  
Mitochondrial mutations have been detected in brains of AD [58], PD [420], and ALS 
patients [421].  Thus in hq mice, mitochondrial DNA may be more susceptible to ROS-
induced mutations than nuclear DNA.  To test the hypothesis that the mitochondrial DNA 
in hq mice is more susceptible to ROS-induced mutations, the mitochondrial random 
mutation capture assay [422] could be used to measure mutations in WT and hq mice. 
  
4.4.5 Lipofuscin levels in hq mice were not elevated compared to WT mice   
Lipofuscin accumulation in the cerebellum was detected in hq mice and did 
increase with age but was similar to cerebellar lipofuscin accumulation in WT mice.  
Lipofuscin autofluorescence was elevated in lobules I/II and VIa that are located in the 
anterior and central lobes of the cerebellum.  Although only two lobules show an increase 
of lipofuscin autofluorescence with age, one has to keep in mind that the Purkinje cells, 
which are demonstrating lipofuscin autofluorescence, are also being lost with age, which 
would impact the levels detected as Purkinje cells are no longer there.  These lipofuscin 
results in the cerebellum of hq mouse were different when compared to a previous study 
of lipofuscin in the olfactory epithelium in hq mice, that found elevated lipofuscin 
autofluorescence in 6-month-old hq mice and not in WT mice [245].  Even though the 
olfactory epithelium in hq mice has increased apoptotic neurons when compared to age-
matched littermate controls, the olfactory epithelium is a site of neurogenesis that is 
stimulated by neuronal cell death [423-425], thus explaining why the layers of the 
olfactory epithelium have elevated lipofuscin and do not decrease in thickness or cell 
number when compared to the retina or the cerebellum [232, 269, 376].  Had the Purkinje 
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cells in hq mice survived, it is reasonable to think that lipofuscin autofluorescence would 
have been elevated with age in hq mice compared to WT mice. 
 
4.4.6 Superoxide anions were not elevated in hq compared to WT mice 
Superoxide anions were elevated with age in hq mice in lobules I/II, III, and VIa, 
but this was not different from WT mice.  This pattern of elevated levels of superoxide 
anions is opposite to the profile of granule cell loss.  The lobules with the most initial 
granule cell loss were lobules IX and X, but the ROS profiles in these lobules did not 
change with age.  Lobules that did not have detectable granule cell loss until late in 
disease progression had a superoxide anion profile that increased with age.   The 
increased levels of superoxide anions with age are likely a reflection of mitochondrial 
dysfunction combined with the granule cell density in individual lobules.  Since oxidative 
stress was not elevated initially in the 3-month-old hq cerebellum, elevated ROS is not 
likely responsible for increased cell death in hq mice seen with apoptosis staining at 7 
months of age, or lipofuscin accumulation in Purkinje cells.  
This observation of no initial elevation of superoxide anion levels is similar to a 
report of superoxide anion levels in the retina of hq mice [269] but is in contrast to other 
reports that ROS is elevated in hq heart and skin [239, 240] as well as the retina of female 
hq carrier mice [426].  The reason for this discrepancy is likely due to the lower number 
of neurons in the cerebellum and retina of hq mice, since quantification of DHE intensity 
depends on the density of nuclei containing ethidium.  The heart and skin tissue of hq 
mice shows increased ROS but they do not display any cell loss.  The retina of the female 
hq carrier mice does display cell loss, however, the phenotype is not as severe as in hq 
mice [427], indicating that measurement of ROS levels in the cerebellum of hq mice were 
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confounded by granule cell loss.  In the future, it is suggested that the ROS levels be 
normalized to the number of granule cells.   
 
4.4.7 mRNA levels do not indicate a transcriptome response to elevated levels of ROS  
Oxidative stress can lead to changes in the expression of many genes including 
additional antioxidant enzymes like superoxide dismutase, catalase, glutathioine S-
transferase, glutathione reductase, thioredoxin, peroxiredoxin, as well as genes involved 
in DNA repair, and heat shock proteins. Only the ROS scavenger, Glutathione 
peroxidase 3 (Gpx3), was up-regulated in hq cerebellum.  Alterations at the mRNA level 
for antioxidants other than Gpx3 were not detected, nor were there alterations in DNA 
repair enzymes or heat shock proteins in hq mice.  The limited number of genes related to 
oxidative stress response in the transcriptome data suggests that oxidative stress may not 
be a major initator of cerebellar cell loss in hq mice.  
 
4.5 The role of AIF in the production or detoxification of ROS remains unknown 
 The results herein, show that hq mice did not have elevated levels of ROS or 
lipofuscin at 3 months of age when compared to WT mice, which was contrary to the 
expectation if one of AIF’s roles was to scavenge ROS.  However, complex I deficiency 
alone can lead to elevated oxidative stress [428], which could explain the increase in 
ROS in hq mice with age as more mitochondria degenerate.  However, AIF’s role in 
scavenging ROS is based on its amino acid sequence similarity with prokaryotic 
oxidoreductases [238] but conflicting results have been found about its ability to reduce 
or produce ROS.  In hq mice, AIF-deficiency leads to increased peroxide sensitivity in 
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granule neurons [232] and cardiomyocytes [235], suggesting a protective effect of AIF as 
an antioxidant.  In vitro, AIF has NADH oxidase activity and mediates the reduction of 
oxygen to superoxide radical [429].  In contrast, there are decreased levels of superoxide 
anions generated in AIF-deficient tumour cell lines [250].  A different study shows no 
difference in oxidative damage or ROS levels in WT and AIF-deficient mouse embryonic 
stems cells [248].  In addition, neither the basal rate of ROS release or hydrogen peroxide 
removal are different in WT and hq mice [430], so AIF's role in the production or 
removal of ROS remains unclear.   
To further evaluate the ROS production and detoxification function of AIF, the 
NADH oxidoreductase activity of AIF needs to be further studied.  NADH 
oxidoreductases accept electrons from NADH and in the process convert NADH to 
NAD
+
 to be used in various cellular processes [431, 432].  In a cell free system, AIF 
oxidizes NADH and transfers electrons to molecular oxygen, ferricyanide, and 
dichlorophenolindophenol (a redox indicator), but does not show any hydrogen 
peroxidase scavenging activity [429].  However, this superoxide generation of AIF is not 
detected in vivo and suggests that there are other substrates and targets of AIF that have 
not yet been detected.  Until we know what all of the substrates, targets, and proteins that 
interact with AIF are, we won’t fully understand its function in the mitochondria.  If 
elevated ROS was the mechanism of cerebellar degeneration in hq mice, PB 
administration may have been an effective treatment but more evidence is consistent with 
mitochondrial dysfunction with AIF deficiency.  
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4.6 Early hq mechanisms were elucidated from the transcriptome of the cerebellum 
 To examine the hypothesis that pathways involved in ROS, mitochondrial 
dysfunction, and inflammation would be up-regulated in hq mice, a gene expression 
experiment was performed in 3-month-old WT and hq mice. 
 
4.6.1 The up-regulation of Melanoma antigen suggests that the proviral insertion in Aif is 
transcribed 
 The Melanoma antigen (Mela) gene was up-regulated 14.5 fold in the cerebella of 
3-month-old hq mice compared to WT mice.  Mela is expressed during development at 
embryonic day 14.5 in the central nervous system and the thymus [433].  Mela has a 
similar nucleotide sequence to the env gene that is located at the 3’ end of the mouse 
murine leukemia virus.  The murine leukemia virus is the proviral insertion located in 
intron one of the Aif gene [232], suggesting that the microarray is able to detect proviral 
mRNA from the transcription of Aif.  Whether the up-regulation of the env gene leads to 
ENV production in hq mice is unknown and should be confirmed with a western blot to 
determine ENV protein expression levels.  Whether the proviral insertion in hq mice is 
able to produce active viral components has not been studied, but ENV is not sufficient 
on its own to cause infection and requires mature viral components [434].  Infection with 
ENV induces spongiform neurodegeneration [435], which was not observed in hq mice 
suggesting that ENV expression is not a cause of cerebellar degeneration in hq mice. 
 
4.6.2 The complement pathway is activated in 3-month-old hq mice 
  As expected, 3-month-old hq mice had alterations in pathways involving the 
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immune and inflammatory response.  The complement pathway was the most 
significantly up-regulated pathway in the cerebellum of hq mice. The liver is the main 
source of the complement proteins but in situ hybridization has identified complement 
proteins expressed in the brain [436].  Complement component 1, q subcomponent (C1Q) 
is the initial target and recognition protein of the complementation pathway and is 
required for the clearance of pathogens and apoptotic cells [437].  C1Q has a 
heterotrimeric structure composed of 18 polypeptide chains, 6 each of C1QA, CIQB and 
C1QC [438].  Both C1qb and C1qc were up-regulated in the cerebellum of 3-month-old 
hq mice, but C1qa is also required to form the C1Q complex.  C1qa had a fold increase 
of 1.3 and did not make the 1.5 fold cut off for the microarray analysis, consistent with a 
limited sensitivity of the microarray technology to detect small increases in fold change 
due to the dilution of gene expression by the heterogeneous cell types in the brain [439].  
However, small increases in fold change still have a biological impact [440], as 
evidenced by the fact that full C1Q complex is needed for the activation of the 
complement pathway, and genes downstream of C1Q were up-regulated in the 
cerebellum of 3-month-old hq mice, including Complement component 3a receptor 1 
(C3ar1) and the basic form of Complement component 4b (C4b).  In the cerebellum of 4-
month-old hq mice, C1qa is up-regulated as well as C1qb and C1qc [427].  With the C1Q 
complex assembled, it is able to directly bind to apoptotic cells resulting in the activation 
of the classical complement pathway [437] and facilitates the clearance of apoptotic cells 
by microglia.  The fact that genes in the complement cascade were up-regulated, in 
particular the early activation products, shows that there was initiation of the 
phagocytosis response to get rid of apoptotic cells as early as 3 months of age in the 
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cerebellum of hq mice.  Also, the limited number of degenerating neurons also supports 
effective clearance of apoptotic cells.  Up-regulation of the complement pathway in hq 
mice compared to WT mice still needs to be validated with real time PCR or protein 
expression. 
 Although complement activation is required in defense against pathogens and 
removal of apoptotic cells, constant up-regulation is detrimental and leads to host tissue 
damage.  Complement activation has been implicated in normal aging [200-202, 290, 
291] and the pathogenesis of several diseases including systemic lupus 
erythematosus/rheumatoid arthritis [441], multiple sclerosis [442], spinal cord injury 
[443], psoriasis [444], age-related macular degeneration [445],  and neurodegenerative 
diseases [436, 446, 447].  Complement proteins are associated with amyloid deposits in 
AD [448].  A mouse knockout of C1q crossed with APP transgenic mice, shows 
decreased glial cell activation without reducing amyloid deposition, suggesting a role for 
complement activation in the pathology of AD [449, 450].  In early stages of AD, the 
presence of the early complement components is found in plaques including C1Q, C4D 
and C3D but components C5B-9 are absent [451, 452].  At later stages of AD, in addition 
to C1Q, C4D, and C3D, C5B-9 are present in plaques and neurofibrillary tangles [453], 
further suggesting a role for early complement activation in AD.  In addition, the 
prominence of early complement components is in line with a study comparing a 
transgenic mouse model of AD to WT mice [454], which is similar to what was found 
here in the cerebellum of 3-month-old hq mice suggesting that early complement 
components play a role in neurodegeneration in hq mice.  
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4.6.3 There was up-regulation of the pathway termed crosstalk between dendritic cells 
and natural killer cells  
There was significant up-regulation in the crosstalk pathway between dendritic 
cells and natural killer cells.  Dendritic cells and natural killer cells are both components 
of the immune response in the circulatory system.  Dendritic cells process antigens and 
present antigenic material on their surface leading to activation of other immune cells.  
Natural killer cells are lymphocytes, capable of killing cells that have been infected with 
viruses or cells that are cancerous.  Genes that were up-regulated in this pathway 
included TYRO protein tyrosine kinase binding protein (Tyrobp), the major 
histocompatibility complex I (MHC1) component Histocompatibility 2, K1, K region 
(H2-K1), and Actin alpha 2 smooth muscle aorta (Acta2).  TYROBP is an adaptor 
molecule that binds to activating receptors on the natural killer cells and is required for 
natural killer cell activation [455].  Since dendritic and natural killer cells are part of the 
immune system in the circulatory system, it is unlikely that the cells were able to 
infiltrate the cerebellum through the blood-brain barrier.  Since microglial cells are the 
macrophages of the central nervous system, it is possible that both Tyrobp and H2-K1 
were up-regulated due to microglial activation.  TYROBP is expressed in microglial cells 
and up-regulation can lead to an increase in superoxide formation and can lead to 
increased apoptosis [456].  H2-K1 can also be expressed in microglial cells after 
engulfment of apoptotic cells [457].  The Acta2 gene codes for -actin in vascular 
smooth muscle cells and is important for the contractile function in vasculature [458].  
Since down-regulation of Acta2 results in a decrease in the structural integrity of 
vasculature, and mutations in Acta2 can lead to familial aortic aneurisms [459], up-
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regulation of the Acta2 gene could be due to maintenance of the integrity of the blood-
brain barrier in hq mice.  In hq mice, blood vessels are thicker, longer, and more 
numerous compared to WT mice [234] indicating maintenance of the blood-brain barrier.  
Up-regulation of Tyrobp, H2-K1, and Acta2 suggests microglial activation in the 
cerebellum rather than infiltration from the circulatory system by dendritic and natural 
killer cells due to a compromised blood-brain barrier in 3-month-old hq mice.  
 
4.6.4 There is maintenance of the extracellular matrix and an active immune response 
In hq mice, genes that were up-regulated in the neuroprotective role of THOP1 in 
Alzheimer’s disease pathway included Serine peptidase inhibitor, clade A, member 3N 
(Serpina3n) and H2-K1.  THOP1 is a metalloprotease that has been associated with APP 
[460] processing and the indirect degradation of the amyloid  [461] thereby preserving 
the integrity of axons and dendrites and maintaining connectivity and extracellular matrix 
functionality of neurons in AD.  Despite the neuroprotective role of this pathway, the 
differentially-expressed genes that were up-regulated have a detrimental role in the 
THOP1 neuroprotective pathway.  SERPINA3N is closely associated with amyloid  
[462] and decreased THOP1-dependent amyloid  degradation by 60% [461] either by 
inhibiting amyloid  degrading proteases or preventing proteases in the brain from 
clearing APP thus contributing to amyloid deposits.  In addition, SERPINA3N is detected 
in astrocytes in normal human aging [462] suggesting that Serpina3n overexpression is 
not limited to pathology in AD.  Serpina3n co-localizes with astrocytes in the retina after 
inflammatory stimulation with lipopolysaccharide [463].  The co-localization of 
Serpina3n and astrocytes could be beneficial as SERPINA3N can inhibit Cathepsin G 
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and Elastase, which can hydrolyze proteins in the extracellular matrix [464].  Since hq 
mice don’t have amyloid  pathology, SERPINA3N would have a beneficial effect in 
limiting breakdown of the extracellular matrix in the cerebellum of hq mice.  THOP1 also 
hydrolyzes oligopeptides ranging in size from 6-17 amino acids in length [465] including 
antigenic peptides [466] thus limiting MHC I presentation [467], which could eventually 
lead to suppression of the immune response.  However, in the cerebellum of 3-month-old 
hq mice the MHCI component was up-regulated suggesting an increased immune 
response.   Thus, it is possible that hq mice have down-regulated the neuroprotective role 
of THOP1 in Alzheimer’s disease pathway leading to a maintenance of the extracellular 
matrix and increased immune response.  Validation is still needed with real time PCR or 
protein expression.  
 
4.6.5 Immune response activation is consistent with microglial activation 
 The final pathway up-regulated in hq mice related to immune response was 
communication between innate and adaptive immune cells.  The two genes that were up-
regulated in the communication between innate and adaptive immune cells pathway were 
Chemokine (C-C motif) ligand 3 (Ccl3) and H2-K1. The innate immune system is an 
immediate defense system used to protect the host from infection from pathogens through 
the production of chemokines and inflammatory cytokines.  The adaptive immune system 
is activated by the innate immune system and provides an organism with the ability to 
recognize and remember specific pathogens so that it may trigger stronger attacks each 
time the same pathogen is encountered.  The innate and adaptive immune systems can be 
activated through microglial activation [468].  Microglial cells are the resident 
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macrophages of the central nervous system and are activated by infection, injury, or 
apoptotic cells [62].  CCL3 is a chemokine secreted by activated microglial cells in order 
to attract additional microglial cells to the point of injury [468].  Microglial cells are 
antigen presenting cells, capable of expressing MHC I and II.  Histocompatibility 2-K1 is 
one of the components of the MHCI antigen [469] and is presented on the surface of 
microglial cells after phagocytosis of dead or foreign cells [457].  Since pathways related 
to immune responses were up-regulated in the cerebella of 3-month-old hq mice without 
any evidence of invading bacteria, viruses, or a compromised blood-brain barrier, a more 
plausible hypothesis is that an immune response is occurring in the cerebellum through 
the activation of microglial cells by damaged or apoptotic neurons.  Indeed, manual 
annotation of the differentially-expressed genes, revealed markers of microglial 
activation and needs further validation.   
 
4.6.6 Multiple transcripts identified by gene expression indicate microglial activation  
 Microglial activation is associated with the release of ROS [73], proteases [74], and 
inflammatory cytokines [70].  Markers of microglial activation in hq mice included Ccl3, 
which attracts microglia to the site of injury [468].  Cluster of differentiation 68 (Cd68) a 
cell surface glycoprotein present on activated microglial cells [470].  Cluster of 
differentiation 93 (Cd93), also known as Complement component 1 subcomponent 
receptor 1 (C1QR1) that is required for the engulfment of apoptotic cells by microglia 
[471].  Histocompatibility 2-K1 (H2-K1), is one of the components of MHCI [469] and is 
presented on the surface of microglial cells after phagocytosis of dead or foreign cells 
[457].  In addition, Lysozyme 2 (Lyz2) and Cathepsin S (Ctss) are proteases present in 
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lysosomes of microglial cells.  Lyz2 is required for the degradation of apoptotic cells 
[472] and Ctss is required for MHC II presentation [473] and for degradation of the 
extracellular matrix [474].  Microglial activation is a necessary component in the removal 
of cellular debris in the brain, but constant stimulation or unregulated response of 
microglial cells leads to inflammation.  Microglial activation and inflammation is 
prevalent in neurodegenerative disorders including AD [82], PD [82], and ALS [86].  The 
up-regulation of microglial markers suggests activated microglia play a role in the early 
stages of neurodegeneration of the cerebellum of 3-month-old hq mice.  
 
4.6.7 Similar cerebellar transcriptome features exist in 3 and 4-month-old hq mice 
Reproducibility of scientific results is a fundamental principle in scientific 
research.  This is of particular importance with microarray technology, which has been 
known to show a high amount of variability in lists of differentially-expressed genes 
[475].  Variability can be explained by the use of different platforms and laboratory 
processing but the reproducibility herein was found in the gene list in the cerebellum of 
3- and 4-month-old hq mice.  Of the 55 differentially-expressed genes found in the 
cerebellum of 3-month-old hq compared to WT mice, 48 were also differentially 
expressed in the cerebellum of 4-month-old hq compared to WT mice (Appendix B, 
Table B.1) [427].  And in both cases, the fold change was in the same direction for genes 
that were differentially expressed.  Genes that were not reproduced included a predicted 
gene of unknown function (Gm11428), an enzyme that converts ethanol to acetaldehyde 
(Adh1), a nicotine, acetylcholine, and cation ligand channel (Chrnb4), a guide RNA 
involved in methylation of pre-rRNA (Snord82), a lipid kinase that is a negative regulator 
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of apoptosis (Cerkl), a receptor for the neurotransmitter GABA (Gabra6), and a 
mitochondrial protein involved in the assembly and/or maintenance of complex I in the 
electron transport chain (Aifm1).  However, down-regulation of Aifm1 was confirmed 
through Taqman
®
 assays in hq mice at 5 weeks of age, 4 months of age and 7 months of 
age for both the retina and cerebellum (Edwards, unpublished)(Thwaites, unpublished) 
[476].  Ctss up-regulation was confirmed with Taqman
®
 assays in the cerebella of hq 
mice at 5 weeks and 4 months of age (Thwaites, unpublished).  Thus, most of the genes 
in the cerebellum of 3-month-old hq mice were replicated in the cerebellum of 4-month-
old hq mice. 
 
4.6.8 Similarities and differences exist between cerebellar and retinal transcriptomes in 
hq mice 
 Altered pathways in the cerebellum of 3-month-old hq mice included those 
involved in the immune and inflammatory response.  This is similar to a report of gene 
expression in the retina [427] and cerebellum of 4-month-old hq mice (Appendix B, 
Table B.1) [427].  At 4 months of age, both the retina and cerebellum show evidence of 
altered metabolism with a shift to glycolysis [427], as a result of reduced oxidative 
phosphorylation [248].  When glycolysis is inhibited in AIF-deficient embryonic stems 
cells, there is increased cell death [248] suggesting an increased dependence on 
glycolysis for ATP production.  Similarly, altered pathways in the retina in 4-month-old 
hq mice are involved in immune and inflammatory response as well as altered 
metabolism with a shift to glycolysis [427]. 
One difference between the cerebellum and retina is that the retina appears to 
have an earlier onset of degeneration compared to the cerebellum.  In the retina, 
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functional deficits measured by electroretinography, are observed as early as 2 months of 
age in hq mice [269], apoptotic retinal cells are detected at 3 months of age [232], and 
retinal structural deficits are first seen in the ganglion cell layer and outer nuclear layer at 
4 months of age [269].  In the cerebellum, apoptotic cells are first seen at 4 months of age 
in the hq mice leading to a decrease in rotarod performance, a measure of motor co-
ordination, at 6 months of age [233] and structural deficits in the granule and Purkinje 
cell layer of the cerebellum at 7 months of age [232].  Although, it should be noted that 
the retina has had a detailed monthly characterization of the degeneration in different 
layers, whereas, the cerebellum has been studied at a fewer number of time points, so 
comparisons between the two tissues are difficult.  One difference in the disease 
mechanism between the retina and cerebellum is that the retina of hq mice shows 
evidence of extracellular matrix remodeling.  Altered pathways identified in the retina of 
4-month-old hq mice are related to extracellular matrix receptor interaction, focal 
adhesions involved with the regulation of the extracellular matrix, and cytoskeletal 
elements [427].  In addition, hematoxylin and eosin staining shows nuclear displacement 
in the retina [269, 426], confirming remodeling of extracellular matrix.  In contrast, the 
cerebellum did not show altered gene expression in pathways involved in extracellular 
matrix remodeling or nuclear displacement of the granule or Purkinje cells. 
 
4.6.9 Transcriptome changes with degeneration of hq olfactory epithelium implicated 
different underlying mechanisms 
The reports on gene expression in the retina and cerebellum differ when compared 
to the olfactory epithelium in hq mice.  None of the differentially expressed genes in the 
cerebellum of 3- and 4-month-old hq mice were detected in the olfactory epithelium in 6-
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month-old hq mice [245].  In the olfactory epithelium, altered genes are classified into 
cell signaling/apoptosis, oxidative stress/aging, cytoskeleton/extracellular matrix, 
transport, and neurogenesis pathways [245].  Several reasons could explain this 
discrepancy, the first being that the tissues although they are neural, could have different 
degeneration timelines.  This has been demonstrated for the retina and the cerebellum in 
hq mice.  Retinal degeneration is detected as early as 2 or 3 months of age and cerebellar 
degeneration occurs at 4 months of age [232, 234, 269], but since there is only one study 
in the olfactory epithelium in hq mice [245], a neurodegenerative timeline has not been 
established for the olfactory epithelium.  In addition, different ages of hq mice have been 
studied thus far, and at 6 months of age, disease progression in the olfactory epithelium is 
well underway, whereas 3 months of age is considered early in the disease onset [232, 
234].  Also, the olfactory epithelium is directly exposed to the external environment 
unlike the cerebellum, and exposure to environmental agents could alter gene expression.  
Thus, the underlying mechanisms of neurodegeneration in the olfactory epithelium need 
to be characterized further with an increased number of time points to better compare the 
differences in the neurodegeneration timeline.   
 
4.7 Chronic low-dose PB treatment produced few alterations in the transcriptome of 
the cerebellum 
4.7.1 The effect of PB on the transcriptome in the cerebellum was limited in WT and hq 
mice 
Phenobarbital treatment had little effect on the transcriptome in WT and hq mice 
and may not be acting through the induction of gene expression.  Administration of 10 
mg/kg/day of PB for 28 days leads to very little change in the gene expression in the 
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liver, as two genes were up-regulated and three genes were down-regulated more than 1.5 
fold [477].  Even at a higher dose, 100 mg/kg/day, only seven genes are up-regulated and 
one gene is down-regulated more than 1.5 fold.  The two genes that are up-regulated with 
10 mg/kg/day are both cytochrome P450 enzymes.  Enzyme activity assays, however, 
show increased activity for four different cytochrome P450 enzymes even though 
alteration in the gene expression is not significant [477], suggesting that PB may work 
through the induction of enzyme activity rather than a change in gene expression in the 
brain.  
 
4.7.2 Down-regulation of the GABAA receptor may impede the effectiveness of PB 
The gene expression assay showed that hq mice have a down-regulated Gabra6 
gene, potentially leading to down-regulation of functional GABAA receptors.  A down-
regulation in functional GABAA receptors could explain why PB treatment had little 
effect on the behavior of hq mice.  Additionally, hq mice require increased levels of 
ketamine anesthetic for sedation during retinal function testing because hq mice are 
coming out of sedation earlier than expected.  Current literature suggests that ketamine is 
able to act upon GABAA receptors, in particular the alpha6beta2delta receptor subtype, 
as well as the N-methyl-D-aspartic acid receptors to produce the anesthetic effect [478].  
Both the lack of activity of hq mice with PB administration and the increased ketamine 
doses required for sedation in hq mice are consistent with the hypothesis that hq mice 
have decreased Gabra6 levels.  To test the hypothesis that hq mice have a decreased 
amount of the GABRA6 subunit, a western blot could be performed to determine levels 
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of the subunit in WT and hq mice.  Decreased Gabra6 levels potentially make PB an 
unsuitable hormetic agent in hq mice.   
 
4.8 The hq disease mechanisms and phenotype are consistent with mitochondrial 
dysfunction 
While PB treatment did not reveal any benefit in WT or hq mice, the data are 
consistent with disease mechanisms associated with mitochondrial function.  In cell 
culture, AIF-deficient cells have compromised oxidative function and rely on ATP 
generated from glycolysis [248] suggesting that decreased AIF leads to mitochondrial 
dysfunction.  Degenerating mitochondria are seen as early as 2 months of age in hq 
cerebellum and the rate of degenerating mitochondria increases progressively starting at 
41% at 2 months of age to 81% at 6 months of age in cerebellar granular cells [234].  At 
4 months of age, transcriptome analysis in the retina and cerebellum reveals altered 
metabolism with various genes related to glycolysis [426].  Also, mitochondrial complex 
I deficiencies are tissue specific.  In humans, tissues that can be adversely affected by 
mitochondrial complex I deficiencies include the retina [252], brain [252, 380, 381], heart 
[380], skeletal muscle [252, 381], skin [382], and hair [382].  A mouse model of complex 
I deficiency, displays a decreased growth rate, ataxia, blindness, and encephalomyopathy 
[479].  In humans and mice, the symptoms of the mitochondrial complex I deficiencies 
are similar to symptoms in hq mice.  Since mitochondrial dysfunction leads to elevated 
ROS production [480], this would explain increased lipofuscin and ROS with age in hq 
mice.  Since we know that there is a lobule specific pattern of neuron loss, one caveat of 
the study regarding mitochondrial dysfunction in hq mice [234], was that it did not 
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specify the mitochondrial dysfunction on a per lobule basis in hq mice to see whether 
lobules IX and X had more dysfunctional mitochondria relative to the other lobules.  
Elevated ROS are likely a consequence of mitochondrial dysfunction and do not appear 
to be associated with early cerebellar degeneration in hq mice.  Thus, the cause of 
degeneration is likely mitochondrial dysfunction leading to a decrease in ATP production 
and eventually cell death.  In order to prevent cerebellar degeneration in hq mice, 
mitochondrial dysfunction would have to be addressed either through increasing the 
amount of complex I, or by increasing the efficiency of the electron transport chain.  
Phenobarbital treatment did not address the mitochondrial dysfunction aspect of the hq 
cerebellar degeneration thus, the targets of PB that made it successful in preventing 
cancer, did not make it successful in preventing or delaying cerebellar degeneration in hq 
mice.  Thus, PB was not a suitable choice as a hormetic agent in hq mice. 
 
4.9 Other hormetic therapies can be considered for cerebellar degeneration in hq mice 
4.9.1 Caloric restriction may reverse inflammation 
Although, hq mice treated with low doses of PB did not show a hormetic 
response, this does not mean that other hormetic agents would also prove to be 
ineffective in hq mice.  Caloric restriction has been extensively studied for its ability to 
increase lifespan in species of yeast [481] to mammals [289].  Also, caloric restriction 
decreases lipofuscin accumulation in the different regions of the brain [482], decreases 
ROS production [483], decreases damaged lipids and proteins [291, 484], and increases 
mitochondrial membrane potential in yeast [485].  Mitochondrial energy production 
relies on the membrane potential so an increase in mitochondrial membrane potential 
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would lead to an increase in ATP production, however, ATP levels are not altered under 
caloric restriction and non-caloric restriction conditions [486].  Gene expression analysis 
in the brain of mice shows that caloric restriction has varied effects depending on the 
region of the brain studied, but gene expression in regions of the central nervous system 
are still more similar to each other than they are to other organs [290].  Aging leads to 
increased expression of complement components as well as antigens (Cd48, Cd52, Cd53) 
in multiple brain regions, including the cerebellum, and caloric restriction is able to 
oppose the effects of aging in genes associated with immunity, defense, and inflammation 
[200, 202, 290, 291].  Generally, caloric restriction can counter some age-associated 
changes in gene expression, immune response, and inflammation, but is not able to 
reverse all age-associated changes in gene expression [290].  Thus far, caloric restriction 
appears to be the most promising anti-aging strategy available.  It would be interesting to 
study caloric restriction in the context of neurodegeneration to see whether the beneficial 
effects of reduced caloric intake can lead to decreased neurodegeneration in hq mice.  
Although, caloric restriction would be a difficult strategy to employ in the human 
population, understanding of the molecular mechanisms leading to increased longevity is 
needed.  Perhaps in the future there will be developments of drug compounds that can 
mimic the beneficial effects of caloric restriction without having to decrease caloric 
intake.  Caloric restriction could reduce the inflammatory and immune responses in the 
cerebellum of hq mice. 
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4.9.2 Physical exercise may increase the electron transport chain efficiency 
Exercise has shown promise in slowing the decline of neurodegeneration in 
mouse models of AD, PD, and mitochondrial DNA mutator mice [293, 294, 487].  
Exercise is able to ameliorate the decline in mitochondrial DNA and components of the 
electron transport chain in 3xTg-AD mice [129], and protects against mitochondrial 
dysfunction in a PD mouse model by increasing mitochondrial respiration, and ATP 
production [294].  In the mitochondrial DNA mutator mouse, exercise is able to increase 
mitochondrial copy number while reducing the frequency of mutations in the 
mitochondrial DNA, increasing the amount of mitochondrial electron transport chain 
subunits, and increasing mitochondrial activity [487].  Although exercise is beneficial in 
these mouse models, it might not be as beneficial in hq mice because exercise decreases 
adipose tissue in the 3xTg-AD mice [129], and hq mice have very little adipose tissue.  
Nonetheless, exercise shows promise in ameliorating the decline in mitochondrial 
function in neurodegenerative diseases, and could be a possible strategy to use in hq 
mice. 
 
4.10 Riboflavin administration is a targeted therapy that may increase the electron 
transport chain efficiency 
Since hq mice have decreased Aif expression leading to decreased complex I 
assembly [430], activity, and ATP production [248], another possible treatment would be 
to increase the amount of assembled complex I in the mitochondria to restore complex I 
activity and ATP production.  Riboflavin is a precursor for flavin adenine dinucleotide 
and flavin mononucleotide that is required for redox enzymes in energy metabolism.  
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Oral treatment with riboflavin in doses ranging from 9 mg in children to 100 mg in 
adults, increases complex I activity in the muscle of three out of the five individuals 
tested, as well as decreasing lactate levels in both the serum and cerebrospinal fluid 
[488].  The sample size of the previous study is very small but the results in the literature 
are fairly consistent.  Administration of riboflavin, sometimes in conjunction with other 
components, is able to successfully treat different patients [254, 489-492].  Riboflavin 
supplementation in C. elegans is able to increase the activity and the amount of fully 
assembled complex I but the exact mechanism is not known [493].  Riboflavin has very 
low toxicity as demonstrated by administering riboflavin orally at 10 g/kg of body weight 
in rats with no toxic effects [494].  Riboflavin is also capable of crossing the blood-brain 
barrier with the human riboflavin transporter hRFT3, which is highly expressed in the 
brain [495].  In humans with manifestation of complex I deficiency in the muscles, rather 
than manifestation in both muscles and central nervous system, fare better with riboflavin 
treatment [253, 488, 496], suggesting that riboflavin may not be as effective in hq mice as 
the main effects of complex I deficiency are seen in the cerebellum and retina but defects 
can also be seen in the cardiac muscle of hq mice in conjunction with added stressors 
[235].  One reason for this could be that riboflavin levels in the brain remain fairly 
constant despite diets rich or deficient in riboflavin [497].  Despite the drawback, it 
would still be of interest to test riboflavin administration as a potential treatment in 
cerebellar degeneration in hq mice. 
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4.11 Caveats  
 The transcriptome data should be confirmed at the protein level.  A change in the 
mRNA expression of a gene may not reflect a change in the protein expression [498], as 
there are mechanisms of post-transcriptional control including microRNAs [499], and 
RNA binding proteins [107].  There are also mechanisms of post-translational control 
that can regulate protein activity including phosphorylation, acetylation, glycosylation, 
ubiquitination, and cleavage.  Indeed, if there are changes in the protein expression, this 
may still not result in an up- or down-regulation in a pathway as many genes are involved 
and a change in the expression of one gene may not lead to a change in the overall 
pathway.  The next step would be to confirm the gene expression data at the protein level 
with western blotting.  
 Another caveat regarding the Fluoro-Jade
 
B stain is that the identity of the 
compound that Fluoro-Jade  B binds to in degenerating neurons in unknown.  Fluoro-
Jade  B is a poly-anionic fluorescein and thus is thought to bind to molecules with 
multiple positive charge groups, but the exact protein has not been determined [500].  
Because the mechanism of action is unknown it is still uncertain at what time point 
during the degeneration process this molecule with affinity to Fluoro-Jade  B is 
expressed.  The use of Fluoro-Jade  B could lead to increased false negatives, neurons 
that were degenerating but not stained with Fluoro-Jade  B.  For an example, a previous 
study compared the use of terminal deoxynucleotide transferase-mediated, deoxyuridine 
triphosphate nick-end labeling (TUNEL) and Fluoro-Jade  B in the leaner mutant mouse 
[501].  A total of 796 granule cells were evaluated using TUNEL, Fluoro-Jade  B and 
double staining for both TUNEL and Fluoro-Jade  B.  Only staining with TUNEL 
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yielded 29.5% positive granule cells while only staining with Fluoro-Jade  B yielded 
17.5% positive granule cells.  Double staining for both TUNEL and Fluoro-Jade  B 
yielded 53% positive granule cells.  To improve the accuracy of detecting degenerating 
neurons, staining with both TUNEL and Fluoro-Jade  B should be incorporated in future 
studies.  
 
4.12 Summary and Conclusions 
 This was the first characterization of nocturnal behaviour in hq mice and it was 
determined that nocturnal activity is not affected by cerebellar degeneration.  No new 
early behavioural markers of cerebellar degeneration were identified.  This was the first 
quantitative characterization of cerebellar degeneration in hq mice with normal aging 
while previous studies of hq mice focused on qualitative aspects of granule and Purkinje 
cell loss [232, 376].  Both granule and Purkinje cell numbers decreased in hq mice and 
cell loss had an anterior-posterior patterning.  This pattern of cell loss in the hq 
cerebellum may provide insight into early mechanisms of degeneration and provide 
benchmarks for assessing the efficacies of potential treatments.  This was the first 
characterization of mutations in the cerebellum of hq mice using the Big Blue  cII 
mutation detection assay which determined that nuclear mutations did not play a large 
role in cerebellar degeneration.  A detailed characterization of the transcriptome was 
achieved in the cerebellum of 3-month-old hq mice.  The transcriptome data were 
consistent with inflammation and microglial activation as early mechanisms in cerebellar 
degeneration in hq mice.  Preventing the inflammatory response early in hq mice may 
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help to stem cerebellar degeneration.  A down-regulation of Gabra6 may explain the lack 
of response by hq mice to low doses of PB.  
Multiple lines of data do not show association of ROS with cerebellar 
degeneration in hq mice.  Superoxide anion levels and ROS-induced damage such as 
lipofuscin and mutations were not the major contributing factors to cerebellar 
degeneration as was previously suggested.  Lipofuscin accumulation, mutations, and 
ROS were not elevated initially in the cerebellum of hq mice early in disease progression, 
suggesting that a decrease in energy production due to mitochondrial dysfunction was the 
major contributing factor to cell death.  Mitochondrial dysfunction also led to an 
elevation in the mRNA of genes related to the inflammatory response in the cerebellum 
of hq mice.  Thus, mitochondrial dysfunction and inflammation would be potential 
targets for therapies in preventing cerebellar degeneration in hq mice.  
New treatment targets indicated for use in preventing cerebellar degeneration in 
hq mice were identified.  Although, low-dose administration of PB was unsuccessful in 
treating cerebellar degeneration, this does not mean that hormesis cannot be effective in 
hq mice.  Caloric restriction could be used to reverse inflammation and exercise can 
increase complex I activity.  In addition, one other targeted treatment was documented.  
Riboflavin administration has shown efficacy in increasing complex I activity of the 
electron transport chain and has been an effective treatment in humans with 
mitochondrial dysfunction.  Future studies assessing the effectiveness of riboflavin to 
prevent or delay cerebellar degeneration in hq mice should be done. 
The function AIF and its effect on ROS are still unexplained.  Even though 
evidence of ROS-induced damage was not overwhelming in the data presented herein, 
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superoxide anion levels and lipofuscin increased with age, and a ROS mutation signature 
was identified.  Previous research in hq mice has reported evidence of ROS-induced 
damage [232, 241, 245, 280], as well as sensitivity of neurons and cardiomyocytes to 
exogenous ROS [232, 235, 502], suggesting an antioxidant role for AIF.  However, the 
rate of ROS production or detoxification was similar in WT and hq mice [430] and yet, 
AIF accepts electrons from NADH and transfers them to molecular oxygen to produce 
superoxide anions in vitro [429]. If AIF has the ability to accept and transfer electrons, it 
is possible that AIF is involved in the transfer of electrons from NADH or an unidentified 
associated protein to another associated protein for detoxification. In the absence or 
down-regulation of AIF, there would not be an increase in ROS but rather a 
mismanagement of ROS, which would lead to increased oxidative damage but not 
increased ROS production.  
This research has furthered our knowledge of the mechanisms of cerebellar 
degeneration in hq mice.  Phenobarbital may be a suitable treatment in preventing 
hepatocarcinogenesis, but the data do not support its efficacy in preventing 
neurodegeneration in hq mice.  Alternatively, potential hormetic and targeted therapies 
were suggested in treating mitochondrial dysfunction and inflammation in hq mice.  The 
key to unlocking the mystery of AIF remains in discovering the function of AIF in the 
context of ROS and its involvement in the assembly and/or maintenance of complex I.  
Further understanding of the role of AIF in these two capacities could advance our 
knowledge of the complex I assembly and the necessary factors required for proper 
function.  Since mitochondrial dysfunction is a common feature of neurodegenerative 
diseases, insight into the factors required for proper mitochondrial function would be 
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beneficial in testing treatments for mitochondrial dysfunction or neurodegenerative 
diseases.   
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Figure B.1 – Identification of apoptotic neurons in the mouse cerebellum of wild 
type (WT) and harlequin (hq) mice.  A) An image of the cerebellum of a WT mouse 
stained with Fluoro-Jade
®
 B with no visible degenerating neurons.  B) An image of the 
cerebellum of a hq mouse stained with Fluoro-Jade
®
 B, with the white arrow indicating 
degenerating neurons. C) The negative controls were created by injecting WT mice with 
10 mg/kg of a vehicle control.  D) The positive controls were created by injecting WT 
mice with 10 mg/kg of paraquat.  Scale bar = 100 µm.
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Figure B.2 – Identification of lipofuscin autofluorescence indicative of damaged 
lipids and proteins in cerebellum of wild type (WT) and harlequin (hq) mice.  A)  An 
image of the yellow and green autofluorescence in the apex of lobule I/II of the 
cerebellum of a WT mouse.  The white arrows are indicating lipofuscin autofluorescence.  
B) An image of the yellow autofluorescence of the apex of lobule I/II of the cerebellum 
of a WT mouse after setting the 140 threshold to remove the green autofluorescence.  The 
white arrows are indicating lipofuscin autofluorescence.  C) A hematoxylin and eosin 
image of the apex of lobule I/II of the cerebellum of a WT mouse showing the location of 
the lipofuscin in the Purkinje cell layer. Six yellow autofluorescence measurements were 
made at the apex of lobules I/II, III, VIa, IX, and X for two different cerebellar sections.  
The yellow autofluorescence measurements for the two separate sections were averaged 
together.  Yellow autofluorescence measurements were taken in three different mice per 
experimental group.  Scale bars = 100 µm
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Figure B.3 – Identification of reactive oxygen species (ROS) in the mouse 
cerebellum of wild type (WT) and harlequin (hq) mice. A) A hematoxylin and eosin 
image of lobule I/II of the cerebellum of a 3-month-old WT mouse. B) A fluorescent 
image of lobule I/II of the cerebellum of a 3-month-old WT mouse stained with 
dihydroethidium (DHE).  C) A fluorescent image of lobule I/II of the cerebellum of a 3-
month-old hq mouse stained with DHE.  Three DHE fluorescence measurements were 
made at the apex of lobules I/II, III, VIa, IX, and X for two different cerebellar sections.  
The DHE fluorescence measurements for the two separate sections were averaged 
together.  DHE fluorescence measurements were taken in three different mice per 
experimental group.  D) An image of a positive control of lobule I/II of the cerebellum of 
a 3-month-old hq mouse.  The positive control was created by exposing sections to 0.5 M 
hydrogen peroxide for 5 min prior to DHE staining.  E) An image of a negative control of 
lobule I/II of the cerebellum of a 3-month-old hq mouse created by exposing sections to 
20 l of 1000 U/ml superoxide dismutase solution for 10 min prior to DHE staining.  F) 
An image of a negative control of lobule I/II of the cerebellum of a 3-month-old hq 
mouse created by staining with dimethyl sulfoxide (DMSO) in the absence of DHE 
staining. Scale bars = 100 µm 
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